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Sézary Syndrome (SS) is an aggressive leukaemic variant of cutaneous T-cell 
lymphoma (CTCL). After the tumour suppressor gene TP53, PLCG1 is the most 
frequently mutated gene in CTCL. PLCγ1 (encoded by PLCG1) is fundamental in T-
cell receptor (TCR) signalling as it hydrolyses a plasma membrane component to 
trigger pathways that induce NFκB, NFAT and AP-1 transcriptional activity. This 
thesis aimed to functionally interrogate nine PLCγ1 mutations (p.R48W, p.S312L, 
p.D342N, p.S345F, p.S520F, p.R1158H, p.E1163K, p.D1165H and the indel 
p.VYEEDM1161V) identified in SS. PLCG1 mutations detected in diagnostic 
samples persisted in multiple tumour compartments several months after diagnosis, 
suggesting that these are likely driver gene mutations. A comprehensive analysis of 
whole-exome and targeted gene sequencing studies in addition to database 
interrogations revealed frequent PLCG1 mutations in 7/10 different types of mature 
T-cell lymphomas and highlighted five hotspot mutations. In basal conditions, five 
mutant proteins directly increased PLCγ1 activity by elevating inositol phosphate 
production and significantly enhanced downstream NFκB and NFAT activity, 
demonstrating bona fide gain-of-function properties. The hotspot p.R48W protein 
required stimulation to significantly elevate NFκB activity. Four activating mutations 
mapped to the PLCγ2 protein surface that likely interacts with the plasma membrane. 
These four mutant proteins are hypothesised to have increased access to substrate, 
resulting in augmented TCR signalling. Abrogation of the key PLCγ1 phosphorylation 
residue did not influence the elevated NFκB, NFAT and AP-1 activity induced by 
gain-of-function proteins in basal conditions or NFκB activity in stimulated cells, 
suggesting that the mutant proteins act in a phosphorylation-independent manner. The 
indel in the C2 domain of PLCγ1 reduced total protein expression but importantly 
mediated gain-of-function, proposing a novel and critical role for this domain in 
regulating protein activity. An IKKβ inhibitor was ineffective at reducing PLCγ1-
induced NFκB activity. In conclusion, PLCG1 mutations frequently occur in mature 
T-cell lymphomas and persist in multiple tumour tissues throughout the course of 
disease in SS. Five mutant proteins potently activate proximal and distal signalling 
independently of extracellular stimuli and contribute to the dysregulated TCR 
signalling that is characteristic of CTCL. The data presented here provides compelling 
evidence for the development of novel mutation-specific PLCγ1 inhibitors. 
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Chapter 1  Introduction 
 
1.1 Cutaneous T-cell lymphomas  
Cutaneous T-cell lymphomas (CTCL) are a rare and heterogeneous group of non-
Hodgkin lymphomas characterised by clonal proliferation of mature malignant skin-
resident CD4+ T-cells (1). Many clinical variants of CTCL have been reported with 
Mycosis Fungoides (MF) and Sézary syndrome (SS) being the most common and 
accounting for 54% of CTCL cases (2). MF is an indolent variant and SS is classed as 
an aggressive form of CTCL (3). MF normally affects older adults and SS exclusively 
affects adults (4). The age-adjusted incidence of MF and SS are 5.5 and 0.1 per million 
person years, respectively (5).  
MF and SS, although considered sub-types of CTCL, are classified as distinct disease 
entities by the World Health Organisation (WHO) rather than conditions on a disease 
continuum (6). However, this is still contentious as a recent study demonstrates 
plasticity of T-cell differentiation markers from a clonal population of cells (7), 
supporting the disease continuum theory as will be discussed in section 1.6.1. MF and 
SS demonstrate variable clinical presentation, histopathology and immunopathology 
as will be discussed in this chapter. 
 
1.2 Diagnosis of CTCL 
The diagnosis of primary CTCL is based on multiple factors including examining 
clinical presentation, histological analysis of lesional skin biopsies and 
immunophenotypic characterisation of cells. Each diagnostic criterion will be 
described in this section.  
1.2.1 Clinical manifestation 
MF is localised to the skin and initially presents with erythematous patches, which can 
progress over many years or decades into plaques that can further develop into tumours 
(Figure 1. 1) (8). The patches and plaques occur in sun-protected areas including the 
trunk and buttocks (4). MF patches are flat and can be scaly compared to normal skin 
(9). In contrast, plaques are raised skin lesions that can be smooth, crusted or ulcerated 
(9). Tumour-stage MF patients typically present with patches, plaques and tumours 
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that are frequently ulcerated (4). In advanced stage MF, the lymph node and visceral 
organs may be involved (4). MF is an indolent form of CTCL and 71% of early stage 
patients have a median survival of 12.9 years, but disease progression slowly occurs 
in approximately 30% of cases (10, 11). The incidence of MF is greater in males 
compared to females and the age of clinical presentation varies greatly from 12 to 88 
years, with a median age of 57 years (11, 12). The diagnosis of early stage MF can be 
challenging as the clinical presentation can mimic other dermatological conditions 






Figure 1. 1. Clinical presentation of MF. (A) MF initially presents with patches that 
can be hyper- or hypo-pigmented, the latter of which is shown. (B) The patches 
progress to form plaques. (C) The most advanced stage of MF presents with tumours. 
Images adapted from Kim et al. (2005) (1). 
 
SS is an aggressive leukaemic variant of CTCL (3). SS is characterised by generalised 
erythroderma with at least 80% skin involvement (Figure 1. 2. A), lymphadenopathy 
and the spread of neoplastic T-cells known as Sézary cells in the peripheral blood, skin 
and lymph nodes (3). Sézary cells are enlarged malignant CD4+ T-helper (Th) cells 
that have characteristic hyper-convoluted and cerebriform nuclei (Figure 1. 2. B) (15, 
16). SS occurs more frequently in adult males than females (4, 12). SS patients have a 
poor prognosis due to rapid disease progression with a median survival of between 2 
– 4 years (17, 18).  
Patients with advanced stage CTCL characteristically have disease-associated 
immunosuppression (as discussed in section 1.6) and frequently die from opportunistic 










Figure 1. 2. Characteristic features of SS. (A) A SS patient with generalised 
erythroderma. (B) Sézary cells characterised by hyper-convoluted and cerebriform 
nuclei. Images adapted from Kim et al. (2005) and Lutzner and Jordan (1968) (1, 21). 
 
1.2.2 Histological analysis 
The histopathological features of early stage MF overlap with other inflammatory 
dermatoses and add to the challenge of achieving an early diagnosis (13). MF skin 
lesions have abnormal infiltration of neoplastic lymphocytes in the epidermis 
(epidermotropism), which form cellular clusters known as Pautrier microabscesses 
(Figure 1. 3) (22). Histological changes in the patch stages are subtle, however in MF 







Figure 1. 3. Pautrier microabscesses in a MF skin section. Histological staining 
showing clusters of atypical cell infiltrates (Pautrier microabscesses), indicated by 




In SS, involved lymph nodes show a diffuse infiltrate of atypical cells that have 






Figure 1. 4. Infiltration of cells with cerebriform nuclei in a SS lymph node section. 
The image on the left and right side were obtained with low and high magnification, 
respectively. Image adapted from Scheffer et al. (1986) (24). 
 
1.2.3 Immunophenotypic characterisation 
Immunophenotypic analysis of CTCL is required to confirm that the dominant cell 
population is composed of T cells and not B cells or other cell types. The following 
markers are used to confirm the T-cell phenotype by flow cytometry: CD3+ (T-cell 
marker), CD45+/common leukocyte antigen (CLA; bone-derived leukocyte marker) 
and CD20- (B-cell marker) (25). MF patients characteristically have monoclonal 
proliferation of atypical CD2+, CD3+, CD4+, CD5+, CD45RO+, CD8- mature memory 
T-helper cells (26). As disease progresses, these neoplastic cells lose expression of 
CD2, CD5 and CD7 (26, 27). Atypical cells in SS have a CD2+, CD3+, CD4+, CD5+, 
CD45RO+, CD30- mature memory T-helper cell phenotype (28). As with neoplastic 
cells in advanced stage MF, Sézary cells have loss of CD7 and also demonstrate loss 
of CD26 (29). Immunophenotypic analysis also includes analysis of the CD4+:CD8+ 
T-cell ratio, which normally occurs in a 2:1 proportion (25). In patch stage MF, an 
elevated CD4:CD8 ratio has been detected, which reduces with disease progression 
(25). In contrast, the ratio of CD4+ cells is amplified over 10-fold compared to CD8+ 
cells in SS (25). 
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1.3 CTCL staging   
As described in section 1.2, the diagnosis of MF and SS depends on clinical, 
histological and immunophenotypical analyses. The tumour-node-metastasis-blood 
(TNMB) classification specified by the International Society for Cutaneous 
Lymphomas/ European Organisation for Research and Treatment of Cancer (ISCL/ 
EORTC) shown in Table 1. 1 is used to amalgamate the analyses and determine which 
compartments are involved (22).  
 
Table 1. 1. ISCL/EORTC classification of tumour-node-metastasis-blood (TNMB) for 





A key criterion for determining blood involvement and the stage of involvement is by 
quantifying circulating Sézary cells (Table 1. 1). Blood stage B0 is characterised by 
no significant blood involvement with ≤5% of peripheral blood lymphocytes being 
Sézary cells (22). Stage B1 is defined by a low blood tumour burden with greater than 
5% of peripheral blood lymphocytes being Sézary cells (22). Stage B2 is classified by 
a high tumour burden with ≥1000 Sézary cells per microliter (22). Sézary cells are 
quantified by flow cytometric analysis of CD4+CD7- or CD4+CD26- T-cells (30).  
Once patients have been classified using the TNMB classification, the disease stage is 
determined using the criteria shown in Table 1. 2 (22). Correct staging is crucial as it 
determines which therapeutic interventions should be administered and therefore 
impacts the prognosis and survival outcome of patients (31, 32). 
 
Table 1. 2. ISCL/EORTC staging guidelines for TNMB involvement in MF and SS. 











1.4 Treatment modalities 
Several treatment approaches are used to manage the symptoms of MF and SS. Early 
stage disease is treated with skin-directed therapies, whereas systemic therapies are 
used for advanced MF and SS cases.  
1.4.1 Skin-directed therapies 
The skin-directed therapies for early stage disease induce apoptosis of malignant cells 
(1, 33). Categories of skin-directed treatments include phototherapy, topical 
corticosteroids, topical retinoids, topical chemotherapy and radiotherapy, each of 
which will be described. Two forms of phototherapy are used: Psoralen+Ultraviolet A 
(PUVA) and Ultraviolet B (UVB). Early stage MF patients can benefit from Psoralen 
consumption followed by ultraviolet A phototherapy. Psoralen is a light-sensitive 
mutagen that incorporates into DNA and forms adducts that are activated by UVA 
radiation, leading to inhibition of cell proliferation and induction of apoptosis (32). 
UVB therapy does not require administration of Psoralen, making it an easier form of 
phototherapy for clearing skin patches in early MF (34). Topical corticosteroids are 
effective for treating patch stage MF and are available as creams and ointments (35). 
Carmustine and Nitrogen mustard are types of topical chemotherapy (36, 37). In 
addition to treating patch stage, Carmustine is also used for plaque stage MF (36). 
Nitrogen mustard ointment can clear skin lesions and re-pigment hypo-pigmented skin 
regions (38). Radiotherapy in the form of total-skin electron-beam therapy targets the 
entire surface area of the skin and effectively eliminates malignant cells (39). 
Superficial X-irradiation is another form of radiotherapy also used to treat early stage 
MF (40).  
1.4.2 Systemic therapies 
Systemic treatments for advanced stage (IVA2 and IVB) disease include biologics or 
immune-regulators such as Interferon-γ (IFN-γ) and IFN-α or the retinoid Bexarotene 
and rexinoid Isotretinoin (1). Patients who do not benefit from skin-directed therapies 
should also be considered for treatment with single agent systemic therapy (41).  
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1.4.2.1 Current systemic therapies 
IFN-γ and IFN-α inhibit production of the Interleukin (IL)-4 and IL-5 cytokines, which 
are characteristically elevated in CTCL and contribute to disease pathogenesis (41). 
Retinoids and rexinoids bind to retinoid x receptors and activate transcription factors 
that regulate cell proliferation and differentiation gene expression (42). Although 
effective treatments in some CTCL cases, the specific mechanism by which retinoid 
and rexinoids elicit their effects remains to be determined (42). Histone deacetylase 
(HDAC) inhibitors are used as systemic therapies to induce cellular growth arrest and 
apoptosis (43). HDAC enzymes remove acetyl groups from lysine bases on histones, 
enabling DNA to wrap around the histones to prevent transcription (44). Romidepsin 
is a HDAC inhibitor that is intravenously administered and works to epigenetically 
alter gene transcription and induces apoptosis (45). This inhibitor has been deemed 
safe and effective for CTCL patients that have previously received at least one 
systemic therapy (45). Vorinostat is an orally administered HDAC inhibitor also used 
to treat advanced stage CTCL (44).  
Systemic phototherapy such as extracorporeal photopheresis (ECP) induces apoptosis 
of malignant cells in SS by treating peripheral blood ex-vivo with PUVA and infusing 
it back into the patient (1). Advanced stage disease may also benefit from combination 
therapies such as ECP with IFN-α or Bexarotene (46).  
1.4.2.2 The emergence of monoclonal antibodies as immune checkpoint inhibitors 
Immunotherapy, the use of monoclonal antibodies and drugs that suppress or stimulate 
the immune system, has emerged as an appealing strategy for CTCL. Immune 
checkpoint inhibitors are a form of immunotherapy currently undergoing investigation 
for use in CTCL, with programmed cell death-1 (PD-1) inhibitors being an important 
example. PD-1 is a member of the CD28 co-stimulatory receptor family of cell-surface 
proteins expressed on T-cells that provides immunosuppressive signals upon 
interaction with the PD-L1 or PD-L2 ligands (47). Interaction of PD-1 with its ligands 
maintains peripheral tolerance by preventing T-cells attacking host tissues in an 
autoimmune manner, making it a key immune checkpoint that can contribute to 
lymphomagenesis if dysregulated (47). Samimi et al. (2010) reported higher PD-1 
expression on CD4+ T cells from SS patients compared to MF and healthy individuals 
(48). Subsequently, frequent PD-1 expression has been reported in patch and plaque 
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stage MF, but greatly reduced expression in tumour stage CTCL samples and in 
patients with large cell transformation (49). PD-L1 expression has also been detected 
in the majority of atypical lymphocytes from all CTCL stages, which increased as 
disease progressed (49). Recently, Querfeld et al. (2018) performed a larger study and 
reported significantly increased PD-1 and PD-L1 expression in all stages of CTCL, 
with greater expression in advanced stage disease compared to patch and plaque stage 
(50). Overexpression of PD-1 in all stages of CTCL suggests that MF and SS are part 
of a disease continuum as opposed to separate disease entities. Immunosuppression is 
a key feature of CTCL and frequent expression of PD-1 and PD-L1 may be 
mechanisms by which immunosuppression develops (49). In light of the increased PD-
1 and PD-L1 expression, antibodies targeting these cell surface molecules may be an 
effective therapeutic approach for CTCL. Pembrolizumab is an anti-PD-1 monoclonal 
antibody that has shown clinical efficacy and was well-tolerated by most MF and SS 
patients in a phase II trial (51). Another phase II trial (NCT02243579) with the same 
sample size of stage IB-IVB relapsed or refractory MF or SS patients treated with 
Pembrolizumab is currently underway (52, 53). Nivolumab is also a PD-1 blocking 
monoclonal antibody that has been shown to induce a partial response in 2/13 MF 
patients in a phase I trial with only mild side effects including fatigue (54). Nivolumab 
has also been shown to induce complete response in 1/11 diffuse large B-cell 
lymphoma cases, a disease in which increased PD-1+ tumour-infiltrating lymphocytes 
have been reported (54, 55). 
Mogamulizumab is a further antibody under investigation as a therapy for CTCL (41). 
This antibody targets the CCR4 chemokine receptor that is expressed on neoplastic T-
cells in approximately 40% of CTCL patients and has been approved as a therapeutic 
agent in Japan and the U.S.A. (41, 56). Alemtuzumab, a monoclonal antibody that 
targets CD52, which is highly expressed by malignant T-cells has been shown to be 
effective in SS patients but not advanced stage MF (41, 57). This suggests that 
Alemtuzumab binds to circulating malignant T lymphocytes more effectively than 
skin-resident neoplastic cells (57). Brentuximab vedotin is a monoclonal anti-CD30 
antibody conjugated to monomethyl auristatin E (MMAE), a drug that inhibits tubulin 
polymerisation and thereby cell division (58). The antibody binds to cells expressing 
CD30 (which varies in CTCL) and enables the cells to endocytose MMAE, leading to 
cell cycle arrest and the induction of apoptosis (41). Brentuximab vedotin has proven 
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clinically effective in phase II studies of advanced stage or treatment-refractory MF 
or SS patients who had variable levels of CD30 expression (59, 60).  
1.4.2.3 Challenges associated with immune checkpoint inhibitors 
Although immune checkpoint inhibitors seem promising, there are challenges 
associated with these therapeutic approaches. The first challenge is that tumours 
harbour mutations in different genes with variable frequencies (61). This can influence 
the response patients have to immune checkpoint inhibitors as demonstrated by 
melanoma patients treated with CTLA-4 blockers (62, 63). CTLA-4 is a T-cell surface 
molecule that functions in a similar manner to PD-1, by providing negative signals to 
T-cells to prevent cells being activated against self-antigens (64). Melanoma patients 
with a high mutation burden of over 100 missense mutations responded better to anti-
CTLA-4 antibodies compared to patients with a lower mutation burden who did not 
respond (62, 63). Therefore, patients being considered for CTLA-4 therapy should 
have their tumour mutation burden assessed by whole-exome sequencing to serve as 
a biomarker for clinical response to anti-CTLA-4 therapy (62, 63). The mutation 
burden in haematological malignancies including peripheral T-cell lymphomas-not 
otherwise specified (PTCL-nos) and angioimmunoblastic T-cell lymphoma (AITL) is 
significantly lower (approximately 25 mutations per tumour) than in solid tumours 
such as melanoma (65, 66). However, CTCL is an exception as the mutation burden 
ranges from an average of 50 – 100 missense mutations and some tumours have 
significantly higher rates of over 300 mutations per tumour (61, 67-71). Therefore, 
immune checkpoint inhibitors may be effective in CTCL due to the high mutation 
burden and PTCL-nos and AITL cases may not benefit from such inhibitors (61).  
Another challenge of immune checkpoint inhibitors was demonstrated by Postow et 
al. (2015), who showed that melanoma patients with a diverse T-cell repertoire had a 
higher response rate to the anti-CTLA-4 monoclonal antibody, Ipilimumab, than 
patients with a restricted repertoire (72). This observation suggests that such inhibitors 
may be less effective in CTCL due to the loss of T-cell repertoire resulting from late-
stage disease pathogenesis and immunosuppressive therapies commonly used in 
advanced stage disease (61).  
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1.4.2.4 Chemotherapy and haematopoietic stem cell transplantations 
Single-agent chemotherapy with cytotoxic agents such as Methotrexate, Gemcitabine, 
Cyclophosphamide, Pentostatin and Temozolomide are used for advanced stage 
disease and for patients who have relapsed or refractory disease (32, 44). However, as 
chemotherapy is associated with poor survival outcomes it is not used as a first line 
therapy but is considered as a second line therapy for patients who do not respond to 
biological agents (41, 73).   
Transformed MF (T-MF) is a rare and aggressive form of MF in which small 
neoplastic cells transform into large cells in 6% to 55% of MF patients (74-76). T-MF 
patients have a poor prognosis and reduced overall survival (74, 77). Systemic 
therapeutic interventions for T-MF include ECP, Bexarotene, IFNα, Vorinostat, low-
dose Gemcitabine or Methotrexate or allogenic haematopoietic stem cell 
transplantation for non-responders (74, 77). 
Combination chemotherapy (CHOP), a multi-agent chemotherapy regimen 
comprising of cyclophosphamide, doxorubicin, vincristine and prednisolone are 
reserved for advanced stage CTCLs including T-MF (78). However, such therapies 
are associated with high rates of rapid relapse compared to patients treated with IFNα 
and HDAC inhibitors, demonstrating that the aggressive treatment has no superior 
benefits to other non-chemotherapeutic systemic drugs (79). Furthermore, multi-agent 
therapies including total-skin electron-beam radiation and CHOP have comparable 
disease-free and overall survival outcomes for MF patients compared to topical 
treatment with mechlorethamine or topical mechlorethamine and oral methotrexate 
treatment for stage IVB disease, showing that combination therapies are not more 
effective than conventional skin-directed treatments (80).  
Treatments currently aim to manage disease symptoms by clearing the skin, reducing 
tumour burden, preventing disease progression and improving the patient’s quality of 
life (32). Investigations into autologous haematopoietic stem cell transplantations as a 
cure for advanced stage disease have not been promising (81). In contrast, allogeneic 
haematopoietic stem cell transplantations are currently the only effective cure that 
increase overall survival of advanced stage MF and SS patients (3, 82, 83). There are 
however major limitations in this therapeutic approach, the first being difficulty in 
identifying an HLA-matched donor and the second, patients succumbing to graft 
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versus host disease (3, 82). It is therefore pivotal to understand the genetic and 
molecular mechanisms causing advanced stage disease for the identification of novel 
therapeutic targets. 
 
1.5 Differentiation of CD4+ T-cells  
CD4+ T-cells have a fundamental role in maintaining a healthy adaptive immune 
system by protecting against pathogenic infections (84). Naïve CD4+ T-cells 
differentiate into either effector T-helper (Th1, Th2, Th17 and Tfh) or regulatory T-
cells (Tregs) (Figure 1. 5) (84, 85). Cell fate is determined by the cytokine milieu at 
the time of naïve T-cell activation by antigens presented from antigen presenting cells 
(APCs), such as dendritic cells (86). Transcription factors are also essential in 
determining cell fate as they control the expression of key cytokines that influence 
differentiation (87).  
IL-12 induces Th1 cell differentiation and inhibits Th2 development, whereas IL-4 
promotes Th2 cell fate and antagonises Th1 expansion (87). The transcription factors 
STAT4 and T-bet drive IL-12 production and promote Th1 differentiation (87). 
STAT6 and GATA-3 induce IL-4 expression to produce Th2 cells (87). Th1 cells 
produce IFNγ, which drives cell-mediated immunity and Th2 cells produce IL-4, IL-
5 and IL-13, which promote a humoral response against allergens and parasitic 
infections including helminths (87). CTCLs have a Th2 predominant cytokine 
expression profile, which suppress anti-tumour Th1 cytokines as will be described in 
section 1.6.2. 
TGFβ-1 in conjunction with the IL-6, IL-21 and IL-23 cytokines and the signal 
transducers and activators of transcription 3 (STAT3) and Rorγ transcription factors 
induces differentiation to Th17 cells (84). Th17 cells produce the pro-inflammatory 
IL-17 cytokine and also IL-22, which plays a key role in defending mucosal surfaces 
of organs and tissues from infections (84, 88).  
IL-6, IL-21 and STAT3 induce differentiation to follicular helper T-cells (Tfh), which 
produce IL-21 that aids Tfh cells in providing help to B-lymphocytes to differentiate 
into memory B cells or high-affinity antibody-secreting plasma cells which clear 
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pathogens (89). Expression of Tfh markers have been reported in CTCL, suggesting a 
role for these cells in disease pathogenesis as will be described in section 1.6.4.  
The STAT5 and Forkhead box P3 (FOXP3) transcription factors drive IL-2 
production, which in combination with TGFβ-1 induces Treg differentiation (87). 
Tregs produce TGFβ-1, which inhibits differentiation of Th1 and Th2 cells and 
thereby suppresses immune responses as a regulatory mechanism (87). Tregs also play 
a fundamental role in maintaining tolerance to self-antigens (84). Dysregulated Treg 
expression is a key feature of CTCL as will be discussed in section 1.6.5.  
Figure 1. 5. Differentiation of naïve CD4+ T-cells. Antigen presentation from APCs 
induces differentiation of naïve T-cells to effector T-helper cells (Th1, Th2, Th17 and 




Memory CD4+ T-cells are sub-classified into central memory T-cells and effector 
memory T-cells (91). Central memory T-cells home to secondary lymphoid organs 
including lymph nodes as they express the lymph node homing CCR7 molecule (91). 
These cells have limited or no capability to remove antigen but can rapidly proliferate 
and differentiate to generate effector memory cells upon antigenic stimulation by 
mature dendritic cells (91). As will be described in section 1.6.1, malignant cells in SS 
express CCR7 and have a central memory T-cell immunophenotype. 
Effector memory T-cells originate from naïve T-cells that have encountered antigen 
and undergone differentiation (92). These cells can migrate to peripheral tissues and 
therefore have a more rapid effector function than central memory cells at clearing 
pathogens (91). Effector memory T cells are characterised by lack of CCR7 expression 
and rapidly produce high levels of the effector cytokines IL-4, IL-5 and IFNγ upon 
antigen stimulation (92). Th1 (produce IFNγ) and Th2 (produce IL-4 and IL-5) cells 
are classed as effector memory T-cells (91). Neoplastic cells in MF lack CCR7 
expression and have a skin-resident effector memory T-helper phenotype as will be 




1.6 Immunopathogenesis of CTCL  
Primary cells from MF and SS patients and CTCL cell lines have several abnormal 
characteristics that contribute to disease pathogenesis as will be described in this 
section.  
1.6.1 Neoplastic cells in CTCL have central and effector memory T-cell 
immunophenotypes 
Memory CD4+ or CD8+ T-cells are fundamental for mounting a rapid immune 
response when re-exposed to antigens (93). There are three types of memory T-cells: 
central memory cells that localise to lymph nodes, effector memory cells that circulate 
the body and resident memory cells which reside in peripheral tissues including the 
skin (94).  
CTCL cells have memory cell phenotypes (95). Specifically, clonal malignant cells 
from the blood of SS patients demonstrate a central memory T-cell phenotype, 
characterised by expression of the lymph node homing molecules L-selectin and 
CCR7 in addition to CD27, a cell differentiation marker (95). Skin lesions from MF, 
on the other hand, display a skin-resident effector memory T-cell phenotype defined 
by the expression of CCR4 and CLA but lack L-selectin, CCR7 and CD27 expression 
(95). These distinct immunophenotypes support the classification of MF and SS as 
separate disease entities, however this is still contentious.  
This theory has recently been challenged by a study in which mice immunised through 
the skin demonstrated identical T-cell receptor (TCR)-β chain sequences in abundant 
clones of both skin-resident memory cells and central memory T-cells in lymph nodes 
(7). This demonstrates the plasticity of T-cell differentiation marker expression and 
shows that skin-resident cells like those detected in MF and central memory cells such 
as those reported in SS can originate from a common clonal population of naïve T-
cells (7). This suggests that neoplastic cells in MF and SS may have a common origin, 
making them part of a disease spectrum as opposed to separate disease entities. 
1.6.2 Advanced stage CTCL has a Th2 predominant cytokine expression profile 
SS and advanced stage MF highly express the Th2 cytokines IL-4, IL-5, IL-10 and IL-
13 (96, 97). Importantly, expression of these cytokines is regulated by the nuclear 
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factor kappa B (NFκB), nuclear factor of activated T-cells (NFAT) and activator 
protein-1 (AP-1) transcription factors, of which NFκB is characteristically 
overexpressed in CTCL as discussed in section 1.6.6.  
Elevated IL-4 levels produced by Th2 cells have been reported in the serum of SS 
patients, demonstrating a skew towards Th2 cytokine production (98). Furthermore, 
stimulated peripheral blood mononuclear cells (PBMCs) from SS patients produce 
higher levels of IL-4 and less of the Th1 cytokines IL-2 and IFNγ compared to healthy 
individuals (98). A reduction in the elevated IL-4 production was observed when 
PBMCs from these patients were co-cultured with IFNγ in vitro, demonstrating that 
the low level of IFNγ produced by SS patients is insufficient to maintain the balance 
of Th1-Th2 cytokine production (98). These data support the use of IFNγ as a form of 
systemic therapy in advanced stage CTCL as discussed in section 1.4.2. Expression of 
the IL-4 and IL-5 cytokines has also been detected at the transcriptional level in 
lesional skin from all stages of CTCL (96). Specifically, IL-4 and IL-5 mRNA were 
detected in skin biopsies of plaque and tumour stage CTCL but patch stage MF showed 
only expression of IL-5 (96). Targeting the elevated IL-4 levels with an anti-IL-4 
antibody results in reduced proliferation of CD4+ T-cells from SS patients in vitro 
(99). 
The increasing expression of cutaneous IL-10 mRNA correlates with disease stage in 
MF (97). Wu et al. (2018) confirmed these findings and also showed that blocking IL-
10 in a CTCL mouse model with a monoclonal anti-IL-10R antibody reduced tumour 
growth (100). These findings suggest that blockade of IL-10 signalling may be an 
effective therapeutic strategy for CTCL (100). Furthermore, IFNγ gene expression 
decreases in lesional skin as MF progresses from patch to plaque stage with no IFNγ 
detected in tumour lesions (97). Importantly, IL-10 is an immunosuppressive cytokine 
that contributes to the immunopathogenesis of CTCL by enabling immune evasion of 
tumour cells (97).  
Immunohistochemical analysis has identified high expression of IL-13 and its 
receptors IL-13Rα1 and IL-13Rα2 in lesional skin of CTCL patients (99). Geskin et 
al. (2015) showed that culturing enriched CD4+ T-cells from SS patients with IL-13 
in vitro induced cell proliferation, demonstrating that this Th2 cytokine promotes 
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growth of neoplastic cells in SS (99). Blocking IL-13 signalling with an anti-IL-13 
antibody greatly reduces the proliferation of SS cells in vitro (99).  
Collectively, these data indicate that neoplastic T-cells have a Th2 helper cell 
phenotype characterised by elevated Th2 cytokines in the peripheral blood of SS 
patients and lesional skin from all stages of CTCL, which contributes to the disease 
pathogenesis. Furthermore, Guenova et al. (2013) show that both malignant and 
benign (non-clonal) T-cells from patients with leukaemic CTCL have a Th2 bias and 
produced more IL-4 and IL-13 than T-cells from healthy individuals and malignant 
cells also produced higher levels of IL-10 (101). IL-4 and IL-13 produced by 
malignant cells were shown to reduce production of the Th1 cytokine IFNγ from T-
cells of healthy individuals, demonstrating the ability of cells to induce a Th2 
microenvironment. (101). The elevated Th2 cytokine levels override the anti-tumour 
effects of the Th1 cytokine IL-2 in addition to IFNγ and thereby provide an 
advantageous microenvironment for tumour growth (102). 
1.6.3 Activated T-cells in CTCL display an exhausted phenotype   
CD4+ T-cells in CTCL undergo clonal proliferation in a milieu of chronic 
inflammation (50). As a result, these cells are chronically activated leading to an 
exhausted phenotype that makes them unresponsive to antigens presented by 
cutaneous dendritic cells (50, 103). Exhausted T-cells contribute to 
immunosuppression as the cells do not effectively clear pathogenic infections, which 
are the leading cause for death in SS (104). 
Exhausted CD4+ T-cells from SS patients have increased PD-1 expression compared 
to MF patients and healthy controls (48, 103). A recent study confirmed and extended 
these findings by reporting significantly increased gene expression of PD-1, LAG-3 
and CTLA-4 in all stages of CTCL compared to healthy skin, with greater expression 
in advanced stage disease than patch and plaque stage MF (50). PD-1, CTLA-4 and 
LAG-3 are suppressive immune checkpoints that negatively regulate TCR signalling, 
therefore overexpression of these inhibitory receptors may contribute to the 
characteristic immunosuppressive nature of CTCL cells (47, 48, 50).  
Cytotoxic CD8+ T-cells from CTCL patients also have increased CTLA-4 and LAG-
3 expression compared to T-cells from healthy skin (50). Furthermore, tumour-
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infiltrating CD8+ cytotoxic T-cells have an exhausted phenotype and do not fully 
induce their anti-tumour effect to remove malignant CD4+ T-cells from the skin (103). 
Thus, advanced stage disease is characteristically less cytotoxic and more 
immunosuppressive (1). Overexpression of the mentioned cell surface markers has 
made them prime therapeutic targets for immune check point inhibitors as discussed 
in section 1.4.2.2. 
1.6.4 Neoplastic Tfh cells are detected in CTCL  
PD-1 expression is a marker of not only activated T-cells but also of Tfh cells (105). 
To distinguish between the two cell types, co-expression of at least three Tfh markers 
including PD-1, ICOS, CXCL13, BCL-6, or CD10 is required to determine whether 
cells have a Tfh cell phenotype (105). Bosisio et al. (2015) have shown frequent 
expression of at least 3 of these markers in more than 10% of tumour cells in MF 
(106), suggesting a role for neoplastic Tfh cells in CTCL. Malignant cells in SS have 
also been reported to express PD-1, BCL6 and CXCL13 implicating a Tfh origin of 
the neoplastic cells (107). Another study reports 5 primary CTCLs which express Tfh 
markers and proposes that these cases are therefore referred to as primary cutaneous 
Tfh lymphomas (108). This suggests that a subset of CTCLs may arise from malignant 
Tfh cells and raises the question of whether such cases should be classed as a separate 
disease entity. The expression of PD-1, BCL-6, CXCL13, and CD10 on neoplastic 
cells is a characteristic feature of AITL, a lymphoma of Tfh cells (107). 
1.6.5 Dysregulation of Tregs in CTCL 
Tregs (CD4+CD25+) have immunosuppressive properties and play a key role in 
maintaining tolerance to self-antigens (20). MF skin lesions demonstrate high 
infiltration of Tregs, which reduces as disease progresses and lesional skin from SS 
show low Treg infiltration (109). An ex vivo study performed by our group identified 
no significant difference in Treg frequency in 10 SS patients compared to healthy 
control individuals (110). This study also showed that high burden CTCL tumours 
encompass dysfunctional Tregs that did not suppress T-cell proliferation and identified 
a significant association between these cells and elevated Sézary cell counts in four 
patients (110). The remaining six patients had functional Tregs that suppressed T-cell 
proliferation and had a relatively lower tumour burden (110). Reduced mRNA 
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expression of FOXP3, a transcription factor considered the master regulator of Tregs, 
was detected in patients with a high tumour burden and dysfunctional Tregs (110).  
A subsequent study on a larger cohort of MF and unclassified CTCL patients also 
demonstrated no or very weak FOXP3 expression in tumour cell infiltrates from 85/86 
cases (111). However, all cases demonstrated strong FOXP3 expression in tumour-
infiltrating Tregs. Patch and plaque stage MF had a greater number of FOXP3+ Treg 
cells than advanced stage disease, showing that expression is related to disease stage 
(111). Furthermore, an association between the high number of FOXP3+ Tregs and 
improved survival was also demonstrated (111). 
1.6.6 NFκB is constitutively active in CTCL 
CTCL cell lines and primary cells from MF and SS patients characteristically have 
constitutive NFκB activity and overexpression of NFκB target genes. The HUT-78 
cell line, which is derived from a SS patient, has constitutively active NFκB unlike the 
Jurkat cell line, which originates from an acute T-cell leukaemia patient (112, 113). 
HUT-78 cells were identified to produce high levels of tumour necrosis factor-α 
(TNFα), a pro-inflammatory cytokine that acts in an autocrine manner to constitutively 
activate NFκB, which further drives TNFα expression (112, 113). Treating HUT-78 
cells with anti-TNFα antibodies drastically reduces NFκB activity, confirming that 
TNFα functions as a growth factor for this cell line (112, 113). HUT-78 cells, unlike 
Jurkat cells, are resistant to TNF-induced apoptosis which may be due to constitutive 
NFκB activity (113). 
Immunohistochemical analysis has revealed that MF skin lesions have strong nuclear 
and cytoplasmic expression of the p65 NFκB subunit (114). Electrophoretic mobility 
shift assays and confocal microscopy have shown that in addition to HUT-78 cells, 
MyLa cells (MF cell line), SeAx cells (SS cell line) and peripheral blood cells from 
SS patients with a high proportion of tumour cells, all have constitutive NFκB activity 
(115). Treating SeAx and MyLa cells and tumour cells from SS patients with the 
proteasome inhibitor Bortezomib reduces NFκB activity and induces apoptosis, 
demonstrating that NFκB plays a key role in apoptosis resistance, a hallmark of CTCL 
cells (115). Inhibition of IKK2 (also known as IKKβ, a subunit of the IKK complex 
that regulates NFκB activity) also reduces nuclear localisation and activity of NFκB 
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and potently induces apoptosis of CTCL cell lines and tumour cells from SS patients 
(116).  
An alternative mechanism of constitutive NFκB signalling is that of NFKB2 gene 
rearrangements detected in CTCL cell lines and two CTCL patients (117). An NFKB2 
gene rearrangement identified in HUT-78 cells is likely to result in an abnormal 
truncated protein instead of the p100 NFκB subunit. High levels of this truncated 
protein have been detected in the nucleus of HUT-78 cells, suggesting that it may 
contribute to the constitutive NFκB activity observed in CTCL (117). 
Recent deep sequencing studies on CTCL tumours have identified alternative 
mechanisms, namely several gene mutations and translocations that may contribute to 
constitutive NFκB activity as will be discussed in section 1.9.  
The findings of the studies described provide evidence for the development of 
inhibitors specific to the NFκB signalling pathway as a therapeutic strategy for CTCL 
(116). Notably, elevated NFκB activity is also a key feature of other mature T-cell 
lymphomas including adult T-cell leukaemia/lymphomas (ATLL) and some subtypes 
of PTCL in addition to mature B-cell malignancies such as chronic lymphocytic 
leukaemia (CLL) and activated B-cell diffuse large B-cell lymphoma (ABC DLBCL) 
(118-120). This supports the pathogenic role of dysregulated NFκB expression and 
further supports the development of NFκB pathway inhibitors that can be used for 
multiple diseases. 
1.6.7 Dysregulated expression of the AP-1 transcription factor family 
Our group has shown increased copy number of JUNB, an AP-1 subunit and also 
demonstrated elevated mRNA and protein expression of this subunit in MF and SS 
patients (121). More than half of the SS patients that had elevated JUNB expression 
also demonstrated total and (activated) phosphorylated ERK1/2 protein expression 
implicating the ERK1/2-AP-1 signalling pathway in the pathogenesis of advanced 
stage CTCL (121). JUND protein expression, another AP-1 subunit, was detected in 
the majority of MF patients but only rarely in SS patients, suggesting that JUND 
dysregulation may contribute to early stage CTCL (121). Nakayama et al. (2012) 
confirmed the findings that JUND mRNA and protein expression is increased in skin 
lesions from MF patients (122).  
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1.6.8 CTCL cells are resistant to apoptosis  
CTCL cells do not have a high replicative potential but are characteristically resistant 
to apoptosis, which results in tumour cell accumulation (33). Constitutive NFκB 
activity has been shown to contribute to apoptosis resistance in SS and CTCL cell lines 
as discussed in section 1.6.6. Furthermore, increased NFκB activation may be 
responsible for overexpression of its target anti-apoptotic genes Bcl-2, cIAP1 and 
cIAP2 in CTCL (123). In addition to NFκB, CTCL cells express constitutively activate 
STAT3, STAT5 and c-MYC transcription factors that also regulate Bcl-2, cIAP1 and 
cIAP2 expression (124-126).  
Chromosomal loss of the 10q24 region that encodes the FAS gene has been identified 
in SS (127). FAS encodes the cell death receptor that induces apoptosis upon 
engagement with Fas ligand (FASL) (127). Therefore, lack of FAS expression on 
malignant SS cells is a potential mechanism by which the cells could resist apoptosis 
(127). Our group has shown reduced FAS expression on both the mRNA and protein 
level in SS and demonstrated that this reduction was associated with hypermethylation 
of the FAS CpG island (128).  
1.6.9 Dysregulated JAK/STAT signalling  
Chromosomal instabilities have been reported in SS including gain of the 17q22-25 
region, which encodes the STAT3, STAT5A and STAT5B transcription factors (127, 
129). These transcription factors are key components of the IL-2 cytokine signalling 
pathway that regulates the activation, proliferation and differentiation of T-cells (127). 
Regions encoding IL-2 and the IL-2 receptor chains (IL-2Rα and IL-2Rβ) are also 
gained in SS (127). These copy number gains would likely increase IL-2 signalling 
and contribute to oncogenesis in SS. 
Constitutive activation of the STAT3 transcription factor has been reported in tumour 
stage MF, SS and in CTCL cell lines (130-132). Furthermore, overexpression of 
STAT3 protects CTCL cells from apoptosis (130). Constitutive STAT5 activity has 
been identified in all stages of CTCL (133, 134). In late stage disease, these 
transcription factors are activated by constitutive Janus Kinases-1 (JAK1) and JAK3 
activity in a cytokine-independent manner (133).  
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The STAT3 and STAT5 transcription factors regulate the expression of Th2 cytokines, 
therefore copy number gains can contribute to the skewed Th2 cytokine profile that is 
characteristic of CTCL (133). Furthermore, chromosomal gains of components of the 
IL-2 signalling pathway are likely to increase the expression of target genes that 
regulate cellular growth and survival (127, 135). 
1.6.10 Loss of cell cycle regulators  
Deletion of the 9p21 region, which harbours the cyclin-dependent kinase inhibitor 2A 
and cyclin-dependent kinase 4 inhibitor B (CDKN2A/CDKN2B) loci has been 
identified in transformed MF and SS by array-comparative genomic hybridisation 
(CGH) and fluorescent in situ hybridisation (FISH) analyses (136, 137). The 
CDKN2A/CDKN2B genes encode the cell cycle progression regulators p14ARF, 
p15INK4b and p16INK4a, which function as tumour suppressors, therefore copy number 
loss can contribute to the pathogenesis of CTCL (136). An alternative mechanism of 
p16INK4a inactivation in MF is hypermethylation of the CpG island in the gene 
promoter reported in 11% (1/9) of plaque lesions that did not progress, 43% (3/7) of 
plaques which progressed and in a total of 71% (5/7) of tumour lesions (138). 
Importantly, deletion of the CDKN2A-CDKN2B locus is associated with reduced 
survival in CTCL (136).  
1.6.11 Genomic instability is a key feature of CTCL 
MF and SS are both associated with recurrent gross genomic rearrangements and 
chromosomal instabilities. Genomic aberrations that occur in both diseases have been 
identified as well as genomic losses and gains that are unique to the diseases. These 
findings add to the deliberation of whether MF and SS are separate diseases or part of 
a disease spectrum.  
In addition to harbouring CDKN2A/CDKN2B, the deleted 9p21 region (see section 
1.6.10) also harbours the methylthioadenosine phosphorylase (MTAP) gene, which 
encodes an enzyme important for the salvage of adenine and methionine (137). Our 
group has shown that copy number loss of MTAP, identified by quantitative reverse 
transcription-polymerase chain reactions (qRT-PCR), occurred more frequently than 
CDKN2A deletions in MF lesional skin and peripheral blood from SS patients (137). 
This copy number loss correlated with reduced MTAP mRNA expression in enriched 
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CD4+ tumours cells from the peripheral blood of SS patients. MTAP loss was also 
identified to occur independently of CDKN2A loss in early stage MF (137). 
In contrast to the deletion of the 9p21 region, there is a high level of genomic 
heterogeneity between MF and SS with distinct genomic aberrations identified in the 
two diseases. There is conflicting evidence of whether copy number gains or losses 
are more frequent in MF and SS. van Doorn et al. (2009) and Vermeer et al. (2008) 
used CGH analyses to identify more frequent chromosomal gains than losses in 
tumour-stage MF and SS, respectively (127, 129). However, Laharanne et al. (2010) 
used the same technique on a similar number of samples to show that chromosomal 
losses are more frequent than gains in transformed MF and SS (139). 
In MF, loss of 5q13 and 9p21 and gain of 1p36.2 and 7q21-36 have been recurrently 
identified by array-based CGH (129). MF patients with loss of 9p21 or gain of 8q24 
(encoding the proto-oncogene cMYC) or 1q21-1q22 have significantly reduced 
survival and poor prognosis compared to patients not harbouring these copy number 
variations (CNVs) (129).  
Genomic instabilities are also frequent in SS and CGH analysis has identified loss of 
the 10q25-q26, 13q21-q22 and 17p13.1 regions (127, 129, 140). The most frequent 
chromosomal gains in SS are those of the 8q24.1–8q24.3 and 17q23–17q25 regions 
(127, 129). Gain of c-MYC (8q24.1–8q24.3) and loss of the tumour suppressor gene 
TP53 encoded by the 17p13.2 region are likely to contribute to the pathogenesis of SS 
(127). Loss of the FAS cell death receptor encoded in the 10q24 region has also been 
identified in SS and may contribute to apoptosis resistance as discussed in section 
1.6.8 (127).   
Low resolution techniques including array-based CGH, FISH, RT-PCR, qRT-PCR 
and microarray analyses have discovered gross genomic instabilities in CTCL and 
have also identified dysregulated expression of genes involved in 
immunopathogenesis including CDKN2A/CDKN2B, MTAP, FAS, cMYC, TP53, 
STAT3, STAT5A and STAT5B. Point mutations in genes have also been reported in 
CTCL. The first missense mutations were identified in the cancer-associated NRAS 
and KRAS genes (components of the RAS/RAF/MEK/ERK signalling pathway) in SS 
and MF, respectively using a mass-spectrometry based genotyping approach (141). 
More recently, deep sequencing techniques, which have superior resolution have 
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detected single nucleotide variants (SNVs), insertions, deletions and insertion-
deletions (indels) in a vast number of genes that were not previously implicated in 
CTCL, as will be discussed in section 1.9.  
 
1.7 Characteristic features of cancer cells 
Cancer can affect any organ but most malignancies regardless of the site of tumour 
have common features that arise from disrupted regulation of cell proliferation and 
apoptosis (142). The disrupted regulatory processes that lead to neoplastic growth 
have been classed into six key features by Hanahan et al. (2000) (142) who further 
review two emerging hallmarks identified by more recent research (143).  
The first characteristic feature is self-sufficiency to growth signals. Normal cells 
depend on growth signals such as cytokines or growth factors to enter an active 
proliferative state, however cancer cells can proliferate in a stimuli-independent 
manner due to oncogenic perturbations that activate signalling pathways.  
The second hallmark is insensitivity to inhibitory anti-growth signals. To maintain 
homeostasis, normal cells receive anti-proliferative signals to regulate the cell cycle. 
Cancer cells become insensitive to such signals and proliferate in an unregulated 
manner.  
The third feature is evading programmed cell death (apoptosis). Cell numbers are 
regulated by a balance between cell proliferation and apoptosis to maintain 
homeostasis. Cancer cells become resistant to apoptosis and lead to an expansion of 
tumour cells.  
The fourth capability is limitless replicative potential. Cells have a regulatory 
mechanism that defines a finite number of cell divisions based on the length of 
telomeres in a process called senescence. Cancer cells evade senescence and result in 
chromosomal instabilities. 
The fifth alteration is sustained angiogenesis. Blood vessels are essential for supplying 
oxygen and nutrients to tissues. When organs are generated, new blood vessels grow 
in a process known as angiogenesis, which is tightly regulated once the tissue has fully 
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formed. In solid cancers, angiogenesis lacks regulation and becomes sustained, 
resulting in a constant supply of nutrients that promote tumour growth. 
The sixth hallmark is tissue invasion and metastasis. In the advanced stages of most 
types of cancer, tumour cells migrate (metastasise) from the primary tumour and 
invade other tissues. 
The first emerging hallmark is avoiding immune attack and destruction by T- and B-
cells, natural killer cells and macrophages. These cell types are fundamental in 
immune surveillance and clearing emerging cancer cells, however tumours cells can 
avoid eradication by mechanisms which currently remain unclear and require further 
investigations.  
The second emerging characteristic is deregulated cellular energetics. This capability 
enables the tumour cells to change the cellular metabolism to allow constant growth 
and proliferation.  
 
1.8 Driver and passenger mutations and tumour mutation burden 
1.8.1 Driver and passenger mutations 
With each mitoses from the stage of fertilisation, somatic DNA replication errors 
known as mutations are acquired and accumulate in cells (Figure 1. 6) (144). The 
errors can be passenger or driver mutations. Passenger mutations are present in both 
normal and tumour (transformed) cells but do not alter cellular growth, proliferation 
or survival and therefore do not contribute to tumourigenesis (145). Driver genes 
however, are only identified in tumour cells as they provide a selective growth and 
survival advantage and contribute to oncogenesis (145). Metastatic and advanced 
stage tumours can harbour multiple driver gene mutations that further amplify the 
growth advantage and make the malignancy more aggressive (145). Driver mutations 
arise due to intrinsic DNA replication errors, lifestyle and environmental factors and 
as chemotherapy-resistant mutations (144). Chemotherapy-resistant mutations are 
acquired in patients who achieve clinical remission but then relapse due to the 
emergence of new drug-associated driver mutations that induce resistance to the 
specific therapeutic agent (144). As a result, tumour cells continue to grow faster and 
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survive longer than non-transformed cells (144). Examples of chemotherapy-resistant 
mutations will be discussed in section 1.16.2. 
Figure 1. 6. The accumulation of somatic passenger and driver gene mutations in cells. 
Passenger mutations are acquired from intrinsic DNA replication errors and exposure 
to mutagens but do not confer cellular growth advantages. The acquisition of driver 
mutations provides a selective growth advantage to transformed cells, leading to clonal 
expansion and oncogenesis. Multiple driver gene mutations are identified in advanced 
stage cancer and chemotherapy-resistant mutations can arise in response to therapeutic 
agents. Image adapted from Stratton et al. (2009) (144). 
 
1.8.2 Tumour mutation burden 
The tumour mutation burden is defined as the number of somatic mutations within a 
tumour (146). The tumour mutation burden varies between different cancer types and 
between patients with the same malignancy. Alexandrov et al. (2013) show that the 
frequency of somatic mutations varies more than 1,000 fold in 7,042 primary tumours 
(507 analysed by whole-genome sequencing (WGS) and 6,535 by whole-exome 
sequencing (WES)) from 30 types of cancers (Figure 1. 7) (146). Pilocytic 
astrocytoma tumours (a paediatric malignancy) have the fewest mutations and 
Melanoma had the greatest median number of somatic mutations (146). 
Haematological and paediatric malignancies harboured fewer somatic mutations 
(Figure 1. 7; left of the graph) compared to solid tumours induced by carcinogens 
including UV radiation (Melanoma) and tobacco smoke (malignancies affecting the 
lungs) (Figure 1. 7; right of the graph) (146). In contrast to other haematological 
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malignancies that have low mutation frequencies, CTCL tumours have a high mutation 
rate that is comparable to mutagen-associated solid tumours including lung cancers 
and melanoma (70, 147, 148).   
Figure 1. 7. The intra- and inter-variation of somatic tumour mutation burden in 
different malignancies. Mutation frequencies identified from whole-genomes and 
whole-exomes of 7,042 tumours from 30 solid and haematological malignancies. The 
number of mutations per megabase are shown on a logarithmic scale with dots 
representing individual samples and red lines representing the median number of 
mutations. ALL: acute lymphoblastic leukaemia, AML: acute myeloid leukaemia, 
CLL: chronic lymphocytic leukaemia. Figure adapted from Alexandrov et al. (2013) 
(146). 
 
Solid tumours can harbour hundreds or even thousands of genetic variations, however 
only a few of these are driver mutations, which promote oncogenesis and the 
remaining are passenger mutations (149). A prominent example of a driver gene 
mutation is observed in advanced melanoma in which half of the patients have 
mutations in the BRAF gene, with p.V600E being the most frequent mutation (150). 
In contrast, no single gene mutation has been associated with such a high number of 
CTCL cases. The identification of somatic driver gene mutations amongst the vast 
number of passenger mutations detected by next-generation sequencing (NGS) is 
particularly challenging as CTCL tumours are genetically heterogeneous with SNVs 
identified in many different genes within one tumour. The first step in identifying 
somatic mutations is to sequence matched non-tumour DNA from patients to enable 
germline mutations to be filtered out. Thereafter, multiple bioinformatic 
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methodologies developed to aid the distinction of driver from passenger gene 
mutations can be applied. The first approach is frequency based and includes filtering 
out genes previously identified to be false positives by exome sequencing and then 
prioritising genes mutated in more than 5% of tumours (151). The second approach 
includes applying the “20/20 rule” proposed by Vogelstein et al. (2013) (149). This 
rule suggests that if more than 20% of the variants are recurrent missense mutations, 
then the gene is likely to be an oncogene, whereas genes with more than 20% of the 
mutations being truncations (and predicted to be inactivating) are probable tumour 
suppressor genes (Figure 1. 8) (149). 
Figure 1. 8. Mutation distribution in oncogenes and tumour suppressor genes. The 
PIK3CA and IDH1 oncogenes harbour recurrent missense mutations (red inverted 
triangles) in their functional protein domains. The tumour suppressor genes RB1 and 
VHL harbour truncating mutations (blue triangles) throughout the genes. Figure 
adapted from Vogelstein et al. (2013) who analysed data from all cancer types using 
the Catalogue of Somatic Mutations in Cancer (COSMIC) database (149). 
 
The third approach to identify driver mutations is by using the MutSigCV algorithm 
to determine which genes are mutated at a significantly higher rate than background 
gene mutations (152). Once the genes that potentially harbour driver mutations have 
been short-listed, pathogenicity prediction algorithms such as SIFT, Provean, 
PolyPhen2, Mutation Taster, MutPred2 and CADD can be used to predict the likely 
effect of mutations on the structure and/ or function of the encoded protein to enable 
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further prioritisation of which mutations may be drivers (153-158). These 
bioinformatic approaches can help filter out likely passenger mutations and generate 
a short-list of candidate driver mutations, but only functional analyses can confirm 
whether a variant is indeed a true driver gene mutation. 
 
1.9 Genetic landscape of CTCL 
Numerous studies including our own (147), have used NGS including WGS, WES, 
targeted capture sequencing (TCS), CNV analysis and whole-transcriptome analysis 
to investigate the genetic architecture of SS and advanced stage MF (Appendix Table 
1). This section will highlight the findings and limitations of these studies. 
1.9.1 CTCLs have prevalent UV signature mutations 
Transition mutations, C>T or G>A, have been frequently identified in CTCL tumours 
by NGS studies (67, 69, 70, 147, 148). Such mutations are commonly induced by 
mutagenic UV exposure (159). CC>TT transitions of dinucleotide variants are also a 
UV mutation signature that have been highly detected in MF and SS tumours (67, 70, 
148, 159). Such high rates of CC>TT dinucleotide transitions are also observed in the 
solid malignancy melanoma, in which UV exposure is a risk factor (148). 
Interestingly, the frequency of mutations with a UVB signature in SS is elevated 
compared to the other haematological malignancies including acute 
lymphoblastic leukaemia and acute myeloid leukaemia (AML) and is comparable to 
the frequency observed in non-melanoma cancers, namely squamous cell carcinomas 
(SCC) (70). This suggests that UV exposure may be causative in generating the 
CC>TT dinucleotide variants in SS (148). The high UVB signature suggests that 
neoplastic cells originate in the skin and then spread to peripheral blood in SS and 
supports the theory that MF and SS are part of the same disease spectrum.  
CC>TT dinucleotide variants are rare occurrences in non-haematological 
malignancies including breast cancer, colon and rectal cancers, ovarian cancer, 
squamous cell lung cancer and lung adenocarcinoma (70, 148). In contrast to the 
frequent transitions detected in CTCL, B-cell cancers including CLL and malignant 
B-cell lymphomas have frequent T>G transversions and solid malignancies including 
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breast, colorectal, liver cancers and neuroblastomas are characterised by C>A 
transversions (146).   
1.9.2 CTCLs harbour mutations in genes that alter key cellular processes and 
pathways 
NGS studies performed on CTCL tumours have identified several signalling pathways 
and cellular processes to harbour mutations in genes involved in T-cell activation: 
PLCG1, CD28, CARD11, VAV1, MALT1, NFAT5 and NFKB2; IL-2 signalling: JAK1, 
JAK3, STAT3 and STAT5; epigenetic modification and chromatin remodelling: ZEB1, 
ARID1A, TET2, DNMT3A, MLL2, MLL3 and SETD1A; genome maintenance: POT1, 
ATM and cell cycle regulation: TP53 and CDKN2A (67-71, 147, 148, 160, 161). 
Pathways and processes identified to harbour gene mutations by NGS studies are 


















Figure 1. 9. Signalling pathways and processes identified to harbour gene mutations 
in CTCL by NGS studies. The size of each segment is not representative of the 

























Different studies have identified identical gene mutations leading to the discovery of 
hotspot mutations, for example the PLCG1 c.C1034T (p.S345F) mutation has been 
detected by all sequencing studies on CTCL samples, except by da Silva Almeida et 
al. (2015), who nevertheless identified other mutations in this gene (69). A meta-
analysis of 220 CTCL samples analysed by nine NGS studies revealed that the most 
frequently mutated genes are the cell cycle regulation gene TP53 and the TCR 
signalling gene PLCG1 (162). Our NGS study also identified PLCG1 to be frequently 
mutated in 11% (11/101) of SS tumours (147). Dysregulated TCR signalling is a key 
feature of CTCL that has been well established prior to NGS studies using array-based 
CGH, FISH, RT-PCR, qRT-PCR and microarray analyses. However, specific gene 
mutations were not identified by these techniques and deep sequencing studies have 
revealed a wealth of data on mutations of numerous genes involved in T-cell 
activation, proliferation, differentiation and death. 
Functional interrogations of some of the identified mutations have been performed. 
McGirt et al. (2015) showed that HUT-78 cells, which harbour the activating JAK3 
p.A573V mutation reported in MF, have increased downstream signalling as 
determined by elevated phosphorylated STAT5 (p-STAT5) expression (148). The 
authors further showed that treating three CTCL cell lines, HUT-78, HH and MyLa 
with the JAK3 inhibitor Tofacitinib reduced cell numbers and also reduced p-STAT5 
expression in HUT-78 and Myla cells (148). These data support the use of JAK3 
inhibitors for CTCL patients with JAK3 mutations and in patients with elevated 
JAK3/STAT5 signalling (148). Notably, Tofacitinib is a Food and Drug 
Administration (FDA) approved drug that is already used to inhibit proliferation of 
activated T-cells in rheumatoid arthritis (148). Kiel et al. (2015) have shown that 
primary cells from SS patients harbouring the JAK1 p.Y654F and p.L710V mutations 
had reduced proliferation and inhibited phosphorylation of STAT1, STAT3 and 
STAT5 when treated with JAK inhibitor I (68). The JAK inhibitor I potently inhibits 
JAK2 and JAK3 in addition to JAK1. Ruxolitinib, a JAK1 and JAK2 inhibitor has 
been shown to decrease proliferation and induce moderate levels of apoptosis in 
MyLa, HUT-78 and HH cells (163). Ruxolitinib treatment also induced a strong 
reduction in DNA synthesis in all three cell lines, suggesting that the JAK inhibitor 
interferes with this process to inhibit cell growth rather than inducing apoptosis (163). 
Furthermore, the inhibitor reduces STAT3 and STAT5 activation in all three cell lines, 
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particularly in HUT-78 cells, which harbour the JAK1 p.Y654F mutation, 
demonstrating that JAK signalling is more sensitive to inhibition in the presence of 
JAK mutations (163). The gain-of-function mutations identified by NGS studies 
present an additional mechanism to copy number gains that can lead to constitutive 
JAK-STAT signalling in CTCL. 
CARD11 is key TCR signalling protein. The CARD11 mutations p.S615F and 
p.E626K have been shown to significantly increase NFκB luciferase reporter activity 
in HEK293T and Jurkat cells (69). Furthermore, these mutations increase JNK 
phosphorylation after stimulation of Jurkat cells with phorbol 12-myristate 13-acetate 
(PMA), demonstrating that the mutations activate the mitogen-activated protein kinase 
(MAPK) pathway (69).  
Wang et al. (2015) identified a significant difference in the elevated expression of the 
CARD11, CCR4 and PLCG1 genes in SS patients with mutations compared to healthy 
controls (70). However, no significant difference in gene expression was detected in 
patients with and without mutations in the three genes suggesting that patients without 
mutations in these genes may have other perturbations that increase the expression of 
these genes (70).  
Choi et al. (2015) showed that the CD28 p.F51V mutation increases IL-2 expression 
in stimulated Jurkat cells but not in basal conditions, demonstrating that this mutation 
requires stimulation to induce its potential and is therefore not a true gain-of-function 
mutation that can trigger oncogenesis (67).  
RLTPR is a scaffold protein that is involved in CD28 signalling (164). The RLTPR 
p.Q575E mutation has been shown to elevate IL-2 mRNA production in Jurkat cells 
upon stimulation with the CD86 ligand of the CD28 receptor, but not in basal 
conditions demonstrating that this mutation cannot drive tumourigenesis in a 
stimulation-independent manner (162). 
Vaqué et al. (2014) have shown that the PLCγ1 p.S345F and p.S520F mutations 
significantly elevated NFAT-luciferase reporter activity in HEK293T cells, which can 
be reduced by treatment with the calcineurin inhibitor FK-506 and the PLC inhibitor 
U73122 (160). Treating the CTCL cell lines, MyLa and HUT-78, with FK-506 
reduced cell proliferation, viability and also NFAT activity (160). Of note, these cells 
do not harbour PLCG1 mutations (160), therefore it remains to be determined whether 
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cells harbouring gain-of-function PLCG1 mutations are sensitive to FK-506 and 
U73122. Immunohistochemical analysis of skin samples from MF patients harbouring 
the p.S345F mutation show nuclear localisation of NFAT, suggesting constitutive 
transcriptional activity (160). No such difference was detected in nuclear expression 
of the NFκB subunits p50 and p52 in MF patients with the p.S345F or p.S520F 
mutations (160).  
Although many gene mutations identified in CTCL have been functionally 
interrogated, a vast number of variants remain to be investigated to determine whether 
they are driver gene mutations. 
1.9.3 Copy number alterations frequently occur in CTCL 
CNV analysis performed using SNP arrays, WGS, WES and TCS data have confirmed 
the CNVs identified using array-based CGH, FISH, RT-PCR, qRT-PCR and 
microarray analysis including amplification of STAT3 and STAT5B (67, 147) and loss 
of CDKN2A, FAS and TP53 (67). As discussed in section 1.6, gain of STAT3 and 
STAT5B is likely to elevate the expression of cytokines that contribute to the Th2 pre-
dominant microenvironment in CTCL. Loss of the tumour suppressor TP53, cell cycle 
regulator CDKN2A and the FAS cell death receptor also likely contribute to the 
immunopathogenesis of CTCL (0). Notably, NGS has identified that genes affected 
by CNVs also harbour point mutations with TP53 being a prominent example (67, 69, 
70, 147, 160, 161). 
NGS sequencing has revealed copy number alterations of genes not previously 
implicated in CTCL (67-69, 71, 147, 161). Copy number loss has been reported in 
genes involved in chromatin remodelling: ARID1A, ARID5B, SMARCC1 and ZEB1; 
histone methyl transferases: MLL2, MLL3, MLL4, SETD1A, SETD1B, SETDB2 and 
SETD6; epigenetic modulator: NCOR1; DNA methyltransferases: DNMT3A, 
DNMT3B, TET1 and TET2; cell cycle regulators: CDKN1B and RB1; T-cell activation: 
JAK2; homologous recombination: BRCA2 and telomere maintenance: ATM  (67, 68, 
147). Copy number gains were identified in genes involved in T-cell activation 
PRKCQ, homologous recombination RAD51C, tumour suppressor regulation PREX2 
and STAT3 regulation SOCS7 (67, 147).  
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CTCL has a higher number of CNVs compared to other malignancies reported in The 
Cancer Genome Atlas database as demonstrated by Choi et al. (2015) (67). The 
authors firstly showed that CTCL has an elevated ratio of somatic CNVs to SNVs in 
TP53 compared to solid cancers and in DNMT3A compared to the haematological 
malignancy AML (Figure 1. 10. A) (67). Furthermore, deletions in CTCL were 
identified to be more prevalent than SNVs and amplifications combined, compared to 
other solid and liquid tumours (Figure 1. 10. B) (67). The prevalence of CNVs in 
CTCL may be attributable to mutations in key genome maintenance genes including 
POT1 and ATM, as identified by our NGS study (147).  
Figure 1. 10. The ratio of somatic CNVs to SNVs is amplified in CTCL. (A) CTCL 
has a higher proportion of somatic CNVs to SNVs in TP53 and DNMT3A compared 
to solid cancers and the haematological malignancy AML, respectively. (B) Deletions 
are more prevalent than SNVs and amplifications in CTCL compared to other cancers. 
BLCA: bladder cancer, BRCA: breast cancer, COAD: colon cancer, GBM: 
glioblastoma multiforme, HNSC: head and neck squamous cell carcinoma, KICH: 
chromophobe renal cell carcinoma, LGG: lower grade glioma, LUAD: lung 
adenocarcinoma, LUSC: lung squamous cell carcinoma, OV: ovarian serous 
cystadenocarcinoma, PAAD: pancreatic ductal adenocarcinoma, READ: rectum 
adenocarcinoma, SKCM: cutaneous melanoma, STAD: stomach adenocarcinoma, 
UCEC: uterine corpus endometrial carcinoma, UCS: uterine carcinosarcoma, 
AML/LAML: acute myeloid leukaemia, CESC: cervical cancer, KIRC: clear cell 
kidney carcinoma, KIRP: papillary kidney carcinoma, PRAD: prostate 





The CNVs reported in CTCL are likely to disrupt multiple signalling pathways and 
cellular processes in tumours. Loss of one copy (loss of heterozygosity) of the ZEB1 
and ARID1A genes and a homozygous deletion of CDKN2A have been shown to 
significantly correlate with reduced gene expression in SS (70). The functional 
consequences of the large number of genes affected by CNVs remain to be 
investigated.  
1.9.4 Chromosomal translocations are infrequent in CTCL  
WGS and RNA sequencing studies have reported chromosomal translocations in 
CTCL tumours (67, 68, 70, 161). The translocations result in the abnormal fusion 
genes CARD11-PIK3R3, CD28-CTLA4, IKZF2-GLI2, FASN-SGMS1, SGMS1-ZEB1, 
TYK2-UPF1, COL25A1-NFKB2, SPATA21-RASA2, TPR-MET and MYBL1-TOX. 
Furthermore, Ungewickell et al. (2015) used a software based approach to detect 
structural variations in MF and SS and identified gain of TNFRSF1B, NFKB2 
truncations and the CTLA4-CD28 and CD274-RAD51B (PD1-RAD51B) fusion genes 
(71). Copy number gain of TNFRSF1B correlates with increased gene expression 
levels in MF and SS tumours and with TNFR2 (encoded by TNFRSF1B) protein 
expression in the HH cell line, which harbours this copy number gain (71). The 
CTLA4-CD28 fusion results from a deletion on chromosome 2 that juxtaposes the 
extracellular portion of CTLA-4, a negative regulator of TCR signalling, with the 
activating cytoplasmic tail of CD28, a co-stimulatory protein for T-cell activation. 
Jurkat cells overexpressing the CTLA4-CD28 fusion demonstrated increased cell 
proliferation compared to cells transfected with CTLA-4 alone, implicating the 
oncogenic potential of the fusion protein in CTCL (71). 
In comparison to the 218 CTCL tumours analysed by WES (67-71, 147, 161), only 13 
have been investigated by WGS (67, 68, 148). The structural rearrangements including 
translocations and gene fusions reported are therefore unlikely to be fully exhaustive. 
WGS analyses on a greater number of samples would also provide information on 
aberrations in gene regulatory regions that may contribute to pathogenesis. 
Despite the low number of WGS studies performed on SS tumours, the occurrence of 
translocations is notably rare compared to other haematological malignancies. A prime 
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example is the balanced BCR-ABL translocation reported in around 90% of chronic 
myeloid leukaemia cases and encodes a constitutively active tyrosine kinase (165). 
1.9.5 Frequently perturbed pathways in CTCL 
The complex heterogeneity of CTCL tumours, harbouring an admixture of SNVs, 
CNVs and structural alterations can alter multiple signalling pathways. As described 
in this section, the NGS studies have identified perturbations of genes involved in 
several signalling pathways and cellular processes including T-cell activation via the 
MAPK, NFκB and NFAT pathways and the TNFR2, CD28 and CTLA-4 receptors; 
IL-2-JAK-STAT pathway, epigenetic regulators and chromatin remodelling, genome 
maintenance, cell cycle regulation and homologous recombination (67-71, 147, 148, 
160, 161). A meta-analysis of 220 CTCL tumours identified genes that were not 
implicated by the smaller individual studies including genes involved in signalling via 
the TCR (PTPRN2 and RLTPR), NFκB (PRKCB and CSNK1A1), MAPK (MAP2K1 
and NF1) and cellular processes including immune surveillance (CD58 and RFXAP) 
and chromatin remodelling (BCOR, KDM6A, SMARCB1 and TRRAP) (162). The 
pathways and cellular processes predicted to be affected by SNVs and CNVs identified 




Figure 1. 11. Pathways affected by recurrent mutations in CTCL. The frequency of 
SNVs (left box) and CNVs (right box) per gene involved in (A) chromatin 
modification processes, (B) T-cell activation and NFκB signalling, (C) JAK/STAT 
signalling and (D) MAPK signalling are represented. Potential oncogenes and tumour 
suppressor genes are highlighted in red and blue, respectively and darker shades 
indicate a higher aberration frequency. The SNV frequencies were determined by Park 
et al. (2017) and CNV frequencies by Choi et al. (2015) (67, 162). Figure adapted 
from Park et al. (2017) (162).  
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As mentioned, the DNA damage response and T-cell activation pathways were the 
most frequently perturbed in CTCL and TP53 (14%) and PLCG1 (9%) were the most 
frequently mutated genes in these pathways, respectively (162). This finding was 
confirmed by Chang et al. (2018) who analysed 139 CTCL tumours from seven NGS 
studies and identified that 19% of tumours harboured TP53 mutations and 10% had 
PLCG1 mutations (166). Importantly, this meta-analysis identified that mutations of 
the NFκB signalling genes PLCG1, TNFRSF1B and CARD11 were mutually 
exclusive, suggesting that mutations in any one of these genes is adequate to disrupt 
signalling and induce oncogenesis in SS (166). PLCG1 mutations have been identified 
in CTCL by several NGS studies and the encoded protein (PLCγ1) plays a pivotal role 
in TCR signalling (as will be discussed in section 1.13). This thesis will therefore focus 
on functionally interrogating PLCG1 mutations to determine their effect on TCR 
signalling components. 
NGS studies have collectively identified frequent aberrations in key pathways and 
some SNVs, CNVs and structural rearrangements increase T-cell signalling, gene 
expression, proliferation and survival in vitro, demonstrating the ability to drive 
lymphomagenesis. Thus, the perturbed pathways and particularly the mutated genes 
highlight key therapeutic targets and provide evidence for the development of novel 
mutation-specific inhibitors. 
1.9.6 Limitations of NGS analyses in CTCL 
Although NGS studies have uncovered a wealth of information on the genetic 
architecture of CTCL these studies have limitations. Deep sequencing studies have all 
analysed advanced stage CTCL, specifically tumour stage MF and SS, therefore the 
genetic events that occur in early stage MF remain to be identified. This can prove 
challenging as the neoplastic cells in patch and plaque stage MF are sparse in 
comparison to normal cells, making it difficult to identify low frequency somatic 
mutations by NGS.  
The approach of using small discovery cohorts to identify mutated genes for targeted 
deep sequencing introduces a bias in the selection of genes analysed. For example, our 
study performed WES on 10 SS tumours and identified 549 genes to harbour somatic 
mutations (147). These genes were deep sequenced in 91 more patients. The mutations 
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identified in our discovery cohort therefore defined the genes that were selected for 
further analyses. The CARD11 gene, identified to be frequently mutated in CTCL, was 
not mutated in our discovery patients and was therefore not deep sequenced in a larger 
cohort of patients (147). However, as shown by Park et al. (2017) and Chang et al. 
(2018), meta-analyses of NGS studies have increased statistical power to identify 
genes implicated in disease pathogenesis (162, 166). 
NGS techniques cannot identify epigenetic changes in CTCL tumours. 
Immunohistochemical analysis of lesional biopsies from MF patients has identified a 
loss of 5-Hydroxymethylcytosine (5-hmC), an important epigenetic regulator (167). 
5-hmC levels decrease as disease progresses and correlate with poor overall survival 
(167). Increasing the levels of 5-hmC using vitamin C in PBMCs from patients with 
leukaemic CTCL and nine CTCL cell lines increased apoptosis, suggesting that 
restoring 5-hmC in patients may have therapeutic benefits (167). This demonstrates 
how NGS studies alone cannot define the pathogenesis of CTCL and the perturbations 





1.10 Phospholipases  
The plasma membrane is composed of a bilayer of phospholipids including 
phosphoinositides (PIs) (168). PIs reside in the inner leaflet/ cytosolic face of cells and 
make up less than 1% of the plasma membrane with phosphatidylinositol-(4,5)-
bisphosphate (PIP2) being one of the predominant cellular PIs (168). Despite being a 
minor component of the plasma membrane, PIP2 has a major role in biological 
functions (169). 
Phospholipases are fundamental enzymes that transduce inter- and intra-cellular 
signals by hydrolysing phospholipids, including PIP2, to generate secondary 
messengers (170). Phospholipases are categorised into three major classes, PLA, PLC 
and PLD, based on the site these enzymes cleave phospholipids (Figure 1. 12) (170). 
The PLA1 and PLA2 enzymes hydrolyse phospholipids to produce saturated and 
unsaturated fatty acids, respectively. PLC cleaves phospholipids to produce inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) and hydrolysis of phospholipids 
by PLD generates phosphatidic acid (PA). The secondary messengers produced by the 
three phospholipase classes have diverse cellular functions, which initiate signalling 
cascades that promote cell survival, proliferation, differentiation, migration and 
apoptosis (170). Thus, dysregulated phospholipase activity is highly likely to 









Figure 1. 12. Cleavage sites of phospholipases. The three major classes of 
phospholipases, PLA, PLC and PLD, are categorised by the position they cleave 
phospholipids, to generate secondary messengers that have diverse cellular functions. 
Figure adapted and modified from Park et al. (2012) (170). 
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1.11 The Phospholipase C family 
Thirteen phospholipase C (PLC) enzymes have been described in mammals and are 
categorised into six families (PLCβ1-4, PLCγ1-2, PLCδ1, PLCδ3-4, PLCε, PLCζ and 
PLCη1-2) (Figure 1. 13) (170). Phospholipases are inactive in resting cells but mediate 
inter- and intra-cellular signalling when cells are activated (170). Therefore, the 
regulation of phospholipase activity is fundamental and PLC enzymes regulate their 
own activity by auto-inhibition (171).  
The PLCγ isozymes have a unique protein domain arrangement known as the γ-
specific array, which comprises of the split PH, nSH2, cSH2, SH3 domains located 
between the catalytic X-Y domains (Figure 1. 13) (172). In contrast, the other five 
PLC families have a linker between the X-Y domains (Figure 1. 13) (172). The γ-
specific array in the PLCγ isozymes interacts with the X-Y catalytic domains and 
blocks substrate accessing the active site as a means of protein auto-inhibition (172) 
as described in detail in section 1.13.3. The linker between the X and Y catalytic 
domains in the PLCβ, PLCδ, and PLCε isoforms mediates auto-inhibition, facilitated 
by the negative charged residues in the linker repelling the enzymes from the 
negatively charged plasma membrane (171). This repulsion prevents substrate 
accessing the active site of these phospholipases (171). Upon interaction of upstream 
signalling proteins such as Rac, the negative residues in the X-Y linkers are 
repositioned, enabling PIP2 to access the active site (171).  
The function and regulation of the PLCη isozymes is not well characterised and 
requires further investigations (173). The PLCζ isozyme is expressed in sperm unlike 
the other PLCs, which are expressed in somatic cells (174). The X-Y linker of PLCζ 
contains positively charged residues and does not mediate auto-inhibition but 
increases protein activity, suggesting a unique function of the gamete-specific PLCζ 












Figure 1. 13. The protein domain organisation of six PLC families. Thirteen PLC 
isozymes are categorised into six families. Figure adapted from Park et al. (2012) 
(170). 
 
1.12 An introduction to PLCγ1 and PLCγ2 
PLCγ1 is ubiquitously expressed in all tissues and is encoded by the PLCG1 gene 
(175). PLCγ2 is a closely related isozyme that is encoded by the PLCG2 gene on 
chromosome 16, whilst PLCG1 is located on chromosome 20 (176). Both isoforms 
have an identical protein domain arrangement encoded by 32 exons. PLCγ1 and 
PLCγ2 have high sequence homology across key functional domains (Figure 1. 14) 
(175, 176). 
The PLCγ isozymes comprise of five core domains (PH, EF, X, Y and C2) and four 
domains in the γ-specific array that mediates auto-inhibition (Figure 1. 14. A). When 
the protein adopts its 3D folded conformation, the core domains interact to form the 
PLCγ catalytic core (Figure 1. 14. B). The cSH2 domain in the γ-specific array forms 
an auto-inhibitory interaction with the triosephosphate isomerase (TIM) barrel of the 
catalytic X-Y domains and is therefore fundamental for regulating protein activity and 
maintaining PLCγ in an inactive state (172). 
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Figure 1. 14. Schematic representation of PLCγ (1 and 2) protein domain organisation. 
(A) PLCγ1 and PLCγ2 have high sequence homology in most functional protein 
domains as represented by the percentages. Figure adapted and modified from Koss et 
al. (2014) (175). (B) In the 3D protein conformation, the catalytic X-Y domains 
interact to form the TIM-barrel, which interacts with the cSH2 domain of the γ-specific 
array to regulate protein activity by auto-inhibition. Figure adapted and modified from 
Poulin et al. (2005) (177). 
 
The PH domain mediates phospholipid substrate binding and stabilises PLCγ at the 
membrane (170, 178). The EF domain forms a flexible tether between the PH and X 
domain (170). The C2 domain binds calcium ions and mediates interactions with the 
membrane (170). The split PH domain defines the n- and c-terminals of the γ-specific 
array. The n-terminal SH2 (nSH2) domain is essential for mediating interactions of 
PLCγ with receptor tyrosine kinases (RTK) and non-receptor tyrosine kinases (nRTK) 
(170). The SH3 domain is a protein-protein interaction domain, which binds proline-
rich motifs on adapter proteins that are involved in signal transduction (170). 
PLCγ1 transduces signals from numerous cell surface receptors including the TCR, 
vascular endothelial growth factor receptor (VEGFR), hepatocyte growth factor 
receptor (HGF), platelet-derived growth factor receptor (PDGFR), epidermal growth 
factor receptor (EGFR), fibroblast growth factor receptor (FGFR) and nerve growth 
factor receptor (NGFR) (Figure 1. 15) (179). Engagement of these receptors by 
antigens or growth factors activates PLCγ1, which triggers extensive signalling 















Figure 1. 15. PLCγ1 mediates signalling from several cell surface receptors to key 
transcription factors that regulate gene expression. 
 
Unlike PLCγ1, PLCγ2 is mainly expressed in cells of a haematopoietic lineage, 
including B lymphocytes, mast cells, natural killer cells and platelets but is also 
expressed at lower levels in T-cells (181). PLCγ2 has an analogous role to PLCγ1 in 
mediating B-cell receptor (BCR) and TCR signalling, respectively (Figure 1. 16) and 
like PLCγ1, PLCγ2 is also activated by growth factors (175). Notably, PLCγ1 is also 
expressed in B-cells (182). PLCγ2 has been reported to be expressed in primary T-
cells and plays a role in TCR signalling and T-cell selection when PLCγ1 is depleted 
in mice, demonstrating functional redundancy between PLCγ1 and PLCγ2 (181). On 
the contrary, expression of basal levels of PLCγ1 were not sufficient to restore platelet 
activation in PLCγ2-deficient mice unless PLCγ1 expression levels were increased to 
those of PLCγ2 in platelets (183). 
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Figure 1. 16. PLCγ2 and PLCγ1 have analogous roles in BCR and TCR signalling. 
The enzymes trigger signalling cascades to activate the NFAT, AP-1 and NFκB 
transcription factor families in B- and T-lymphocytes. 
 
1.13 The pivotal role of PLCγ1 in TCR signalling 
1.13.1 The T-cell receptor 
The TCR on the majority of T-cells is formed of an α and β chain heterodimer, whilst 
in 5-10% of T-cells the receptor is a heterodimer composed of a γ and δ chain (184). 
The αβ-TCR has short intra-cytoplasmic regions which lack signalling domains (185). 
The TCR is therefore non-covalently linked to the CD3 complex (which comprises of 
the γε and εδ heterodimers) and the TCR ζ chains (Figure 1. 17) (185). The TCR, CD3 
complex and the ζ chains form the TCR-CD3 complex. The CD3 molecules and ζ 
chains encompass immunoreceptor tyrosine-based activation motifs (ITAMs), which 
harbour tyrosine phosphorylation residues that are fundamental for signal transduction 
















Figure 1. 17. The TCR structure. The TCR is composed of an α and β heterodimer that 
associates with the γε and εδ CD3 heterodimers and two ζ chains. The CD3 dimers 
and ζ chains harbour ITAMs, which are phosphorylated during T-cell activation to 
mediate signal transduction. Figure adapted and modified from Jahan et al. (2016) 
(186). 
 
1.13.2 TCR activation and signalling to PLCγ1 
A schematic representation of the TCR signalling pathway that will be described in 
the rest of section 1.13 is shown in Figure 1. 18. The TCR is activated by antigen 
peptide molecules presented by major histocompatibility complexes on the surface of 
APCs (187). CD4 is a co-receptor that assists in strengthening the interaction between 
the TCR and APCs (187). TCR activation triggers serial phosphorylation cascades by 
RTKs and nRTKs (187). The SRC-family tyrosine kinase lymphocyte-specific 
protein-tyrosine kinase (LCK), binds to the cytoplasmic tail of CD4 (187). LCK and 
the other SRC-family tyrosine kinase FYN phosphorylate the ITAMs on the CD3-γ, -
δ, -ε and the -ζ chains, leading to the recruitment of the zeta-chain associated protein 
kinase-70 (ZAP70) (187). LCK then phosphorylates and activates ZAP70, which 
phosphorylates the scaffold proteins linker of activation of T cells (LAT) and SLP-76 
(39, 188).  
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Figure 1. 18. The TCR signalling pathway. PLCγ1 is a fundamental signal transducer 
of TCR signalling via the secondary messengers IP3 (metabolised to IP2 and IP1) and 





1.13.3 PLCγ1 auto-inhibition and activation by tyrosine phosphorylation 
In resting cells, PLCγ1 localises to the cytosol (178). PLCγ1 is maintained in an 
inactive state by auto-inhibition to regulate the enzymes’ activity. Interaction of the 
cSH2 domain with the catalytic X-Y domains forms the auto-inhibitory interface that 
blocks substrate accessing the active site and represses PLCγ1 activity (Figure 1. 19. 
A). The phosphorylated residues on LAT act as docking sites for the nSH2 domain of 
PLCγ1 and induce translocation of PLCγ1 from the cytosol to the plasma membrane, 
bringing the enzyme in close proximity to its substrate, PIP2 (178, 189). The PLCγ1 
PH domain stabilises the enzyme at the membrane, where PLCγ1 interacts with SLP-
76 via its SH3 domain (178, 190). LCK phosphorylates and activates IL-2 inducible 
kinase (ITK), which phosphorylates the p.Y783 tyrosine residue on PLCγ1 and 
activates the enzyme (191). The phosphorylated p.Y783 residue forms a high affinity 
interaction with the PLCγ1 cSH2 domain and leads to a conformational shift that 
disrupts the auto-inhibitory interface between the catalytic X-Y and cSH2 domains 
(Figure 1. 19. B, C) (172). Thus, the active site of PLCγ1 is available to hydrolyse 
PIP2 into the secondary messengers IP3 and DAG (Figure 1. 20). 
Figure 1. 19. PLCγ1 activity is regulated by auto-inhibition. (A) PLCγ1 is maintained 
in an inactive state by an auto-inhibitory interaction between the catalytic X-Y 
domains and the cSH2 domain, blocking substrate accessing the active site. (B, C) 
Receptor and non-receptor tyrosine kinases phosphorylate the p.Y783 residue, which 
then interacts with the cSH2 domain and disrupts the auto-inhibitory interface, making 
the active site available for substrate hydrolysis. Figure adapted and modified from 











Figure 1. 20. Hydrolysis of PIP2 by PLC isozymes. The PLC family of enzymes 
hydrolyse the minor plasma membrane phospholipid component PtdIns(4,5)P2 (PIP2) 
to produce the secondary messengers DAG and IP3. Figure adapted from Gresset et 
al. (2012) (192). 
 
ITK also phosphorylates the PLCγ1 p.Y775 residue, which contributes to activating 
the enzyme to a lesser extent than the p.Y783 residue (191). PLCγ1 is phosphorylated 
at three additional tyrosine residues (p.Y472, p.Y771 and p.Y1253) by RTKs and 
nRTKs, however phosphorylation of these residues does not significantly contribute 
to PLCγ1 activation (177, 193). Therefore, phosphorylation of the p.Y775 and p.Y783 
residues are necessary and sufficient to activate PLCγ1.  
1.13.4 Activation of secondary messengers and downstream signalling by PLCγ1 
Activated PLCγ1 is fundamental in TCR signalling as the secondary messengers, IP3 
and DAG, produced by PIP2 hydrolysis transduce signals down three major signalling 
cascades to activate the NFκB, NFAT and AP-1 transcription factors (Figure 1. 18). 
Notably, the PLCγ1 p.Y783 residue has been shown to be critical for proximal TCR 
signalling measured by inositol phosphate (IP) production in vitro (177, 194). The 
p.Y775 and p.Y783 residues are required to induce NFAT and AP-1 reporter activity 
in vitro (193). Importantly, the phosphorylated p.Y783 residue induces transcriptional 
activity more potently than p.Y775, making the former residue fundamental for PLCγ1 
activity (193).  
The secondary messenger IP3 binds to IP3 receptors on the endoplasmic reticulum and 
triggers the release of calcium from intra-cellular stores (Figure 1. 18) (195). IP3 is 
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rapidly metabolised to inositol-1,4-bisphosphate (IP2), which is metabolised to 
inositol-1-phosphate (IP1) (Figure 1. 18). The rise in intra-cellular calcium levels 
activates the calcium-binding protein calmodulin, which in turn activates calcineurin, 
a serine phosphatase (195). In resting cells, constitutively active kinases phosphorylate 
serine residues on the NFAT transcription factor family and maintain the transcription 
factors in inactive forms in the cytoplasm (196). Fourteen serine residues on NFAT 
family members are phosphorylated, of which 13 are dephosphorylated by calcineurin 
in activated cells (196). Dephosphorylation of NFAT unveils the nuclear localisation 
signal (NLS) and concomitantly masks the nuclear export signal, enabling the 
transcription factors to enter the nucleus (196). The transcription factors bind to 
NFAT-specific response elements in the regulatory regions of target genes (Appendix 
Table 2) and initiate transcription (196). The NFAT family comprises of five 
members: NFAT1 – NFAT5. Of the five members, NFAT1-NFAT4 are activated by 
increased intra-cellular calcium levels and dephosphorylation by calcineurin activity, 
whilst NFAT5 is activated by osmotic stress and integrin activation (195).  
The other secondary messenger, DAG, activates protein kinase C-theta (PKCθ), which 
initiates signalling cascades to stimulate two fundamental transcription factor families: 
AP-1 and NFκB (Figure 1. 18). PKCθ activates the MAPK pathway that triggers 
phosphorylation cascades via RAS/ RAF/ MEK1/2 and ERK1/2 to activate the AP-1 
transcription factors (197). AP-1 comprises of homo- or hetero-dimers composed of 
the Fos (cFos, FosB, Fra1 and Fra2), Jun (cJun, JunB and JunD) or activating 
transcription factor (ATF) subunits that bind to the AP-1 binding site in the regulatory 
regions of target genes (Appendix Table 3) (196, 198). ERK1/2 can also activate other 
transcription factors including c-MYC and NFκB (197). 
DAG-induced PKCθ activity also activates the canonical NFκB pathway by 
stimulating the CARMA/BCL10/MALT1 signalosome, which activates the IKK 
complex (Figure 1. 18) (199). The IKK complex comprises of two catalytic kinase 
subunits, IKKα and IKKβ and one regulatory subunit IKKγ (NFκB essential 
modulator; NEMO) (Figure 1. 18) (200). The activated IKK complex phosphorylates 
IκBα, the NFκB inhibitor. IκBα binds to NFκB (p50/p65 heterodimers) and masks the 
transcription factors’ NLS, sequestering NFκB in its inactive state in the cytoplasm 
(201). When the IKK complex phosphorylates IκBα, the NFκB inhibitor is 
ubiquitinated and degraded by the proteasome (200). Dissociation of IκBα from 
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NFκB, unveils the NLS, allowing the transcription factor to translocate to the nucleus 
where it binds to κB sites in the regulatory regions of NFκB target genes (Appendix 
Table 4) and initiates transcription (200). The NFκB transcription factor family 
includes five proteins: p65 (RelA), RelB, c-Rel, p105/p50 (NF-κB1), and p100/52 
(NF-κB2), which form homo- and hetero-dimers (200). All five NFκB proteins have 
a Rel homology domain that enables the proteins to dimerise, translocate to the nucleus 
and bind DNA in target genes (200). 
1.13.5 Common target genes of the NFκB, NFAT and AP-1 transcription factor 
families 
The regulatory regions of some target genes harbour composite binding sites for 
NFAT and AP-1, which bind co-operatively as transcriptional partners (195). NFAT 
dimers can also bind to NFκB binding sites as both transcription factors have Rel 
homology regions with high structural similarity that allow DNA binding  (195). The 
NFAT, NFκB and AP-1 transcription factors have common target genes including 
those that encode FASL, IL-4 and IL-13 (Appendix Table 2 – Appendix Table 4). The 
overlap in target genes can be attributed to their regulatory regions harbouring binding 
sites for all three transcription factors, which can function in synergy (195).  
Notably, all three transcription factors that are regulated by PLCγ1 have been 
implicated in the pathogenesis of CTCL. Specifically, NFκB is constitutively active 
in tumour cells from MF and SS patients and in CTCL cell lines and NFκB target 
genes including IL-10, IL-13 and BCL-2 are also characteristically overexpressed as 
discussed in section 1.6. AP-1 subunits have also been reported to be overexpressed 
in CTCL as have the target genes of this transcription factor: BCL-2, cMYC, IL-4, IL-
5 and IL-13 (section 1.6). Furthermore, the NFAT transcription factor has recently 
been implicated in CTCL, with increased nuclear localisation detected in patients 
harbouring the activating PLCγ1 p.S345F mutation (section 1.9.2) (160). As PLCγ1 
activates NFκB, NFAT and AP-1, mutations in PLCG1 may contribute to the 
characteristic dysregulated expression and/ or activity of these transcription factors 
and their target genes in CTCL. One such example has been demonstrated by elevated 
NFAT-luciferase reporter activity induced by two PLCγ1 mutations, as discussed in 
section 1.9.2 (160). 
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1.14 The crucial role of PLCγ2 in BCR signalling 
The BCR is composed of the membrane-bound heavy and light chain immunoglobulin 
IgM (Figure 1. 21. A) (202). When antigens bind to BCRs, the receptors aggregate 
and induce downstream signalling (Figure 1. 21. B). As with the TCR, the BCR is the 
antigen binding subunit that has short cytoplasmic tails and therefore relies on the 
ITAMs in the Igα and Igβ heterodimers to mediate signal transduction (Figure 1. 21. 
A) (202). The conformational change induced by BCR aggregation induces 
phosphorylation of ITAMs by the SRC-family of tyrosine kinases (Figure 1. 21. C) 
(203). The phosphorylated ITAMs act as docking sites for the spleen tyrosine kinase 
(SYK), which phosphorylates the B-cell linker protein (BLNK/ SLP-65), an adaptor 
that recruits Bruton’s tyrosine kinase (BTK) and PLCγ2 (Figure 1. 21. C) (203). 
Several kinases including BTK, FYN and LCK phosphorylate PLCγ2. BTK 
phosphorylates the PLCγ2 p.Y753, p.Y759 and p.Y1197 tyrosine residues (204, 205). 
LCK also phosphorylates the PLCγ2 p.Y753 and p.Y759 residues and additionally 
phosphorylates p.Y743 (206). The p.Y1217 tyrosine base of PLCγ2 is phosphorylated 
in a BTK-independent manner (207). Phosphorylation of PLCγ2 activates the enzyme 
to hydrolyse PIP2 into IP3 and DAG. As with TCR signalling, these secondary 
messengers trigger multiple signalling cascades to activate the NFAT, NFκB and AP-
































Figure 1. 21. The BCR structure and signalling pathway. (A) The BCR is composed 
of the immunoglobulin IgM, which interacts with Igα-Igβ heterodimers that harbour 
cytoplasmic ITAMs. (B, C) Antigens bind to the BCR and lead to receptor 
aggregation, which induces phosphorylation of ITAMs and recruitment of the LYN, 
FYN and SYK kinases to activate BTK. BTK phosphorylates and activates PLCγ2 to 
hydrolyse PIP2 into IP3 and DAG, which trigger pathways to activate the NFAT, NFκB 
and AP-1 transcription factors. Images adapted from Abbas et al. (2012), Efremov et 
al. (2012) and Kapoor et al. (2016) (208-210). 
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1.15 Mutations and overexpression of PLCγ1 in cancer 
PLCγ1 is ubiquitously expressed in all tissues and is activated by the TCR and 
numerous growth factor receptors (179). Mutations in PLCG1 and aberrant PLCγ1 
expression levels have been detected in several haematological and solid 
malignancies, respectively and will be described in this section.  
1.15.1 Somatic PLCG1 mutations in cancer 
A vast number of NGS studies have reported somatic PLCG1 mutations in many types 
of mature T-cell lymphomas including advanced stage MF, SS, ATLL, PTCL-nos, 
AITL, Hepatosplenic T-cell lymphoma (HSTL) and T-cell-prolymphocytic leukaemia 
(TPLL) (Table 1. 3). Our deep sequencing study also identified PLCG1 mutations in 
11% of SS tumours (Table 1. 4) (147). Furthermore, advanced stage primary and 
secondary angiosarcomas also harbour PLCG1 mutations (Table 1. 3). Angiosarcomas 
are rare neoplasms of endothelial cells that line blood and lymphatic vessels (211). 
Like SS, advanced stage angiosarcomas are aggressive diseases that have a poor 
prognosis and have been shown to be genetically heterogeneous by NGS sequencing 
studies (212-215). 
A large deep sequencing study on 370 ATLL tumours identified that PLCG1 was the 
most frequently mutated gene in 36.2% of cases (Table 1. 3). PLCG1 mutations occur 
most frequently in ATLL compared to other malignancies (Table 1. 3). Notably, 
McGirt et al. (2015), Yoo et al. (2014), Wang et al. (2017), Kunze et al. (2014) and 
Vallois et al. (2016) also report a high PLCG1 mutation frequency of between 20% - 
30.8%, however this inflated frequency can be attributed to analyses of small sample 







Table 1. 3. Deep sequencing studies reporting PLCG1 mutations in mature T-cell 
malignancies and angiosarcomas. ATLL: adult T-cell leukaemia/lymphoma, PTCL-
nos: peripheral T-cell lymphomas-not otherwise specified, MF: Mycosis Fungoides, 
AITL: angioimmunoblastic T-cell lymphoma, SS: Sézary Syndrome, HSTL: 
hepatosplenic T-cell lymphoma, TPLL: T-cell-prolymphocytic leukaemia. 
Malignancy Mutation frequency Reference 
MF 
22.2%  (10/45) 
2.7%  (1/37) 
20%  (1/5) 
9.8%  (4/41) 
Vaqué et al. 2014 (160) 
Caumont et al. 2015 (216) 
McGirt et al. 2015 (148) 
Ungewickell et al. 2015 (71) 
SS 
12.5%  (1/8) 
5.1%  (2/39) 
10%  (4/40) 
9.1%  (6/66) 
18.1%  (19/105) 
12%  (3/25) 
6.7%  (1/15) 
10.9%  (11/101) 
Vaqué et al. 2014 (160) 
Caumont et al. 2015 (216) 
Choi et al. 2015 (67) 
Kiel et al. 2015 (68) 
Wang et al. 2015 (70) 
da Silva Almeida et al. 2015 (69) 
Prasad et al. 2016 (161) 
Woollard et al. 2016 (147) 
PTCL-nos 
14.6%  (6/41) 
30.8%  (4/13) 
14.6%  (6/41)  
Manso et al. 2014 (217) 
Vallois et al. 2016 (218) 
Manso et al. 2018 (219) 
AITL 
20%  (1/5) 
11.7%  (7/60) 
11.1%  (8/72) 
22.2%  (2/9) 
14.0%  (8/57)  
Yoo et al. 2014 (65) 
Manso et al. 2014 (217)  
Vallois et al. 2016 (218) 
Wang et al. 2017 (220) 
Manso et al. 2018 (219) 
ATLL 36.2%  (134/370) Kataoka et al. 2015 (221) 
HSTL 15%  (3/20) McKinney et al. 2017 (222) 
TPLL 5.6%  (2/36) Kiel et al. 2014 (223) 
Primary 
angiosarcomas 
30%  (3/10) 
5.2%  (6/116) 
3%  (1/34) 
Kunze et al. 2014 (213) 
Huang et al. 2016 (220) 
Murali et al. 2015 (215) 
Secondary 
angiosarcomas 
8.8%  (3/34) 
4.3%  (5/116) 
Behjati et al. 2014 (212) 
Huang et al. 2016 (220) 
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Table 1. 4. PLCG1 mutations identified by our TCS study of 101 SS tumours. Identical 
variants identified in more than one patient are highlighted in the same colour (147). 
 
Point mutations, small deletions and indels occur throughout PLCγ1 in mature T-cell 
lymphomas (Figure 1. 22). In contrast, the disease-specific p.R707Q/L mutations only 
occur in primary and secondary angiosarcomas and would influence VEGFR 
signalling in endothelial cells (212-214). The p.R707Q mutation has been reported to 
be acquired after Sunitinib (tyrosine kinase inhibitor) therapy in one case of hepatic 
angiosarcoma (224). Further investigations including larger cohorts of relapsed 
patients are required to determine whether PLCG1 acquires somatic mutations as 
resistance mechanisms to Sunitinib treatment. Notably, the p.S345F mutation has been 
reported in all the mature T-cell malignancies listed in Table 1. 3 and in primary 
angiosarcoma of the breast and spleen (214). Multiple PLCG1 mutations per tumour 
have been identified in ATLL (221), but not in other mature T-cell lymphomas and 
angiosarcomas in which patients harbour a single PLCG1 mutation. In secondary 
angiosarcomas, PLCG1 mutations co-occur with PTPRB or cMYC mutations, an 
observation unique to this disease subtype (212, 214). 
Patient I.D. Patient DNA number Nucleotide substitution Amino acid change
1 6885B c.C142T p.R48W
2 8004B c.C142T p.R48W
3 L11_0158B c.C935T p.S312L
4 3297B c.G1024A p.D342N
5 8344B c.G1024A p.D342N
6 3451B c.C1034T p.S345F
7 9308B c.C1034T p.S345F
8 4736B c.C1559T p.S520F
9 L12_0697B c.G3487A p.E1163K
10 4142B c.G3487A p.E1163K


























Figure 1. 22. PLCγ1 mutations reported in mature T-cell lymphomas and angiosarcomas. Mutations reported in angiosarcomas are shown in blue 
text. The p.S345F mutation occurs in T-cell malignancies and primary angiosarcomas. Refer to Table 1. 3 for references. 
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Eleven PLCG1 mutations have been functionally characterised, nine of which occur 
solely in mature T-cell lymphomas, one in angiosarcomas (p.R707Q) and the p.S345F 
mutation in both (Table 1. 5). Nine of the ten mature T-cell lymphoma mutations 
increase NFAT activation and MALT1 activity in HEK293T cells (Table 1. 5) (160, 
218). The p.R707Q mutation increases IP1 production (in HEK293 cells), apoptosis 
resistance, cell migration and invasion in the endothelial HUVEC cell line (213). As 
discussed in section 1.9.2, the p.S345F mutation has been associated with increased 
nuclear expression of NFAT in lesional skin of MF patients. 
Notably, there are no reports of disease-associated germline PLCG1 mutations 
demonstrating that mutations are somatically acquired during oncogenesis. The 
prevalence of PLCG1 mutations in many different malignancies strongly suggests that 
this gene harbours driver mutations, which play a key role in tumourigenesis. This is 
supported by the ability of the mutations to increase components of TCR or VEGFR 
signalling pathways, in vitro (Table 1. 5).  
PLCγ1 plays a fundamental role in mediating TCR and VEGFR2 signalling to key 
transcription factors including NFκB. The TCR signalling pathway harbours 
mutations in many genes in CTCL (section 1.9.2), but importantly PLCG1 is the most 
frequently mutated T-cell activation gene (162, 166). PLCG1 mutations have been 
shown to occur in mutual exclusivity to other NFκB pathway genes in SS, suggesting 
that perturbation of one gene in this signalling cascade is sufficient to disrupt the 
pathway and lead to oncogenesis (166). This is significant as dysregulated TCR 
signalling, in particular constitutive NFκB activity, is a characteristic feature of 
neoplastic CTCL cells (section 1.6.6). As PLCγ1 induces the NFκB pathway, 
signalling from mutant PLCγ1 proteins may contribute to the dysregulated NFκB 
activity in mature T-cell lymphomas. Vallois et al. (2016) demonstrate that PLCγ1 
mutations increase MALT1 activity (218), which is suggestive of increased NFκB 







Table 1. 5. A summary of the functional interrogations performed on PLCγ1 mutations. Arrows denote an increase in the readout of the assays 










Migration Invasion References 
p.E47K ↑ ↑ n/a n/a n/a n/a (218) 
p.R48W - - n/a n/a n/a n/a (218) 














n/a n/a n/a n/a 
(160) 
(218) 
p.R707Q n/a n/a ↑ ↑ ↑ ↑ (213) 
p.E730K ↑ ↑ n/a n/a n/a n/a (218) 
p.G869E ↑ ↑ n/a n/a n/a n/a (218) 
p.E1163K ↑ ↑ n/a n/a n/a n/a (218) 
p.D1165G ↑ ↑ n/a n/a n/a n/a (218) 
p.D1165H ↑ ↑ n/a n/a n/a n/a (218) 
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1.15.2 CNV of PLCG1 
Our TCS analysis identified a partial amplification of PLCG1 in one patient who did 
not harbour any mutations in this gene. The amplification initiates in intron 21 of 
PLCG1, spans the ZHX3, LPIN3, EMILIN3 genes and ends in intron 6 of the CHD6 
gene on chromosome 20 (co-ordinates: 39797710 – 40126876). The copy number gain 
would result in amplification of exon 22 – 32 of PLCG1 and amino acid p.W828 in 
the PLCγ1 SH3 domain and beyond. The CNV could not be validated as the DNA 
sample in which it was identified had been depleted. No other CNVs of PLCG1 have 
been reported in mature T-cell lymphomas. Copy number gain of PLCG1 and other 
PLC isoforms including PLCB1 and PLCB4 have been detected in glioblastoma 
multiforme (225). It is likely that amplification of PLCγ1 would augment downstream 
signalling and contribute to tumourigenesis, however this remains to be functionally 
validated. 
1.15.3 Overexpression of PLCγ1 in solid carcinomas  
Many solid tissue carcinomas frequently demonstrate elevated PLCγ1 expression. 
Overexpression of PLCγ1 has been detected in breast cancer and in the majority of 
tumours the active phosphorylated form of PLCγ1 (p-PLCγ1) was also detected (226). 
Furthermore, breast tissues expressing p-PLCγ1 also expressed the EGFR or Human 
epidermal growth factor receptor-2 (HER2), known to activate PLCγ1 (226). These 
findings suggest that two consecutive steps of the epidermal cell signalling pathway 
are amplified and may contribute to carcinogenesis (226). A subsequent study 
identified variable PLCγ1 expression in the cytoplasm of breast tumour cells and 
importantly demonstrated p-PLCγ1 expression predominantly in the nucleus (227). 
Elevated expression of PLCγ1 and p-PLCγ1 are associated with unfavourable clinical 
outcomes including metastasis occurrence, therefore PLCγ1 overexpression is 
considered a marker for metastasis development in breast cancer (227). 
Increased PLCγ1 expression has also been detected on both the mRNA and protein 
level in colon cancer (228). Treatment of the human colorectal cell line (LoVo) with 
the PLC inhibitor U73122 demonstrated decreased cell migration after stimulation, 
suggesting that PLCγ1 plays a key role in cell migration (229). LoVo cells were 
identified to have constitutive NFκB activity, which was enhanced by EGF stimulation 
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(via the EGFR-PLCγ1 pathway) and reduced by U73122, demonstrating that PLCγ1 
signalling regulates NFκB activity (229). Notably, the PLC inhibitor has been shown 
to elevate PLCγ1 activity in cell-free systems and also has a broad range of cellular 
targets and therefore lacks specificity (230). The effect of PLCγ1 on regulating 
migration and NFκB activity in LoVo cells should be reviewed with more specific 
inhibitors. A recent study has reported a significant correlation between PLCG1 copy 
number gain and increased PLCG1 RNA expression in colon cancer, demonstrating 
that CNVs can influence gene expression in tumours (231). 
PLCγ1 overexpression has been detected in the basal layer of epidermal skin from 
SCC patients and cell lines (232). A correlation between lower PLCγ1 expression and 
significantly improved overall survival, disease-free survival, and a better clinical 
response to chemotherapy in locally advanced and surgically removable oral 
squamous cell carcinoma (OSCC) patients has also been reported (233). Therefore, 
PLCγ1 expression may serve as a prognostic marker for advanced OSCC (233). 
Furthermore, PLCγ1 expression is associated with a higher incidence of OSCC and 
increased expression correlates with disease progression of potentially malignant oral 
lesions to OSCC (234). Thus, PLCγ1 may also serve as a biomarker for the 
identification of high-risk patients that could progress to develop OSCC (234).  
 
1.16 Disease-associated germline and somatic mutations in PLCG2 
As described in section 1.12, PLCγ1 and PLCγ2 are closely related isozymes, which 
mediate TCR and BCR signalling, respectively. Germline PLCG2 mutations have 
been reported in immune disorders and somatic mutations in drug-resistant mature B-
cell malignancies as will be described in this section.  
1.16.1 Germline PLCG2 mutations in immune disorders  
Linkage analysis of three families affected by a syndrome characterised by cold-
induced urticaria, antibody deficiency and susceptibility to auto-immunity and 
infections, revealed a partial deletion of the n-terminus of the cSH2 domain (p.646-
685) in two families and partial deletion of the c-terminus of the cSH2 and n-terminus 
of the SH3 domain (p.686-806) in the third family (Figure 1. 23) (235). In vitro 
analyses demonstrate that the deletions increase PLCγ2 activity by elevating IP 
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production. The increased activity is attributed to deletions of the cSH2 domain, which 
disrupt PLCγ2 auto-inhibition (235). This syndrome was therefore coined 
phospholipase Cγ2-associated antibody deficiency and immune dysregulation 
(PLAID) (235).  
WES of a family with a dominantly inherited auto-inflammatory condition revealed 
the PLCγ2 p.S707Y mutation in both affected individuals (236). This mutation was 
shown to increase IP production and intra-cellular calcium levels in vitro (237). As 
with the deletions in PLAID, the p.S707Y mutation locates to the cSH2 domain and 
disrupts auto-inhibition to elevate PLCγ2 activity. This syndrome was therefore 
named autoinflammation and PLCγ2-associated antibody deficiency and immune 
dysregulation (APLAID) (236).  
Figure 1. 23. Germline and somatic PLCγ2 mutations mapped to the functional protein 
domains. Germline mutations including two deletions identified in the auto-immune 
condition PLAID and the p.S707Y mutation in APLAID are denoted in blue. Somatic 
mutations identified in Ibrutinib-resistant CLL and Waldenström macroglobulinemia 
are shown in black. The p.S707Y mutation is also somatically acquired in Ibrutinib-
resistant CLL (235, 236, 238-247). 
 
1.16.2 Somatic PLCG2 mutations in mature B-cell neoplasms 
PLCG2 frequently harbours somatic mutations in Ibrutinib-resistant CLL. CLL is a 
mature B-cell malignancy in which BCR signalling is constitutively active, leading to 
apoptosis resistance of tumour cells (238, 248). CLL is the most common type of 
leukaemia in western countries and with the exception of allogenic stem cell 
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transplantation it is considered incurable (238, 249). The orally administered small 
molecule inhibitor Ibrutinib is the first BTK inhibitor that effectively brings CLL 
patients into remission (249). This inhibitor is also an effective treatment for other B-
cell lymphomas including Waldenström macroglobulinemia (WM), mantle-cell 
lymphoma and ABC DLBCL (250-252), but resistance to this inhibitor has been 
reported in all three malignancies (218, 245, 253, 254). Notably, PLCG2 mutations 
have also been identified in Ibrutinib-resistant WM (245).  
RNA sequencing and deep DNA sequencing studies have demonstrated frequent 
mutations in the PLCG2 and BTK genes in around 80-90% of Ibrutinib-resistant CLL 
patients (238-241, 243, 244, 246, 247, 255). Ibrutinib forms an irreversible covalent 
bond with the p.C481 residue of BTK, a key kinase that mediates BCR signalling (see 
section 1.14) and inhibits the elevated downstream BCR signalling observed in CLL 
(243, 249). The most frequent BTK mutation (p.C481S) occurs at the key Ibrutinib 
binding residue and results in reversible as opposed to irreversible binding of the drug, 
which decreases the inhibitor’s ability to reduce elevated BCR signalling in CLL 
(239). The BTK p.C481S mutation therefore confers resistance to Ibrutinib in some 
relapsed patients (239).  
The somatically acquired PLCG2 mutations identified in Ibrutinib-resistant CLL and 
WM are shown in Figure 1. 23. Studies have revealed that Ibrutinib-resistant CLL 
patients can harbour (i) BTK mutations alone (238, 240, 241, 244, 247), (ii) PLCG2 
mutations alone (238, 240, 241, 243, 247), (iii) BTK and PLCG2 mutations (238, 240, 
243, 247) or (iv) multiple PLCG2 mutations (238, 240, 241, 247). Highly sensitive 
sequencing techniques have enabled the identification of resistance-associated BTK 
and PLCG2 mutations up to 15 months prior to disease progression from drug-induced 
relapse (256). The identification of multiple PLCG2 mutations per patient strongly 
suggests that these are putative driver gene mutations that are positively selected 
during the development of drug resistance (240).  
Of all the PLCG2 mutations identified in Ibrutinib-relapsed CLL patients (Figure 1. 
23) the p.R665W and p.L845F mutations have been functionally validated as gain-of-
function mutations, which elevate intra-cellular calcium levels and IP production in 
vitro (239, 242, 243). Notably, the p.S707Y mutation is somatically acquired in 
Ibrutinib-resistant CLL and also inherited as a germline mutation in the immune 
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disorder APLAID (237). p.S707Y is an activating mutation that increases PLCγ2 
activity and downstream signalling by elevating intra-cellular calcium levels (236). 
Thus, PLCG2 mutations confer a BTK-independent resistance mechanism to 
Ibrutinib.  
The BTK p.C481S mutation and PLCγ2 p.R665W, p.S707Y and p.L845F mutations 
mediate gain-of-function implicating their role as drug-induced driver gene mutations 
that confer resistance to Ibrutinib, however this remains to be proved by reversing the 
effects using mutation-specific inhibitors. 
 
1.17 Hypothesis  
PLCG1 mutations frequently occur in mature T-cell lymphomas including CTCL, in 
which this gene is the most frequently mutated amongst TCR activation genes. PLCγ1 
plays a pivotal role in TCR signalling and activates key transcription factors including 
NFκB, which is constitutively active in CTCL. Therefore, this thesis hypothesises that 
PLCγ1 variants are true gain-of-function mutations that elevate TCR signalling and 
contribute to the molecular pathogenesis of SS. 
 
1.18 Aims 
To investigate the hypothesis that PLCγ1 variants are bona fide activating mutations 
that increase TCR signalling, this study aims to: 
1. Prioritise which of the nine PLCγ1 mutations (p.R48W, p.S312L, p.D342N, 
p.S345F, p.S520F, p.R1158H*, p.E1163K, p.D1165H and the in-frame indel 
p.VYEEDM1161V*) identified in SS tumours by our deep sequencing study and 
Kiel et al. (2015)*, should be taken forward for functional analyses (68, 147).  
2. Functionally interrogate the prioritised mutations to determine the influence on 
protein expression and activity by assaying proximal and downstream signalling 
and also investigate the efficacy of an IKKβ inhibitor to reduce NFκB activity. 
3. Investigate where the mutations map onto a 3D protein model and to optimise an 




Chapter 2 Materials and Methods 
2.1 Materials 
Table 2. 1. General reagents used for various techniques. 
Item Catalogue Number Manufacturer 
Ethanol absolute  20821.330 VWR Chemicals 
β-mercaptoethanol M3148 Sigma-Aldrich 
Isopropanol 109634 Merck 
 
Table 2. 2. DNA extraction kit for isolating DNA from frozen CD4+ enriched T-cells. 
Item Catalogue Number Manufacturer 
QIAamp DNA Blood Mini Kit 51104 Qiagen 
 
Table 2. 3. RNA extraction kit for isolating RNA from frozen CD4+ enriched T-cells.  
Item Catalogue Number Manufacturer 
RNeasy Plus Mini Kit 74134 Qiagen 
QIAshredder 79656 Qiagen 
 
Table 2. 4. Reverse Transcription kit. 
Item Catalogue Number Manufacturer 








Table 2. 5. Agarose gel electrophoresis and polymerase chain reaction (PCR) product 
clean-up reagents. 
Item Catalogue Number Manufacturer 
Agarose powder Bio-41025 
Bioline reagents 
Limited  
10x Tris-Borate-EDTA (TBE) EC-860 
National 
diagnostics 
Ethidium Bromide E1510 Sigma-Aldrich 
100 bp ladder CSL-MDNA-100BP 
Cleaver Scientific 
Ltd 







Table 2. 6. Ultracompetent bacterial culture reagents. 
Item Catalogue Number Manufacturer 
Sodium chloride  27810.295 VWR Chemicals 
Bacto tryptone 211705 BD Biosciences 
Bacto yeast extract 212750 BD Biosciences 
Bacto agar 214010 
BD Diagnostic 
Systems 
Ampicillin sodium salt A0166 Sigma-Aldrich 
Kanamycin sulfate  K1377 Sigma-Aldrich 
SOC Outgrowth Medium B9020S 
New England 
Biolabs UK Ltd 






Table 2. 7. Site-directed mutagenesis and plasmid DNA extraction kits used to isolate 
DNA from bacterial cultures. 
Item Catalogue Number Manufacturer 
QuikChange Lightning Site-




QIAprep Spin Miniprep Kit 27106 Qiagen 
HiSpeed Plasmid Midi Kit 12643 Qiagen 
HiSpeed Plasmid Maxi Kit 12662 Qiagen 
 
Table 2. 8. Cell culture reagents. 
Item Catalogue Number Manufacturer 
Dulbecco Modified Eagle Medium 
(DMEM), high glucose, GlutaMAX  
61965026 Gibco 
TrypLE™ Express Enzyme (1x), 
phenol red 
12605010 Gibco 
Fetal Bovine Serum (FBS) 51800-500 Biosera 
Penicillin-Streptomycin         
(10,000 U/mL) 
15140122 Gibco 
Phosphate Buffered Saline (PBS), 
pH 7.2 
20012-019 Gibco 
Opti-MEM I Reduced Serum 
Medium 
31985062 Gibco 
Hydrogen Peroxide Aseptic (35%) GPC2698 Atom Scientific 
Sodium Orthovanadate (Vanadate) P0758S 
New England Biolabs 
UK Ltd 







Table 2. 9. Cytokines and growth factors for cell culture. 
Item Catalogue Number Manufacturer 
Recombinant Human epidermal 
growth factor (EGF) protein 
PHG0314 Gibco 
Recombinant Human tumour 





Table 2. 10. Kits and reagents used to test cell cultures for Mycoplasma contamination. 
Item Catalogue Number Manufacturer 
PCR Master Mix M7501 
Promega 
Corporation 




Table 2. 11. Transfection reagents. 
Item Catalogue Number Manufacturer 
FuGENE HD Transfection Reagent E2311 
Promega 
Corporation 




Table 2. 12. Inhibitors used to treat cell cultures. 
Item Catalogue Number Manufacturer 







Table 2. 13. Western blotting reagents. 
Item Catalogue Number Manufacturer 
Amersham enhanced 
chemiluminescence (ECL) prime 
western blot detection reagent 
RPN2232 
GE Healthcare Life 
Sciences 








X-ray film RX NIF sheets  47410 19230 Fujifilm 
Pierce BCA protein assay kit 23227 Thermo Scientific 
Trizma Base T1503-1kg Sigma-Aldrich 
Trizma HCl T5941-500g Sigma-Aldrich 
Glycine G7126-5kg Sigma-Aldrich 
0.1% ponceau S (w/v) in 5% acetic 
acid 
P7170-IL Sigma-Aldrich 
Tween 20 P9416-100ml Sigma-Aldrich 





Methanol  20847.307 VWR Chemicals 
Polyvinylidene difluoride (PVDF) 














30% Acrylamide EC-201 National diagnostics 








Table 2. 14. Antibodies used for western blotting. 
Item Catalogue Number Manufacturer 
Rabbit monoclonal anti-PLCγ1 









Mouse monoclonal anti-Penta-His 34660 Qiagen 
Rabbit anti-β-Actin 4967 
Cell Signaling 
Technology 
Goat anti-rabbit IgG H&L (HRP) ab97051 Abcam 
Goat anti-mouse IgG H&L (HRP) ab6789 Abcam 
 
Table 2. 15. Immunofluorescence reagents. 
Item Catalogue Number Manufacturer 
13 mm diameter, No #1 round cover 
slides 
630-1597 VWR 






Phalloidin, CF568 00044-T Biotium 





0.8 – 1.0 mm microscope slides FB58626 Fisher Scientific  
 
Table 2. 16. Recipe for 250 mL of 1.5 M Tris buffer (pH 8.8) for western blotting. 
Reagent Quantity   Final concentration  
Tris base (Sigma-Aldrich) 45.41 g 1.5 M 
MilliQ water Dissolve in 200 ml -  
Adjust pH to 8.8 





Table 2. 17. Recipe for 250 mL of 1 M Tris buffer (pH 6.8) for western blotting. 
Reagent Quantity   Final concentration  
Tris base (Sigma-Aldrich) 30.29 g 1.5 M 
MilliQ water Dissolve in 200 ml -  
Adjust pH to 6.8 
MilliQ water Up to 250 mL -  
 
Table 2. 18. Recipe for 500 mL of 10x TBS buffer (pH 7.6) for western blotting. 
Reagent Quantity   Final concentration  
Sodium chloride (VWR) 40 g 1.4 M 
Trizma-Base (Sigma) 12.1 g 0.2 M 
MilliQ water Up to 500 mL -  
Adjust pH to 7.6 
 
Table 2. 19. Recipe for 400 mL of 1x TBS-Tween (TBS-T) buffer for western blotting. 
Reagent Quantity   Final concentration  
10x TBS 40 mL 1x 
MilliQ water 360 mL -  






 Patient samples  
All SS patients participating in this study had a diagnosis of primary Sézary Syndrome 
(de novo) and fulfilled the WHO classification of tumours of haematopoietic lymphoid 
tissues (6). All patients demonstrated an identical T-cell clone in peripheral blood and 
lesional skin by TCR gene rearrangement studies and were classified as blood stage 
B2. None of the patients received PUVA therapy before diagnosis. Tumour samples 
were obtained with informed consent from a national approved research tissue bank 
and blood samples were obtained from healthy volunteers (IRAS Project ID: 238203). 
The clinical outcomes of all 11 patients harbouring PLCG1 mutations are shown in 














Death related to lymphoma 
2 09/06/2009 Alive 
Allogenic haematopoietic stem cell 








Death due to disease 
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Death due to disease 
 
No association was found between the survival outcomes of patients harbouring 
PLCG1 mutations compared to those without mutations in this gene in our NGS study 
of 101 SS tumours (147). This may be due to a lack of power from a small sample set 
and analysis of a larger cohort of patients whose clinical outcomes and PLCG1 
mutation status are known would be more insightful. In particular, expansion of the 
integrated database of CTCL cases generated by Chang et al. (2018) may serve as a 




 DNA extraction from enriched CD4+ T-cells 
DNA was extracted from frozen enriched CD4+ T-cells from SS patients using the 
QIAamp DNA Blood Mini Kit (Qiagen) as per the manufacturer’s guidelines. DNA 
was eluted in 200 µL AE buffer and quantified using the Nanodrop ND-1000 
spectrophotometer. 
 RNA extraction from enriched CD4+ T-cells 
RNA was extracted from frozen enriched CD4+ T-cells from SS patients using the 
RNeasy Plus Mini Kit (Qiagen) as per the manufacturer’s guidelines. RNA was eluted 
in 30 µL RNase-free water and quantified using the Nanodrop ND-1000 
spectrophotometer. 
 Two-step Reverse Transcription-PCR  
Total RNA was extracted from enriched CD4+ T-cells as per section 2.2.3 and reverse 
transcribed to produce cDNA using the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems). Twenty microliter reactions were prepared as per Table 2. 
21 and subjected to the thermal conditions shown in Table 2. 22. cDNA was stored at 
-20°C. 
Table 2. 21. Reverse transcription reaction composition. 
Reagent Final concentration 
Volume                    
(20 µL reaction) 
10 x RT Buffer 1 x 2 µL 
25 x dNTP mix (100mM) 1 x 0.8 µL 
10 x RT Random primers 1 x 2 µL 
MultiScribe Reverse Transcriptase 50 units 1 µL 
Nuclease-free water - Variable 





Table 2. 22. Thermal cycling conditions for reverse transcription. 
Temperature Duration 
25°C 10 minutes 
37°C 120 minutes 
85°C 5 minutes 
 
 Targeted Capture Sequence alignment analysis 
Integrative Genomics Viewer (IGV) (257) was used to visualise and confirm the 
location of gene variants that had been detected by TCS and also to check the coverage 
of sequence reads at specified co-ordinates prior to validation by Sanger sequencing. 
 Primer design and optimisation 
Genomic (g)DNA and complementary (c)DNA sequences were obtained from the 
genome browser Ensembl (176) and the Primer3 software (258) was used to design 
PCR and Sanger sequencing primers. The specificity of primers to amplify the region 
of interest was analysed in silico using the Primer-Blast tool (259). The optimal 
annealing temperatures for primer pairs (Eurofins MWG) was determined by 
performing PCRs at different annealing temperatures using 20 – 50 ng gDNA or 1 – 
10 ng cDNA derived from the peripheral blood of healthy individuals or cell lines as 
a template. Five percent (v/v) DMSO (Agilent Technologies) was used in reactions 
containing GC-rich primers to prevent intra- and inter-strand re-annealing (260). 
 Polymerase Chain Reaction  
Fifteen microliter PCRs were prepared as per Table 2. 23 and subjected to the thermal 
conditions shown in Table 2. 24, using the optimal annealing temperatures specified 
in Table 2. 25 - Table 2. 28. gDNA or cDNA from the peripheral blood of healthy 
individuals or cell lines and nuclease-free water (Ambion) were used in positive and 




Table 2. 23. PCR composition. 
 
Table 2. 24. PCR thermal cycling conditions.  
Step Temperature Duration Cycles 
Initial denaturation 95°C 10 minutes 1 
Denaturation 94°C 30 seconds 
25 – 35 Annealing x°C 30 seconds 
Extension 72°C 1 minute 
Final extension 72°C 7 minutes 1 
Reagent Manufacturer Volume Final concentration 
10 x PCR Buffer II Applied Biosystems 1.5 µL 1 x 
25 mM MgCl2 Applied Biosystems 1.2 µL 2 mM 
10 mM dNTP VWR 0.3 µL 0.2 mM 
10 µM Forward primer Eurofins MWG 0.15 µL 0.1 µM 
10 µM Reverse primer Eurofins MWG 0.15 µL 0.1 µM 
AmpliTaq Gold DNA 
polymerase 
Applied Biosystems 0.075 µL 0.375 Units 




0.75 µL 5% (v/v) 
DNA/ cDNA - Variable 20-50 ng/ 1-10 ng 
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Table 2. 25. gDNA primers for PCR amplification and Sanger sequencing to validate PLCG1 mutations. 
Primer name Sequence (5' to 3') 









c.C142T p.R48W 316 bp 60°C 
PLCG1_C142T_R GTGGGCGCACTTACTGGC 
PLCG1_C935T_F AGCACTCTCTCTCCTACCCC 
c.C935T p.S312L 207 bp 64°C 
PLCG1_C935T_R TGTTGTGCGAGGAGGAGATC 




310 bp 59°C 
PLCG1_3_R CACACTCAATGCAGCGACAG 
PLCG1_C1559T_F GACCCTGGCTCACAAGTCC 
c.C1559T p.S520F 227 bp 60°C 
PLCG1_C1559T_R CCTGTCAGGGGAAGGCAA 









Table 2. 26. cDNA primers for PCR amplification and Sanger sequencing to validate PLCG1 mutations. 










c.C142T p.R48W 379 bp 60°C 
PLCG1_ cDNA_C142T_R AGCTGGGTCCTCTTGATAGC 






243 bp 62°C 
PLCG1_ cDNA_C935T_R TCCCAGCAGTCCAACTCAAT 
PLCG1_cDNA_C1559T_F ACTCTGAGAACGACATCAGCA 
c.C1559T p.S520F 219 bp 58°C 
PLCG1_ cDNA_C1559T_R TCCCATGGAACCACTTCTCA 




179 bp 61°C 





Table 2. 27. Sanger sequencing primers used to sequence the open reading frame (ORF) of PLCγ1 plasmids. These primers were also used to PCR 
amplify and sequence the PLCG1 ORF from the SeAx, HUT-78, MyLa and Jurkat cell lines. 
Primer name Sequence (5' to 3') Target exons Amplicon size Annealing Temperature  
PLCG1_cDNA_1_F CCTCAGCCCCAACCTCAG 
1 – 3  493 bp 64°C 
PLCG1_cDNA_1_R GCCCTTGATCCACATGTTCA 
PLCG1_cDNA_2_F CCTGAAAACGCTGAGCCTG 
2 – 10 590 bp 65°C 
PLCG1_cDNA_2_R GCGAGTTCCACACACTGTTC 
PLCG1_cDNA_3_F CTTCCTCCGAGACCCCTTAC 
9 – 14 568 bp 55°C 
PLCG1_cDNA_3_R CTCAGCCAGCTTCTTGTGC 
PLCG1_cDNA_4_F CCCTCACCCAACCAGCTTAA 
13 – 17 600 bp 57°C 
PLCG1_cDNA_4_R AAACTCATTACAGCGCAGGG 
PLCG1_cDNA_5_F GTATCCACTCCCGGCAAGAT 
17 – 21 593 bp 55°C 
PLCG1_cDNA_5_R CCTCTGGGCCTTGTAGTCAA 
PLCG1_cDNA_6_F ACGCAACCCTGGCTTCTAT 
20 – 25 571 bp 57°C 
PLCG1_cDNA_6_R TTCATCAAAGGGAACAGGCC 
PLCG1_cDNA_7_F CCCTGGAGCTCTCTGAACTT 
25 – 29 599 bp 63°C 
PLCG1_cDNA_7_R GATCTGGAAGTGGAAGGGCT 
PLCG1_cDNA_8_F GGAGATTGAGGTGGCTGGAG 




Table 2. 28. PCR and Sanger sequencing primers used to sequence the PLCG1 exons from gDNA of ATLL cell lines.  
Primer name Sequence (5' to 3') Target exons Amplicon size Annealing Temperature  
PLCG1_cDNA_C142T_F CCTCAGCCCCAACCTCAG 
1 379 bp 58°C 
PLCG1_ cDNA_C142T_R AGCTGGGTCCTCTTGATAGC 
PLCG1_Ex2-4_F GAATGAGGAAACCAGGCTGC 
2 – 4 695 bp 61°C 
PLCG1_Ex2-4_R CTGGCTAAGGTTCTGGATGC 
PLCG1_Ex5-7_F CCACAGGTCAGAGGTCATGA 
5 – 7 672 bp 61°C 
PLCG1_Ex5-7_R ATCAAGAATCGCCCAGTGGA 
PLCG1_Ex8-10_F GGCAGTGGGAGTAGGGAAC 
8 – 10 848 bp 61°C 
PLCG1_Ex8-10_R CTGGATAGGCAAGGAGAGGC 
PLCG1_Ex11-12_F AGCACTCTCTCTCCTACCCC 
11 – 12 655 bp 61°C 
PLCG1_Ex11-12_R AGTCTTTCTGCCCTCTGTCC 
PLCG1_Ex13-15_F CACTGTGAGGGGCTACTTAGA 
13 – 15 826 bp 61°C 
PLCG1_Ex13-15_R TCCCATGGAACCACTTCTCA 
PLCG1_Ex16-17_F CAACGAGGATGAGGAGGAGC 




Table 2. 28. Continued. 
Primer name Sequence (5' to 3') Target exons Amplicon size Annealing Temperature  
PLCG1_Ex18-19_F AGCAAAGAGTGAGGGAAGGG 
18 - 19 573 bp 61°C 
PLCG1_Ex18-19_R CAACACACCAGGTCTTGCTG 
PLCG1_Ex20_F TCCAGAAACCAGTAGCTGCT 
20 233 bp 61°C 
PLCG1_Ex20_R AGATGGCCCAGAACACAGAA 
PLCG1_Ex21-23_F GCTCTGACTGGTGCTTCTCA 
21 - 23 816 bp 61°C 
PLCG1_Ex21-23_R GGGCAAGAGAAACAGATGGG 
PLCG1_Ex24_F TGAGATGTCTATTCCCAGCTGT 
24 398 bp 61°C 
PLCG1_Ex24_R ACACAACCTAAACACACCACA 
PLCG1_Ex25-27_F CTACAGGGCCTTGTGTGTGT 
25 - 27 820 bp 61°C 
PLCG1_Ex25-27_R TGACCACCTTGATGCCTGAA 
PLCG1_Ex28-30_F AATTGGAGGGAGCAGGAAGG 
28 - 30 694 bp 61°C 
PLCG1_Ex28-30_R CTGGCTCTCCTCCCACCTA 
PLCG1_Ex31-32_F AGAAGTGCAGAGGAGTCATTG 




 Agarose gel electrophoresis  
Two percent and 0.8% (w/v) agarose gels were made by dissolving 2 g or 0.8 g agarose 
powder (VWR) in 100 mL 1x TBE buffer (National Diagnostics), respectively and 
supplemented with 0.5 µg/mL ethidium bromide (Sigma). PCR products (3 μL) or 100 
ng plasmid DNA were mixed with 3 μL glycerol loading dye and analysed adjacent to 
5 μL of 100 bp molecular weight marker (Cleaver Scientific Ltd) or 1 kb DNA ladder 
(Thermo Fisher Scientific), respectively. Gels were immersed in 1x TBE buffer and a 
voltage of 180 V was applied to separate DNA fragments by molecular weight. Gels 
were visualised with a UV transilluminator and the GelDoc-ITTM imaging system 
(UVP). 
 Sanger sequencing 
PCR products were purified using the ExoSAP-IT enzyme (Affymetrix) that was 
diluted in a 1:24 ratio with nuclease-free water (Ambion). Reactions were warmed to 
37°C for 30 minutes to facilitate enzyme activity and then heated to 80°C for 15 
minutes to inactivate the enzyme. Purified PCR products or 300 ng plasmid DNA were 
sent to Source Bioscience (Cambridge) for Sanger sequencing with aliquots of 3.2 µM 
forward and reverse primers (Table 2. 25 – Table 2. 28). Sequencing data files were 
analysed using the FinchTV software (version 1.4; Geospiza) or the Sequencher 
software (version 4.9; Gene Codes Corporation). PCR products of DNA amplified 
from the peripheral blood of a healthy control individual were used to obtain wild-
type sequences for the chromatograms shown in Chapter 3. 
 Cell line DNA and cDNA 
Stocks of cDNA from the SeAx, HUT-78, MyLa and Jurkat cells lines were available 
in our research group. gDNA from 19 ATLL cell lines (CY-6, USH'2, UR1, OGF20, 
MKI-1, KAW2, EE8, OKA3, YGS13, JSH4, HAM9, YK8, KOB, KKI, SO4, LMY1, 
LMY2, LMWT5 and HUT102) was kindly provided by Professor Matilda Katan 
(University College London; UCL). MT2 cell line gDNA was gifted by Professor 




 Pathogenicity predictions 
The pathogenicity prediction algorithms Sorting Intolerant from Tolerant (SIFT) 
(153), Protein Variation Effect Analyzer (Provean) (154), Polymorphism Phenotyping 
(PolyPhen2) (155), Mutation Taster (156), MutPred2 (157) and Combined Annotation 
Dependent Depletion (CADD) (158) were used to predict the potential effect of 
PLCG1 variants on the protein level. Damaging, deleterious, probably damaging or 
disease-causing variants are predicted to affect the protein structure and/ or function, 
whereas neutral, benign or tolerated variants are unlikely to have an impact on the 
protein. A consensus conclusion was drawn from 5/6 algorithms for missense 
mutations. The PolyPhen2 and MutPred2 algorithms cannot predict the likely effect 
of indels on the protein, therefore a consensus was drawn for p.VYEEDM1161V from 
3/4 of the remaining algorithms. 
 Mapping mutations to the functional protein domains 
PLCG1 variants were mapped to the PLCγ1 and PLCγ2 protein domains based on the 
amino acid numbering and protein domain schematics published by Bunney et al. 
(2012) and Liu et al. (2015) respectively (194, 243). 
 Mapping mutations to the PLCγ2 crystal structure  
Mapping of the PLCγ1 mutations onto a composite structure of the closely related 
PLCγ2 isozyme was performed by Dr. Katie Everett (University of Cambridge) as 
follows: The 3D model of the full length PLCγ protein was generated using the 
structure of PLCγ2 to represent the core of PLCγ. PLCγ2 structures were obtained 
from the Protein Data Bank (PDB) for the spPH (PDB: 2K2J), nSH2 (PDB: 2DX0), 
cSH2 (PDB: 2EOB) and SH3 (PDB: 2EQI) domains. The structure of the tandem SH2 
domains from PLCγ1 (PDB: 3GQI) were used to arrange these domains relative to 
each other. Docking of the domains to the TIM barrel was carried out using the 
ClusPro web-server (261, 262). The two SH2 domains were docked with the catalytic 
domain and then the spPH domain was added to this complex, followed by the SH3 
domain. At each stage the most likely conformation was chosen based on biochemical 
data. The models were analysed using DeepView-Swiss-PdbViewer and the Pymol 
molecular visualisation software (263, 264). PLCγ1 mutations were subsequently 
mapped to this model. 
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 Phylogenetic conservation analysis 
To determine whether the amino acids changed by the mutations are evolutionarily 
conserved, the PLCγ1 protein sequences from 12 vertebrate species (human, chimp, 
monkey, mouse, rabbit, dog, horse, elephant, chicken, lizard, frog and zebrafish) were 
obtained from the genome browser Ensembl and aligned using the multiple sequence 
alignment software Clustal Omega (265). The human PLCγ1 and PLCγ2 protein 
sequences were aligned with Clustal Omega to identify the PLCγ2 residues that 
correspond to the PLCγ1 amino acids altered by mutations. The conservation analysis 
was repeated for these PLCγ2 residues in the same vertebrate species. 
 Determining the PLCG1 mutation frequency in mature T-cell lymphomas 
The frequency of somatic PLCG1 mutations in mature T-cell lymphomas was 
obtained by filtering for variants identified in haematopoetic and lymphoid tissue in 
the COSMIC database (Version 87).  
The following analyses were performed by Dr. Christine Jones (KCL). To determine 
the frequency of PLCG1 mutations per disease subtype, the PubMed database was 
searched to identify publications incorporating the WHO classification of T-cell 
lymphomas: adult T-cell leukaemia/lymphoma, anaplastic large cell lymphoma, 
angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, 
extra-nodal natural killer /T-cell lymphoma (nasal type), hepatosplenic T-cell 
lymphoma, lymphomatoid papulosis, Mycosis Fungoides / Sézary Syndrome, 
peripheral T-cell lymphoma-not otherwise specified, primary cutaneous anaplastic 
large cell lymphoma, primary cutaneous CD30-positive T cell lymphoproliferative 
disorders, T-cell large granular lymphocyte leukaemia or T-cell prolymphocytic 
leukaemia in combination with either the term “next generation sequencing” or 
“whole-exome sequencing”. The resulting publications and corresponding 
supplementary data were interrogated for PLCG1 mutations. 
 Plasmids 
The PLCγ1-pTriEx-4 and eGFP-PLCγ1 vectors, which encode the full length wild-
type human PLCG1 cDNA, with the latter containing a GFP tag, were kindly provided 
by Professor Matilda Katan (UCL). These vectors were used as templates to create 
mutant PLCγ1 constructs by site-directed mutagenesis. The pGL3-NFκB-firefly 
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luciferase reporter plasmid (which contains five NFκB response elements: 
GGGGACTTTCCC), the pGL3-AP-1-firefly luciferase construct (that encompasses 
three AP-1 binding motifs: TGACTCA) and the transfection control pRL-TK-renilla 
luciferase vector were a kind gift from Dr. Susan John (KCL). The pGL3-NFAT-
firefly luciferase reporter construct that harbours three NFAT response elements 
(AGGAAAAACTGTTTCA) was purchased from the Addgene repository (#17870). 
The pBABE-EGFR construct was kindly provided by Professor Mahvash Tavassoli 
(KCL). Table 2. 29 lists all the plasmids used in this study. The primers used to 
sequence the regulatory regions of the plasmid including the cytomegalovirus (CMV) 
enhancer and promoter, T7 and P10 promoters and polyA tail are listed in Table 2. 30. 
The primers used to confirm the transcription factor binding sites in the reporter 
plasmids and the EGFR sequence in the pBABE-EGFR vector are listed in Table 2. 
31. Plasmid features were visualised using the SnapGene Viewer software (version 
2.7.2 from GSL Biotech; available at snapgene.com), as shown for the PLCγ1-pTriEx-





























Table 2. 29. Plasmids used in this study. Full Length (FL); human (h). Ampicillin (Amp), Kanamycin (Kan) Professor Matilda Katan (MK), Varsha 
M. Patel (VMP), Dr. Antoinette Yoxall (AY), Dr. Susan John (SJ) and Professor Mahvash Tavassoli (MT). 




WT FL hPLCG1 wild-type cDNA pTriEx-4 Amp MK 
R48W FL hPLCG1 cDNA: c.C142T mutant pTriEx-4 Amp VMP 
S312L FL hPLCG1 cDNA: c.C935T mutant pTriEx-4 Amp VMP 
D342N FL hPLCG1 cDNA: c.G1024A mutant pTriEx-4 Amp VMP 
S345F FL hPLCG1 cDNA: c.C1034T mutant pTriEx-4 Amp MK 
S520F FL hPLCG1 cDNA: c.C1559T mutant pTriEx-4 Amp MK 
Y783F FL hPLCG1 cDNA: c.A2348T mutant pTriEx-4 Amp MK 
R1158H FL hPLCG1 cDNA: c.G3473A mutant pTriEx-4 Amp AY 
E1163K FL hPLCG1 cDNA: c.G3487A mutant pTriEx-4 Amp VMP 
D1165H FL hPLCG1 cDNA: c.G3493C mutant pTriEx-4 Amp VMP 
VYEEDM1161V FL hPLCG1 cDNA: c.GTGTATGAGGAAGACAdelG mutant pTriEx-4 Amp AY 
S345F-Y783F FL hPLCG1 cDNA: c.C1034T & c.A2348T mutant pTriEx-4 Amp VMP 
S520F-Y783F FL hPLCG1 cDNA: c.C1559T & c.A2348T mutant pTriEx-4 Amp VMP 
E1163K-Y783F FL hPLCG1 cDNA: c.G3487A & c.A2348T mutant pTriEx-4 Amp VMP 
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Table 2. 29. Continued 




eGFP-WT FL hPLCG1 wild-type cDNA & GFP tag pEGFP-C1 gateway Kan MK 
eGFP-D342N FL hPLCG1 cDNA: c.C1024T mutant; GFP tag pEGFP-C1 gateway Kan VMP 
eGFP-S345F FL hPLCG1 cDNA: c.C1034T mutant; GFP tag pEGFP-C1 gateway Kan VMP 
eGFP-S520F FL hPLCG1 cDNA: c.C1559T mutant; GFP tag pEGFP-C1 gateway Kan VMP 
eGFP-Y783F FL hPLCG1 cDNA: c.A2348T mutant; GFP tag pEGFP-C1 gateway Kan VMP 
eGFP-E1163K FL hPLCG1 cDNA: c.G3487A mutant; GFP tag pEGFP-C1 gateway Kan VMP 
eGFP-D1165H FL hPLCG1 cDNA: c.G3493C mutant; GFP tag pEGFP-C1 gateway Kan VMP 
eGFP-VYEEDM1161V 
FL hPLCG1 cDNA: c.GTGTATGAGGAAGACAdelG mutant; 
GFP tag 
pEGFP-C1 gateway Kan VMP 
pGL3-NFAT-luciferase 3x AGGAAAAACTGTTTCA NFAT response elements  pGL3 Amp Addgene 
pGL3-NFκB-luciferase 5x GGGGACTTTCCC NFκB response elements pGL3 basic Amp SJ 
pGL3-AP-1-luciferase 3x TGACTCA AP-1 response elements pGL3 basic Amp SJ 
pRL-TK-luciferase Renilla Thymidine Kinase Luciferase Reporter pRL-TK Amp SJ 
pBABE-EGFR EGF receptor pBABE Amp MT 
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Table 2. 30. Sanger sequencing primers used to sequence the regulatory regions of 
plasmids. The CMV and polyA tails of the pTriEx4-PLCγ1 and eGFP-PLCγ1 
plasmids were sequenced. The CMV promoter and enhancer sequences in all plasmids 
were verified using the pTriEx4_PLCG1_CMV primer pair. The T7 and P10 
promoters were sequenced in the pTriEx4-PLCγ1 vectors and the GFP tag in the 
eGFP-PLCγ1 plasmids. 





pTriEx4_PLCG1_T7_P10_F     TGCTGTCTCATCATTTTGGCA 





Table 2. 31. Sanger sequencing primers used to confirm key characteristics in vectors. 
The sequence of transcription factor binding sites in the reporter plasmids, the 
chimeric intron in the Renilla transfection control plasmid and the EGFR sequence in 
the pBABE-EGFR vector were analysed. 












pRLTK_C_intron_R     CTTTCGAAGTCATGGTGGCT 
EGFR_RTPCR_2F       
pBABE-EGFR 
CCAAGGCACGAGTAACAAGC 




 Luria–Bertani (LB) medium and LB-agar plates 
LB medium and LB-agar medium were made as per Table 2. 32 and Table 2. 33, 
respectively and sterilised by autoclaving at 121°C for 20 minutes. The LB-agar 
medium was cooled to approximately 50°C before an Ampicillin or Kanamycin 
solution (both Sigma-Aldrich) was added to a final concentration of 50 μg/mL. The 
LB-agar medium was poured into sterile petri dishes and allowed to set before storing 
at 4°C. 
Table 2. 32. Recipe for 400 mL of LB medium for bacterial cultures. 
Reagent Quantity   Final concentration  
Sodium chloride (VWR) 4 g 1% (w/v) 
Bacto trypton (BD Biosciences) 4 g 1% (w/v) 
Bacto yeast extract (BD Biosciences) 2 g 0.5% (w/v) 
MilliQ water Up to 400 mL -  
 
Table 2. 33. Recipe for 400 mL of LB-agar for bacterial culture plates. 
Reagent Quantity   Final concentration  
Sodium chloride (VWR) 4 g 1% (w/v) 
Bacto trypton (BD Biosciences) 4 g 1% (w/v) 
Bacto yeast extract (BD Biosciences) 2 g 0.5% (w/v) 
MilliQ water Up to 400 mL -  
Bacto agar (BD Biosciences) 6 g 1.5% (w/v) 
 
 Site-directed mutagenesis  
The PCR-based mutagenesis reactions were prepared as per Table 2. 34 using the 
QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). Salt-
free mutagenesis primers (Eurofins MWG) used to introduce the nucleotide changes 
are listed in Table 2. 35 and the thermal cycling conditions shown in Table 2. 36. 
Mutagenesis reaction products were treated with 2 µL endonuclease Dpn I for 5 
minutes at 37°C to digest methylated and hemimethylated wild-type template DNA. 
109 
 
XL-10 Gold Ultracompetent cells were transformed with the plasmids as per the 
mutagenesis kit manual. Fifty microliters of transformed cells were diluted in 200 µL 
nutrient-rich Super Optimal broth with Catabolite repression (SOC) medium (New 
England Biolabs) and spread on LB-agar plates that contained either 50 µg/mL 
Ampicillin or Kanamycin, to select for cells successfully transformed with the 
plasmids that encode antibiotic resistance genes. Plates were incubated at 37°C for 16 
hours.  
 
Table 2. 34. Site-directed mutagenesis reaction composition. Reactions were set up as 
per the QuikChange Lightning Site-Directed Mutagenesis Kit manual. *DMSO was 
added to the reactions that contained GC-rich primers, namely for the production of 
the PLCγ1-R48W, PLCγ1-S312L and PLCγ1-D342N plasmids. 
Reagent Volume (51 µL reaction) 
10 x reaction buffer 5 µL 
dNTP mix 1 µL 
100 ng dsDNA template Variable 
Forward primer (125 ng/µL) 1 
Reverse primer (125 ng/µL) 1 
QuikSolution reagent 1.5 µL 
DMSO* 2.5 µL 
Nuclease-free water (Ambion) Variable 




Table 2. 35. Primers for site-directed mutagenesis. Underlined bases indicate mutant nucleotides introduced during the reaction. 



































Table 2. 36. Thermal cycling conditions for site-directed mutagenesis reactions. The 
duration of the extension step varied based on the size of the vector and was calculated 
as per the manufacturer’s protocol (30 seconds per kb of plasmid).   
Step Temperature Duration Cycles 
Initial denaturation 95°C 2 minutes 1 
Denaturation 95°C 20 seconds 
18 
Annealing 60°C 10 seconds 
Extension 68°C 
4min 36sec for pTriEx-4 vector 
(9.2 kb) 
or 
4min 21sec for eGFP- vector 
(8.69 kb)  
Final extension 68°C 5 minutes 1 
 
 Bacterial cultures  
Individual bacterial colonies were inoculated in 5 mL LB medium supplemented with 
50 µg/mL Ampicillin or Kanamycin for 16 hours at 37°C with shaking at 180 rpm. 
Bacterial cultures were centrifuged at 3,000 rpm for 10 minutes at 4°C and cell pellets 
were either frozen at -20°C or used immediately for plasmid DNA isolation. 
Alternatively, 5 mL starter cultures were incubated for 8 hours at 37°C with shaking 
at 180 rpm before adding a 1:100 dilution of the culture to 50 mL or 1:500 dilution to 
150 mL LB medium supplemented with 50 µg/mL Ampicillin or Kanamycin. Cultures 
were grown for 16 hours at 37°C with shaking at 180 rpm. Cultures were centrifuged 
at 4,500 rpm for 15 minutes at 4°C and cell pellets were either frozen at -20°C or used 
immediately for plasmid DNA isolation 
 Glycerol stocks 
Glycerol stocks of bacterial cultures were made by mixing 250 µL of 80% (v/v) sterile 
glycerol (Sigma-Aldrich) with 750 µL of bacterial culture and stored at -80°C. 
 Streaking glycerol stocks 
To grow single colonies, 1 µL of bacterial glycerol stocks were diluted in 49 µL LB 




 Plasmid DNA isolation  
Plasmid DNA was isolated from 5 mL, 50 mL and 150 mL bacterial cell pellets using 
the QIAprep Spin Miniprep Kit, the HiSpeed Plasmid Midi Kit and the HiSpeed 
Plasmid Maxi Kit, respectively according to the manufacturer’s guidelines. Plasmid 
DNA was eluted in 30 µL EB buffer when isolated using the QIAprep Spin Miniprep 
Kit and in 1 mL TE buffer when extracted using the larger kits. DNA concentrations 
were quantified using the Nanodrop ND-1000 spectrophotometer and plasmids were 
stored at -20°C. 
 Cell line cultures 
 Cell lines  
HEK293 cells, a Human embryonic kidney cell line, was kindly provided by Dr. 
Francesca Capon (KCL). COS-7 cells, a monkey fibroblast-like cell line was cultured 
and used for experiments by Dr. Marta Martins (Instituto de Medicina Molecular, 
Portugal). HeLa cells, a cervical cancer cell line was a kind gift from Professor Maddy 
Parsons (KCL). All cultures were maintained at 37°C, 5% CO2 and 95% humidity in 
T75 flasks (Corning Incorporated). 
 Reviving frozen cells and maintaining cell cultures 
Frozen cell lines were thawed at 37°C for 1 minute and then centrifuged at 1,500 rpm 
for 5 minutes at 22°C. After washing with 1 mL PBS (Gibco), cells were re-suspended 
in 10 mL complete DMEM medium (Gibco) composed of DMEM supplemented with 
10% (v/v) FBS (Biosera), 100 Units/mL Penicillin and 100 μg/mL Streptomycin 
(Gibco). Cells were sub-cultured twice a week by washing with 5 mL PBS and 
dissociation with 2.5 mL Trypsin (Gibco). 
 Freezing cell line cultures  
Cells in the log phase of growth were frozen at a density of 1 – 3 x 106 cells/mL in 
freezing medium composed of 90% (v/v) FBS supplemented with 10% (v/v) DMSO 
that was filter sterilised. Cells were stored in cryogenic vials at -80°C before being 





 Mycoplasma testing  
Cell line cultures were routinely tested and confirmed to be free from Mycoplasma 
contamination using the techniques described in section 2.2.23.1 – 2.2.23.2. 
 PCR-based Mycoplasma testing 
Cell supernatants were pre-heated at 95°C for 5 minutes and then added to PCRs 
prepared as per Table 2. 37 (266). Negative and positive control reactions contained 
2.5 μL sterile water or Mycoplasma-containing supernatant, respectively. Reactions 
were subjected to the thermal conditions shown in Table 2. 38. PCR products were 
analysed by agarose gel electrophoresis as per section 2.2.8.  
Table 2. 37. Mycoplasma PCR composition. 
 
Table 2. 38. PCR thermal cycling conditions for Mycoplasma testing of cell lines. 
Step Temperature Duration Cycles 
Initial denaturation 94°C 2 minutes 1 
Denaturation 94°C 1 minute 
40 Annealing 55°C 1 minute 
Extension 72°C 2 minutes 





2x PCR Master Mix (Promega Corporation) 6.25 µL 1 x 
GPO-3 forward primer (Eurofins MWG) 
5’ GGGAGCAAACAGGATTAGATACCCT 3’ 
0.25 µL 5 µM 
MGSO reverse primer (Eurofins MWG) 
5’ TGCACCATCTGTCACTCTGTTAACCTC 3’ 
0.25 µL 5 µM 
Nuclease-free water 3.25 µL - 




 Biotool Mycoplasma Detection QuickTest kit 
The Biotool Mycoplasma Detection QuickTest kit was used as per the manufacturer’s 
guidelines. The kit indicates the presence of Mycoplasma metabolites based on a 
visual colourimetric analysis. 
 Transfection of HEK293 cells for western botting 
HEK293 cells were seeded at a density of 4 x 105 cells in 2 mL complete DMEM in 
6-well plates. After 24 hours, the FuGENE HD Transfection Reagent (Promega 
Corporation) and the PLCγ1-pTriEx-4 plasmids were diluted in a 1.5 μL:0.5 μg ratio 
in Opti-MEM I Reduced Serum Medium (Gibco) to a final volume of 100 µL. TE 
buffer was used as a vehicle control for transfections. FuGENE-DNA complexes were 
allowed to form during a 15 minute incubation at room temperature and then added 
dropwise to cells before incubating at 37°C.  
 Pervanadate treatment of HEK293 cells for western blotting 
A 30mM stock of pervanadate, a protein-tyrosine phosphatase inhibitor, was made as 
per Table 2. 39. The stock was sterilised through a 0.2 micron filter and incubated at 
room temperature for 15 minutes in the dark. The stock was then diluted to 1 mM in 
serum-containing DMEM and added to cell cultures at a final concentration of 100 
µM. Cells were treated with pervanadate 23 hours after transfection for 1 hour to 
stabilise PLCγ1 phosphorylation (213). Cells were immediately harvested by 
detachment with Trypsin and centrifugation at 6,000 rpm for 5 minutes at 22°C. Cell 
pellets were washed in 100 µL PBS and centrifuged again before storing at -80°C.  
Table 2. 39. Recipe for 0.3 mL of 30 mM Pervanadate. 
Reagent Quantity   Final concentration  
Sodium orthovanadate (New England 
Biolabs UK Ltd) 
90 μL 30 mM 
Hydrogen Peroxide (Atom Scientific) 1.54 μL 0.18% (w/w) 






 Co-transfection of HEK293 cells for luciferase reporter assays 
HEK293 cells were co-transfected with PLCγ1-pTriEx-4 vectors, NFκB-, NFAT- or 
AP-1-firefly luciferase reporter plasmids and the Renilla transfection control construct 
as described by Vaqué et al. (2014) (160). Briefly, 8 x 104 cells were seeded in 0.5 mL 
complete DMEM medium in 24-well plates. After 24 hours, 50 ng pRL-TK, 100 ng 
firefly luciferase reporter constructs, 1 µg of PLCγ1-pTriEx-4 vectors or TE buffer 
(vehicle control), 3 µL Lipofectamine LTX and 1 µL Plus Reagent (Life 
Technologies) were diluted in Opti-MEM I Reduced Serum Medium to a final volume 
of 100 µL and incubated at room temperature for 10 minutes. The DNA-lipofectamine 
complexes were added drop-wise to cells and incubated at 37°C. After 4 hours, cells 
were starved in 0.5 mL serum- and antibiotic-free DMEM to remove any growth 
factors in the media that can activate PLCγ1. After 16 hours, cells were washed in 100 
µL PBS and lysed in 100 µL passive lysis buffer (PLB) provided in the Dual-
Luciferase Reporter Assay System kits (Promega Corporation). Lysates were used 
immediately to measure luminescence levels or stored at -80°C.  
 EGF stimulation of HEK293 cells for luciferase reporter assays 
For cells to be analysed in stimulated conditions, HEK293 cells were additionally co-
transfected with 0.75 µg of the pBABE-EGFR plasmid as the cells endogenously 
express the EGF receptor at low levels (267, 268). After serum starving for 16 hours, 
cells were stimulated with 100 ng/mL EGF for 8 hours, washed with PBS and lysed 
as described in section 2.2.27.  
 Extraction of whole-cell lysates for western blotting 
Complete RIPA buffer (Santa Cruz Biotechnology) was prepared as per Table 2. 40 
and used to lyse cell pellets that were either freshly harvested or stored at -80°C. 
Lysates were chilled on ice for 20 minutes and then centrifuged at 13,000 rpm for 10 






Table 2. 40. Recipe for 1 mL of complete RIPA buffer for whole-cell lysates. All 
reagents were purchased from Santa Cruz Biotechnology. 
Reagent Quantity   Final concentration  
1x RIPA lysis buffer 0.96 mL 1x 
Phenylmethylsulfonyl fluoride (PMSF) 0.01 mL 2 mM 
Sodium othovanadate 0.01 mL 1 mM 
Protease inhibitor cocktail 0.02 mL 2% (v/v) 
 
 Protein quantification 
The protein concentration of whole-cell lysates was quantified using the Pierce BCA 
protein assay kit (Thermo Scientific) as per the manufacturer’s guidelines. Briefly, 
BSA protein standards were diluted in complete RIPA buffer and the BCA working 
reagent was made by mixing reagent A and reagent B in a 50:1 ratio. Two hundred 
microliters of working reagent were added to 10 µL BSA protein standards or cell 
lysates, mixed thoroughly and incubated at 37°C for 30 minutes. BSA protein 
standards were quantified in triplicates to determine the mean absorbance at 562 nm 
using the FLUOstar Omega plate reader (BMG Labtech) and MARS data analysis 
software. Based on the absorbance and concentration of each protein standard, a 
standard curve was produced using linear regression. The standard curve was used to 
infer the concentration of each lysate, measured in duplicates. 
 Western blotting 
Whole-cell lysates were mixed with 4x Laemmli sample buffer (Bio-Rad Laboratories 
Incorporated) that was supplemented with 10% (v/v) β-Mercaptoethanol (Sigma). 
Lysates were denatured at 95°C for 10 minutes. Protein extracts (10 μg) were loaded 
onto 10% gels made as per Table 2. 41 alongside 7 µL of the Precision plus protein 
dual color standard (Bio-Rad Laboratories Incorporated). Gels were immersed in 1x 
running buffer (25 mM Trizma-Base, 192 mM Glycine and 0.1% (v/v) SDS) that was 
made by diluting 10x buffer (made as per Table 2. 42) in a 1:9 ratio. A voltage of 135 
V was applied for 2 hours to separate proteins by molecular weight. Proteins were 
electro-transferred onto methanol-primed 0.2 μm PVDF membranes (Roche 




Table 2. 43. Membranes were blocked with 5% blocking buffer made as per Table 2. 
44 for up to 2 hours. Membranes were incubated in the primary antibodies: rabbit 
monoclonal anti-PLCγ1 (1:20,000), mouse monoclonal anti-penta-His-tag (1:2,000 
and 1:5,000), rabbit polyclonal anti-Tyr783-phospho-PLCγ1 (p-PLCγ1; 1:50,000) and 
rabbit polyclonal anti-β-Actin (1:10,000) at 4°C overnight or at room temperature for 
up to 2 hours. Antibodies detecting total or phosphorylated proteins were diluted in 
5% milk or 5% BSA blocking buffer, respectively. After washing with TBS-T, 
membranes were incubated in HRP-linked goat anti-rabbit IgG H&L (1:5,000 – 
1:10,000) or goat anti-mouse IgG H&L (HRP; 1:5,000) for up to 2 hours at room 
temperature. Membranes were washed and protein expression detected with The 
Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare Life 
Sciences). Membranes were exposed to X-ray films (Fujifilm) and chemiluminescent 
signals were developed with a medical film processor (SRX-101A, Konica Minolta).  






MilliQ water 4.0 2.1 
30% (w/v) Acrylamide (National 
diagnostics) 
3.3 0.5 
1.5 M Tris-HCl pH 8.8 2.5 - 
1 M Tris-HCl pH 6.8 - 0.38 
10% (w/v) SDS (Bio-Rad Laboratories 
Incorporated) 
0.10 0.03 
10% (w/v) APS 0.10 0.03 
TEMED (Sigma-Aldrich) 0.004 0.003 
 
Table 2. 42. Recipe for 1 litre of 10x running buffer for western blotting. 
Reagent Quantity  Final concentration  
Trizma-Base (Sigma) 30.2 g 250 mM 
Glycine (Sigma) 144 g 1.92 M 
10% (w/v) SDS 100 mL 1% (v/v) 




Table 2. 43. Recipe for 1 litre of 1x transfer buffer for western blotting. 
Reagent Quantity   Final concentration  
Trizma-Base (Sigma) 3 g 25 mM 
Glycine (Sigma) 14.4 g 192 mM 
MilliQ water Up to 800 mL  -  
Methanol (VWR) 200 mL 0.2% (v/v) 
 
Table 2. 44. Recipe for 5% (w/v) of blocking buffer for western blotting. 
Reagent Quantity   Final concentration  
1x TBS-T 40 mL 1x 
Milk or BSA 2 g 5% 
 
 Optimisation of HEK293 transfection and antibody dilution for western 
blotting 
To optimise the transfection of HEK293 cells, different ratios of the FuGENE reagent 
and DNA concentrations (3µL:1µg, 6µL:1µg, 3µL:2µg, 6µL:2µg, 6µL:3µg and 
6µL:4µg) were tested. Whole-cell lysates were probed with 1:2,000 and 1:5,000 
dilutions of a penta-His antibody and analysed by western blotting. The antibody binds 
to the 6-His tag epitope encoded upstream the PLCG1 ORF in the pTriEx-4 vector 
(Figure 2. 1). The 6µL:2µg ratio produced the most intense and specific 150 kDa 
protein band (that corresponds to His-tagged PLCγ1) when probed with both antibody 
dilutions (Figure 2. 2). Therefore, the 6µL:2µg ratio of FuGENE reagent to DNA 














Figure 2. 2. Optimisation of HEK293 cell transfection and penta-His antibody dilution 
for western blotting. Cells were transfected with different ratios of FuGENE reagent 
(µL):DNA concentration (µg) and whole-cell lysates were probed with (A) 1:2,000 
and (B) 1:5,000 dilutions of a penta-His antibody to detect the 6-His-tagged PLCγ1 
protein (150 kDa). β-actin (45 kDa) expression was used as a loading control. The 
blots shown represent one experiment. 
 
The penta-His antibody produced a high level of background and would not be ideal 
for comparing the expression of wild-type and mutant PLCγ1 proteins. Therefore, 
whole-cell lysates from HEK293 cells transfected with wild-type PLCγ1 or a vehicle 
control were probed with 1:8,000 and 1:20,000 dilutions of a monoclonal anti-PLCγ1 
antibody. The 1:20,000 antibody dilution produced a more specific protein band 
corresponding to PLCγ1 than the 1:8,000 dilution, which resulted in a higher level of 
background binding (Figure 2. 3). Therefore, a 1:20,000 dilution of the anti-PLCγ1 











Figure 2. 3. Anti-PLCγ1 antibody dilution optimisation for western blotting. Whole-
cell lysates from HEK293 cells transfected with the wild-type PLCγ1 vector or vehicle 
control were probed with (A) 1:8,000 or (B) 1:20,000 dilutions of the antibody. β-actin 
expression was used as a loading control. The blots shown represent one experiment. 
 
To optimise the detection of phosphorylated PLCγ1 (p-PLCγ1) expression, whole-cell 
lysates of cells transfected with wild-type PLCγ1 or vehicle control were probed with 
increasing dilutions of an anti-p-PLCγ1 antibody. Cells were treated with the protein-
tyrosine phosphatase inhibitor pervanadate for 1 hour before harvesting, to stabilise 
the phosphorylation signal as per Kunze et al. (2014) (213). Transfected cells that were 
not treated with pervanadate did not show a p-PLCγ1 signal (data not shown). Lysates 
were first probed with 1:1,000, 1:3,000 and 1:8,000 antibody dilutions, which resulted 
in intense non-specific signals (data not shown). The antibody was further diluted to 
1:25,000, 1:30,000, 1:40,000, 1:45,000 and 1:50,000. In wild-type PLCγ1-transfected 
cells, all five dilutions produced a strong band with a molecular weight of over 150 
kDa, which corresponds to the 155 kDa weight of p-PLCγ1 (Figure 2. 4). The 1:50,000 
anti-p-PLCγ1 antibody dilution was determined to be optimal for analysing 








Figure 2. 4. Anti-p-PLCγ1 antibody dilution optimisation for western blotting. (A) 
1:25,000, (B) 1:30,000, (C) 1:40,000, (D) 1:45,000 and (E) 1:50,000 dilutions of an 
anti-p-PLCγ1 antibody were used to probe whole-cell lysates from HEK293 cells 
transfected with wild-type PLCγ1 vector or vehicle control. β-actin was used as a 
loading control. The blots shown represent one experiment. 
 
 IP quantification  
IP quantification experiments were performed by Dr. Marta Martins (Instituto de 
Medicina Molecular, Portugal). IP levels were quantified in COS-7 cells transfected 
with PLCγ1-pTriEx-4 vectors as per Everett et al. (2009) (269), with the exceptions 
of cells transfected with 2.5 µg of plasmid DNA and counts per minute quantified 
instead of disintegrations per minute. For stimulation experiments, cells were treated 
with 100 ng/mL EGF for 1 hour before quantifying IP production. All assays were 
performed in internal duplicates and repeated at least twice. IP levels were normalised 
to cells transfected with wild-type PLCγ1 but not subsequently stimulated. 
 IKKβ inhibitor treatment 
HEK293 cells co-transfected with the wild-type or mutant PLCγ1-pTriEx-4 vectors, 
the NFκB-firefly luciferase plasmid and pRL-TK transfection control construct, were 
starved overnight as detailed in section 2.2.27. Cells were treated with increasing doses 
(10 nM – 10 µM) of the IKKβ inhibitor IV (TPCA-1; Santa Cruz Biotechnology) for 




the pBABE-EGFR construct and stimulated with 100 ng/mL EGF for 8 hours, after 
30 minutes of pre-treatment with TPCA-1 (total TPCA-1 treatment for 8.5 hours). The 
cells were washed in 100 µL PBS, lysed in 100 µL PLB and stored at -80°C. 
Transfected cells were also stimulated with TNFα (Peprotech Incorporated) as 
follows. HEK293 cells were co-transfected with the NFκB-firefly luciferase plasmid 
and pRL-TK construct. After 24 hours, cells were pre-treated with TPCA-1 for 30 
minutes before stimulation with 10 ng/mL TNFα for 5 hours (270). Cells were lysed 
as described above and stored at -80°C. 
 Dual-Luciferase Reporter Assays 
The Dual-Luciferase Reporter Assay System (E1910; Promega Corporation) was used 
to quantify luciferase levels in co-transfected cells. Fifteen – twenty microliters of 
lysates from sections 2.2.27, 2.2.28 and 2.2.34 were analysed in duplicate or triplicate 
in white opaque 96-flat well bottom plates (Corning Incorporated) using the Orion II 
microplate luminometer (Berthold Detection Systems). The firefly luciferase reporter 
gene measurement was determined in relative light units by the addition of 100 µL 
Luciferase Assay Reagent II. Addition of 100 µL Stop & Glo Reagent quenched firefly 
luminescence and enabled quantification of Renilla luciferase levels, which were used 
as transfection controls. The mean ± standard deviation firefly and Renilla luciferase 
values were determined from the readings of each sample. The firefly values were 
normalised to the Renilla values (F÷R) for each sample to obtain a fold change for the 
transcription factor reporter genes. The activation fold change of cells expressing 
mutant proteins was normalised to that of cells expressing wild-type PLCγ1. 
 HeLa cell transfection and immunofluorescence analysis 
Thirteen millimetre glass cover slips (VWR International) were placed into 24-well 
plates, onto which 1 x 104 HeLa cells were seeded in 0.5 mL complete DMEM 
medium. After 24 hours, 1.5 µL of the FuGENE HD Transfection Reagent and 350 ng 
of the eGFP-PLCγ1 plasmid DNA were diluted in Opti-MEM I Reduced Serum 
Medium to a final volume of 100 µL. DNA-FuGENE complexes were allowed to form 
during a 15 minute incubation at room temperature. Complexes were added dropwise 
to cells before incubating at 37°C. The following procedures of fixing, permeabilising 




prevent photo-bleaching. Twenty-four hours after transfection, the cells were washed 
twice with PBS and fixed with 4% Paraformaldehyde (Alfa Aesar) for 10 minutes. 
The cells were washed twice and stored in PBS at 4°C for up to three days. Fixed cells 
were permeabilised with 0.2% (v/v) Triton-X (Sigma) for 10 minutes and then washed 
twice. The cells were stained with 4 units of Phalloidin (Biotium) for 20 minutes to 
enable visualisation of F-actin and cell structure. Cells were washed thrice and then 
incubated in 1 µM of 4′,6-Diamidino-2-phenylindole (DAPI) (Thermo Fisher 
Scientific) for 5 minutes to stain the nucleus. After washing three times with PBS and 
once with distilled water the cover slips were mounted onto microscope slides (Fisher 
scientific) using the SlowFadeTM Diamond Antifade Mountant (Thermo Fisher 
Scientific). Slides were stored at 4°C and visualised with the A1 Inverted Confocal 
microscope at the Nikon Centre (KCL). Table 2. 45 details the excitation and emission 
maximum of each fluorophore. 
 
Table 2. 45. The excitation and emission wavelengths of the fluorophores used for 
immunofluorescence. 
Fluorophore Excitation maximum Emission maximum 
Phalloidin 562 nm 583 nm 
DAPI 358 nm 461 nm 
eGFP 488 nm 509 nm 
 
 Statistical analysis 
Two-tailed Student’s t-tests were used to determine whether differences in 
transcriptional activity levels were statistically significant as per Vaqué et al. (2014), 
Kataoka et al. (2015) and Nagata et al. (2014), using the GraphPad QuickCalcs Web 






Chapter 3 Identification of PLCG1 mutations in Sézary Syndrome 
for functional analyses  
 
3.1. Introduction  
Mature T-cell lymphomas have been recurrently identified by deep sequencing studies 
to harbour somatic PLCG1 mutations (Table 1. 3). To investigate the genetic 
architecture of SS, our group also performed deep sequencing on 101 tumours (147). 
The first phase of the study included identifying somatic mutations by WES of DNA 
extracted from CD4+ enriched tumour cell populations from 10 discovery screen 
patients. This led to the identification of 549 genes harbouring at least one somatic 
mutation in the discovery cohort, including one patient harbouring the PLCγ1 p.S345F 
mutation (147). The 549 genes were subsequently included in a prevalence screen for 
TCS of DNA isolated from PBMCs of 91 SS patients (who had a high tumour burden) 
in addition to the 10 discovery screen patients (147). Our study identified that 11% 
(11/101) of SS tumours harboured seven PLCG1 mutations and four of these 
(p.R48W, p.D342N, p.S345F and p.E1163K) were recurrently detected in individual 
tumours (Table 1. 4) (147). PLCG1 encodes the PLCγ1 protein, a key mediator of 
TCR signalling, making mutations in this gene of particular interest in the context of 
mature T-cell lymphomas.  
This chapter aims to prioritise which of nine PLCγ1 mutations (p.R48W, p.S312L, 
p.D342N, p.S345F, p.S520F, p.R1158H*, p.E1163K, p.D1165H and 
p.VYEEDM1161V*) identified in SS by our deep sequencing study and Kiel et al. 
(2015)* should be taken forward for functional analyses (68, 147). The first 
investigation aims to validate the seven mutations identified by our NGS study using 
Sanger sequencing. This technique will also be used to determine if the mutations 
persist in multiple tumour tissues obtained over extended periods of time. Mutations 
shown to persist over time and/ or in multiple tumour compartments are likely to be 
driver gene mutations that provide selective growth advantages to tumour cells. All 
nine mutations will be analysed using six pathogenicity prediction algorithms to 
determine their likely effect on protein structure and/or activity. Furthermore, 
conservation analysis will be used to investigate whether the amino acids altered by 
PLCγ1 mutations affect evolutionarily conserved residues. Finally, as PLCG1 




will be sequenced to determine if they have any of the nine mutations of interest. Cell 
lines harbouring these mutations could serve as models for functional assays.  
The mutations that (i) persist over time and/ or in multiple tumour compartments, (ii) 
are predicted to be damaging on the protein level and (iii) alter evolutionarily 
conserved residues will be prioritised for functional analyses.  
 
3.2. PLCG1 mutations identified by deep sequencing of SS tumours 
The Integrative Genomics Viewer (257) was used to confirm the location of seven 
variants identified in 11 SS patients by our TCS study and to analyse the coverage of 
sequence reads. The number and percentage of reads that harboured the ancestral and 
minor/ mutant allele are shown in Table 3. 1. The coordinates that define the location 
of the variants had good coverage by 53 – 636 reads and 10% – 53% of the reads 













Table 3. 1. Mutant PLCG1 alleles detected in 11 SS patients by targeted capture sequencing. The number and percentage of reads that detected the 
ancestral and minor/ mutant alleles were determined using the Integrative Genomics Viewer. Recurrent mutations identified in different patients 
























1 6885b c.C142T p.R48W C 35 66 T 18 34 53
2 8004b c.C142T p.R48W C 67 81 T 15 18 83
3 L11_0158b c.C935T p.S312L C 93 47 T 105 53 198
4 3297b c.G1024A p.D342N G 160 89 A 18 10 179
5 8344b c.G1024A p.D342N G 222 86 A 36 14 258
6 3451b c.C1034T p.S345F C 174 84 T 33 16 207
7 9308b c.C1034T p.S345F C 172 66 T 88 34 260
8 4736b c.C1559T p.S520F C 107 78 T 30 22 137
9 L12_0697b c.G3487A p.E1163K G 393 62 A 242 38 636
10 4142b c.G3487A p.E1163K G 347 72 A 142 27 517




3.3. Sanger sequencing validation of mutations 
The DNA samples in which the mutations were originally identified by TCS were 
amplified by PCR and analysed by Sanger sequencing to confirm that the variants 
were true mutations and not sequencing artefacts. 
Firstly, primers were designed to amplify the regions of interest using the PLCG1 
gDNA sequence from the genome browser Ensembl and the Primer3 software (176, 
258). The annealing temperatures of all primer pairs were optimised by testing 
increasing temperatures in PCRs using DNA from healthy control individuals. PCR 
products were analysed on agarose gels and the temperature that yielded the most 
intense amplicon was selected as the optimal annealing temperature for each primer 
pair. For example, 59.5°C was the optimal annealing temperature for the 
PLCG1_C142T primer pair that was designed to validate the p.R48W mutation 
(Figure 3. 1. A). Using the optimised conditions, PCRs were performed on the 
diagnostic DNA samples that were used for TCS and identified to harbour PLCG1 
mutations. Nuclease-free water and DNA from a healthy control individual were used 
in negative and positive control reactions, respectively. The PCR products were 
analysed on agarose gels to confirm successful DNA amplification (Figure 3. 1. B) 
and subsequently treated with the ExoSAP-IT enzyme to hydrolyse excess nucleotides 


























Figure 3. 1. PCR primer optimisation and patient DNA amplification. (A) Optimal 
conditions for four primer pairs were determined by performing PCRs at increasing 
annealing temperatures on healthy control DNA. The temperatures yielding the most 
intense amplicons (enclosed in orange) were determined to be optimal and used in 
subsequent PCRs. (B) Successful amplification of peripheral blood DNA from SS 
patient 1 and 2 with the PLCG1_C142T primer pair. Nuclease-free water and healthy 
control DNA were used in negative and positive control PCRs, respectively. 
 
The PCR products were sent for Sanger sequencing (Source Bioscience, Cambridge) 
with aliquots of the primers used to amplify the region of interest. Sanger sequencing 
chromatogram analyses confirmed the presence of PLCG1 mutations identified by 
TCS in all 11 patients. The PCR and Sanger sequencing reactions were performed 
once for each sample. A representative chromatogram of the p.R48W mutation in 
patient 1 is shown in Figure 3. 2. The validation chromatograms for the other 10 
patients are shown in Appendix Figure 1 – Appendix Figure 10. The PLCG1 mutations 
in patient 4 – 7 were validated by Dr. Nelema Begum during a summer research project 




Figure 3. 2. The p.R48W mutation in the peripheral blood of SS patient 1. 
 
3.4. PLCG1 mutations persist in multiple tumour compartments  
Serial tumour samples from the peripheral blood, lesional skin, involved lymph nodes 
and enriched CD4+ T-cells from patients harbouring PLCG1 mutations were analysed 
by Sanger sequencing to determine if the mutations were present in different tumour 
tissues and over extended periods of time. DNA extracted from most serial tumour 
samples was available from the Skin Tumour Unit research tissue bank. Where 
unavailable, DNA and RNA were extracted from frozen CD4+ enriched tumour cell 
populations from peripheral blood and the RNA was reverse transcribed into cDNA. 
The PCR primers used to validate the mutations were used to amplify the regions of 
interest in DNA from the serial samples. Primers were designed to specifically amplify 
cDNA and the annealing temperatures were optimised using healthy control cDNA as 
described in section 3.3. The optimised conditions were used to amplify cDNA 
synthesised from tumour cell RNA. Amplified PCR products were analysed by Sanger 
sequencing. The PCR and Sanger sequencing reactions were performed once. 
Notably, nine of the 11 patients demonstrated persistence of the p.R48W, p.S312L, 
p.S345F, p.S520F, p.E1163K and p.D1165H mutations in more than one tumour 
compartment (Figure 3. 3 – Figure 3. 7, Appendix Figure 11, Appendix Figure 13 – 
Appendix Figure 15). No serial tumour samples were available for patient 5 due to 
loss at follow-up. The p.D342N mutation did not persist in serial tumour samples from 
patient 4 (Appendix Figure 12). This is likely due to a reduced tumour burden through 




monoclonal antibody therapy, which induced lymphopenia. The presence of mutations 
in cDNA synthesised from tumour cell RNA shows that the p.R48W, p.S312L, 
p.S345F, p.S520F and p.E1163K mutations are expressed on the transcriptional level 
in SS tumours. 
Importantly, the p.R48W, p.S345F, p.S520F, p.E1163K and p.D1165H mutations 
persist up to 181 months after diagnosis in 6/8 patients for whom serial tumour 
samples were available (Figure 3. 5, Figure 3. 6, Appendix Figure 11, Appendix Figure 
13 – Appendix Figure 15). No post-diagnostic samples were available for patient 3, 5 
and 9.  
The lack of mutation persistence in some patients may be attributable to therapeutic 
interventions that reduced tumour burden or a lack of detection sensitivity by Sanger 
sequencing for sparse tumour infiltrates in lesional skin. High sensitivity sequencing 
techniques such as locked nucleic acid-clamped real-time PCR, which can detect 
mutant alleles that are present at low frequencies in tumour samples are discussed on 
page 199. Patient 1 underwent an allogenic haematopoietic stem cell transplantation 
after which the p.R48W mutation could not be detected (Figure 3. 3). The p.S345F 
mutation persisted in the peripheral blood of patient 6 for 17 months but not after 
receiving triple therapy (Interferon-α, Photopheresis and Bexarotene) that resolved the 
leukaemic disease (Figure 3. 5). The mutation was subsequently detected in an 
involved lymph node at 72 months as the patient developed nodal progression (Figure 
3. 5). The diagnostic sample for patient 7 was unavailable, however tumour samples 
obtained 4 months after diagnosis did not harbour the p.S345F mutation (Figure 3. 6). 
This is likely due to the patient receiving ECP therapy, which reduced the tumour 
burden. Diagnostic samples were also unavailable for patient 8, therefore peripheral 
blood DNA obtained 4 months after diagnosis was used to confirm the presence of the 
p.S520F mutation (Appendix Figure 13). A summary of the Sanger sequencing results 






Figure 3. 3. The p.R48W mutation was detected in diagnostic tumour tissues in patient 
1. The variant was absent after complete remission from an allogenic haematopoietic 
stem cell transplantation. DNA from a healthy control individual was sequenced to 












Figure 3. 4. The p.S312L mutation was present in multiple tumour compartments at 
diagnosis in patient 3. DNA from a healthy control individual was sequenced to show 





Figure 3. 5. The p.S345F mutation persists over time in the blood of patient 6. The 
mutant allele was absent in peripheral blood after triple therapy (Interferon-α, 
Photopheresis and Bexarotene) but was detected in an involved lymph node during 
nodal progression. DNA from a healthy control individual was sequenced to show the 






Figure 3. 6. The p.S345F mutation persists over time and in multiple tumour 
compartments in patient 7. The mutation was absent 4 months after diagnosis due to 
ECP treatment but was detected thereafter as the tumour burden increased. 
Chemotherapy effectively reduced the tumour burden and eliminated the mutant 
allele. DNA from a healthy control individual was sequenced to show the wild-type 





Figure 3. 7. The p.E1163K mutation is present in multiple tumour tissues at diagnosis 
in patient 9. DNA from a healthy control individual was sequenced to show the wild-






Table 3. 2. PLCG1 mutations persist over time and in multiple tumour compartments 
in SS. The mutations were validated by Sanger sequencing of peripheral blood DNA 
that was analysed by TCS. Serial DNA samples from peripheral blood, lesional skin, 
involved lymph nodes and tumour cell RNA were also screened for the mutations. 
Recurrent variants are highlighted in the same colour. = variant validated, x = variant 
















1 6885B c.C142T p.R48W   x
2 8004B c.C142T p.R48W   
3 L11_0158B c.C935T p.S312L   N/A
4 3297B c.G1024A p.D342N  x x
5 8344B c.G1024A p.D342N  N/A N/A
6 3451B c.C1034T p.S345F   
7 9308B c.C1034T p.S345F   
8 4736B c.C1559T p.S520F   
9 L12_0697B c.G3487A p.E1163K   N/A
10 4142B c.G3487A p.E1163K   




3.5. PLCγ1 mutations are predicted to be damaging 
In addition to the seven PLCγ1 mutations (p.R48W, p.S312L, p.D342N, p.S345F, 
p.S520F, p.E1163K and p.D1165H) identified by our deep sequencing study, two 
further mutations (p.R1158H and the in-frame p.VYEEDM1161V indel) identified in 
SS tumours by Kiel et al. (2015) were also included for further analyses (68, 147). The 
pathogenicity prediction algorithms SIFT, Provean, PolyPhen2, Mutation Taster, 
MutPred2 and CADD were used to predict the effect of PLCG1 mutations on the 
structure and/ or function of the PLCγ1 protein (153-158). The predictions from each 
algorithm are shown in Table 3. 3, with a consensus conclusion drawn based on 5/6 
algorithms for missense mutations and 3/4 algorithms for the indel. The PolyPhen2 
and MutPred2 algorithms only predict the likely effect of point mutations and were 
not applicable for the indel. Using the above defined criteria for a consensus, eight of 





Table 3. 3. Pathogenicity predictions performed with multiple algorithms for nine PLCγ1 mutations identified in SS. Consensus criteria for 





SIFT Provean PolyPhen2 
Mutation 
Taster 
MutPred2 CADD Consensus  




causing       
Damaging Deleterious Damaging 
c.C935T p.S312L Tolerated Deleterious Benign            
Disease 
causing      
Neutral Deleterious Inconclusive 
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Damaging Deleterious Damaging 
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Damaging Deleterious Damaging 




causing      
Damaging Deleterious Damaging 
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Damaging Deleterious Damaging 




causing        
Damaging Deleterious Damaging 




causing       
Damaging Deleterious Damaging 
c.GTGTATGAGG
AAGACAdelG 
p.VYEEDM1161V Damaging Deleterious N/A 
Disease 
causing        




3.6. PLCγ1 mutations alter evolutionarily conserved residues. 
The nine PLCγ1 mutations of interest were mapped to the functional protein domains 
(Figure 3. 8) based on the amino acid numbering and functional domains schematically 
represented by Bunney et al. (2012) (194). Eight mutations map to the protein core 
(blue domains), which mediates the catalytic activity of PLCγ1 in the 3D protein 
conformation. The p.S520F mutation is located in the split PH domain of the γ-specific 
array that mediates protein auto-inhibition.  
Figure 3. 8. PLCγ1 mutations mapped to the functional protein domains. Eight 
missense mutations and one in-frame indel were identified in SS tumours. Protein 
domain arrangement obtained from Bunney et al. (2012) (194). 
 
To determine whether PLCγ1 mutations alter evolutionarily conserved amino acids, 
phylogenetic conservation analysis was performed. The PLCγ1 protein sequences 
from 12 vertebrates were obtained from the genome browser Ensembl (176) and 
aligned using the Clustal Omega multiple sequence alignment tool (265). All nine 
mutations were identified to alter PLCγ1 residues that are highly conserved amongst 
vertebrates (Figure 3. 9). Analysis of PLCγ2 residues, which correspond to the PLCγ1 
residues that are altered by PLCG1 mutations, showed that these PLCγ2 amino acids 
are also highly conserved amongst vertebrates (Figure 3. 9). As all nine mutations alter 
evolutionarily conserved residues, they are likely to influence the structure and/ or 
function of the PLCγ1 protein.  
p.VYEEDM1161V
















Figure 3. 9. PLCγ1 mutations alter evolutionarily conserved residues in vertebrates. 
The corresponding PLCγ2 residues are also highly conserved. 
 
3.7. Mutations occur throughout the PLCG1 gene but particularly at five hotspots 
PLCG1 mutations are reported in several mature T-cell lymphomas (Table 1. 3). Data 
from the COSMIC database confirmed that PLCG1 is frequently mutated in ATLL, 
PTCL-nos, AITL, MF and SS (Figure 3. 10) (272). The COSMIC data also highlighted 
five hotspot mutations: p.R48W, p.S345F, p.S520F, p.E1163K and p.D1165H, with 
the most recurrent p.S345F mutation identified in 63 individual tumours (Figure 3. 








Figure 3. 10. Mature T-cell lymphomas frequently harbour PLCG1 mutations throughout the gene. PLCG1 is a commonly mutated gene in adult 
T-cell leukaemia/lymphomas, peripheral T-cell lymphomas-not otherwise specified, angioimmunoblastic T-cell lymphomas, Mycosis Fungoides 




All PLCγ1 mutations identified in mature T-cell lymphomas by WES, TCS and 
selective sequencing studies were mapped to the protein domains to investigate 
mutation distribution per functional domain. Mutation frequencies were calculated by 
expressing the number of mutations per domain as a percentage of total PLCG1 
mutations reported. Overall, the γ1-specific array encompasses 16% of all mutations 
and the PLCγ1 core domains harbour 82% of the reported mutations (Figure 3. 11). 
Four of the five hotspot mutations map to the core domains and the p.S520F mutation 
maps to the γ1-specific array. 
Figure 3. 11. Distribution of PLCγ1 mutations reported in mature T-cell lymphomas 
per functional domain. Mutation frequencies for domains are shown below and 
frequencies for the linker regions are shown on the upper part of the schematic.  
 
3.8. CTCL cell lines do not harbour PLCG1 mutations  
The aim of this section was to determine whether the CTCL cell lines SeAx (SS), 
HUT-78 (SS) and MyLa (MF) and the acute T-cell leukaemia Jurkat cell line harbour 
any of the nine PLCG1 mutations of interest. Cell lines identified to harbour mutations 
could be used as model systems to investigate the functional effects of the mutations. 
cDNA from the cell lines was available in our group for analysis. PCR and Sanger 
sequencing primers were designed to amplify the PLCG1 ORF and the optimal 
annealing temperatures of eight primer pairs were determined as described in section 
3.3. PCRs were performed using cell line cDNA as templates and the reaction products 
were enzymatically cleaned-up and sent for Sanger sequencing. 
SeAx and HUT-78 cells were identified to harbour one copy of the minor G allele at 
position c.A835 (p.S279G) (Figure 3. 12). The c.C2438T (p.I813T) variant was 
identified in all four cell lines with the SeAx, HUT-78 and MyLa cell lines having a 




3. 13). Both variants are common single nucleotide polymorphisms (SNPs) identified 
in the general population by the 1000 genomes project as determined from the dbSNP 
database (273). The minor alleles of the c.A835G and c.C2438T variants have a 
frequency of 7.9% and 26.7%, respectively. Table 3. 4 summarises the variants 
identified in the cell lines. As the CTCL and Jurkat cell lines do not endogenously 
harbour the mutations of interest, these cells would not serve as models to investigate 

















































Figure 3. 13. The c.C2438T polymorphism is present in CTCL cell lines and Jurkat 
cells. SeAx, HUT-78 and MyLa cells have a heterozygous PLCG1 c.C2438T 
polymorphism and Jurkat cells have a homozygous C/C genotype. 
 
Table 3. 4. A summary of PLCG1 polymorphisms identified in CTCL and adult T-cell 
leukaemia cell lines. Minor allele frequencies (MAF) of the general population were 
obtained from the 1000 genomes project via the dbSNP database.  




c.A835G A/G p.S279G 7.9% rs2228246 
c.C2438T C/T p.I813T 26.7% rs753381
c.A835G A/G p.S279G 7.9% rs2228246 
c.C2438T C/T p.I813T 26.7% rs753381
MyLa
(MF)
c.C2438T C/T p.I813T 26.7% rs753381
Jurkat
(T-cell Leukaemia)








3.9. Cell lines derived from aggressive ATLL tumours harbour PLCG1 mutations 
The search for cell lines harbouring mutations of interest was expanded to 20 ATLL 
cell lines as PLCG1 mutations frequently occur in this mature T-cell malignancy 
(221). The ATLL cell lines were derived from three sub-types of the disease including 
acute (the most aggressive form), carrier (less aggressive) and smouldering (indolent 
disease). Six of each of the carrier and smouldering cell lines and seven acute cell lines 
were analysed in addition to the MT2 cell line, which has no sub-type classification. 
Fourteen primer pairs were designed to amplify the 32 PLCG1 exons. As previously 
described, primer pairs were optimised and the cell line gDNA was amplified by PCR 
and sent for Sanger sequencing.  
Fifteen cell lines were identified to harbour one or both alleles of the common 
c.C2438T; p.I813T polymorphism as shown using representative chromatograms 
from the CY-6 and UR1 cell lines, respectively (Figure 3. 14 and Figure 3. 15) (Table 
3. 5). This polymorphism was also detected in the CTCL and Jurkat cell lines (section 
3.8). The MT2 and smouldering cell lines did not have any PLCG1 mutations. Only 
one of the carrier cell lines, CY-6, harboured the rare p.E650STOP variant (Appendix 
Figure 16), which has not been reported in mature T-cell lymphomas.  
Five (KOB, KKI, LMY1, LMY2 and LMWT5) of the seven acute cell lines were 
identified to have one or more PLCG1 variants (Figure 3. 16 – Figure 3. 22), which 
were not reported as polymorphisms by the dbSNP database. The acute ATLL cell 
lines, KKI and LMY2, harboured one mutation each. The KKI cell line had the 
p.S345F mutation (Figure 3. 18), which frequently occurs in many mature T-cell 
lymphomas including ATLL, CTCL, PTCL-nos and AITL. The 
c.CCGGCGCGCCCTCGGACGC41del-insT; p.P14L indel was identified in the 
LMY2 cell line (Appendix Figure 17), an aberration not reported in mature T-cell 
lymphomas.  
The acute cell lines KOB, LMY1 and LMWT5 harboured two heterozygous PLCG1 
mutations each. KOB cells had the p.R48W and p.M750V mutations (Figure 3. 16 and 
Figure 3. 17), both of which have been detected in ATLL and the p.R48W hotspot 
mutation is also reported in ATLL, SS and AITL. The LMY1 cell line harboured the 
p.N1171I and p.R1252P mutations (Figure 3. 19 and Figure 3. 20), the former of which 




mutations (Figure 3. 21 – Figure 3. 22) and the p.S520F mutation has been reported in 
ATLL, CTCL and AITL. The p.R748 residue has been identified to be mutated to a 
Cysteine or Glycine bases in ATLL (221) but not to a Histidine residue as identified 
in the LMWT5 cell line.  
As summarised in Table 3. 5, indolent smouldering cells had no mutations, one carrier 
cell line had one mutation and cell lines derived from aggressive acute ATLLs 
harboured one or more PLCG1 mutations. PLCG1 mutations frequently occurred in 
the acute subtype of ATLL, suggesting a key role for this gene in the aggressive form 
of the disease. The only cell line identified to harbour a mutation of interest (p.S345F) 




















































































































































Table 3. 5. A summary of the PLCG1 variants identified in 20 ATLL cell lines. Rare 
variants i.e. mutations are shown in red text.  
 
Cell line Clinical Stage Variant Genotype Amino Acid Change MAF SNP I.D.
MT2 - c.T2438C C/C p.I813T 26.7% rs753381
EE8 Smouldering c.T2438C C/C p.I813T 26.7% rs753381
OKA3 Smouldering c.T2438C T/C p.I813T 26.7% rs753381
YGS13 Smouldering - - - - -
JSH4 Smouldering c.T2438C C/C p.I813T 26.7% rs753381
HAM9 Smouldering c.T2438C C/C p.I813T 26.7% rs753381
YK8 Smouldering c.T2438C C/C p.I813T 26.7% rs753381
c.G1948T G/T p.E650STOP - -
c.T2438C T/C p.I813T 26.7% rs753381
USH'2 Carrier - - - - -
UR1 Carrier c.T2438C C/C p.I813T 26.7% rs753381
OGF20 Carrier c.T2438C C/C p.I813T 26.7% rs753381
MKI-1 Carrier c.T2438C T/C p.I813T 26.7% rs753381
KAW2 Carrier - - - - -
c.C142T C/T p.R48W - -
c.A2248G A/G p.M750V - -
c.C1034T C/T p.S345F - -
c.T2438C C/C p.I813T 26.7% rs753381
SO4 Acute c.T2438C C/C p.I813T 26.7% rs753381
c.T2438C C/C p.I813T 26.7% rs753381
c.ATT3512-
3514del
ATT/ATT del p.N1171I - -









c.T2438C C/C p.I813T 26.7% rs753381
c.C1559T C/T p.S520F - -
c.G2243A G/A p.R748H - -











The aim of this chapter was to determine which of the nine PLCγ1 mutations (p.R48W, 
p.S312L, p.D342N, p.S345F, p.S520F, p.R1158H, p.E1163K, p.D1165H and 
p.VYEEDM1161V) identified in SS tumours should be prioritised for functional 
analyses. All seven mutations identified by our study were validated by Sanger 
sequencing. The presence of PLCG1 mutations in diagnostic samples implicates that 
these are early events that may contribute to initiating tumourigenesis. Furthermore, 
persistence of PLCG1 mutations in multiple tumour compartments and/ or over 
extended periods of time suggests that these are driver gene mutations that are 
positively selected by tumour cells. PLCG1 mutations were shown to occur throughout 
the gene in mature T-cell lymphomas and five residues were recurrently mutated 
supporting the role of these hotspot mutations as drivers of oncogenesis (149). 
All mutations except p.S312L were predicted to be damaging by pathogenicity 
prediction algorithms. The mutations alter evolutionarily conserved residues in 
vertebrates. The p.S312L mutation, although not predicted to be damaging, will be 
included in functional analyses as it alters an evolutionarily conserved residue and was 
detected in multiple tumour tissues at diagnosis in patient 3 (Figure 3. 4). Based on 
the analyses performed, all nine mutations will be taken forward for functional 
interrogations. 
Sequencing of the PLCG1 gene in CTCL and ATLL cell lines to identify a potential 
model for functional studies revealed that the KKI ATLL cell line harboured the 
p.S345F mutation. ATLL cell lines are derived from patients with Human T-
leukaemia virus type 1 (HTLV-1) infections, therefore the KKI cell line would need 
to be cultured in a containment level 3 laboratory. As this facility was unavailable in 
our department it was not feasible to perform functional analyses to investigate the 
effect of one mutation of interest in a different research department.  
To functionally interrogate the nine PLCγ1 mutations, mutant constructs will be made 
from a wild-type PLCγ1 vector. The constructs will be used to transiently transfect 






Chapter 4 Activating PLCγ1 mutations mediate p.Y783 
phosphorylation-independent signalling 
4.1 Introduction  
The analyses presented in Chapter 3 identified nine PLCγ1 mutations (p.R48W, 
p.S312L, p.D342N, p.S345F, p.S520F, p.R1158H, p.E1163K, p.D1165H and 
p.VYEEDM1161V) in SS tumours for functional interrogation.  
To investigate the effect of the mutations, a wild-type PLCγ1 construct will be used 
as a template to generate mutant constructs. The constructs will be transiently 
transfected into HEK293 and COS-7 cells as these in addition to derivatives 
(HEK293T cells) are well established models used to study PLCγ1 function (160, 172, 
194, 213, 218, 269, 274). IP production will be quantified and luciferase reporter 
assays will be utilised to analyse the effect of mutant PLCγ1 on proximal signalling 
and downstream transcriptional activity, respectively.  
Phosphorylation of the p.Y783 tyrosine residue has been shown to be critical for 
proximal signalling and production of IP by PLCγ1 hydrolysis (177, 194). The 
requirement of p.Y783 phosphorylation in mutant PLCγ1 proteins will be assessed by 
mutating the tyrosine residue and analysing downstream NFκB, NFAT and AP-1 
transcriptional activity. Finally, the efficacy of an IKKβ inhibitor to reduce PLCγ1-





4.2 Generation of mutant PLCγ1 constructs 
To investigate the effect of PLCγ1 mutations on protein expression and activity, 
mutant constructs were generated. The pTriEx-4 vector containing the full length 
human wild-type PLCG1 cDNA and two constructs harbouring the p.S345F and 
p.S520F mutations were kindly provided by Professor Matilda Katan (UCL). The 
wild-type PLCγ1 vector was used as a template for site-directed mutagenesis to create 
the mutant p.R48W, p.S312L, p.D342N, p.R1158H, p.E1163K, p.D1165H and 
p.VYEEDM1161V constructs. The p.R1158H and p.VYEEDM1161V constructs 
were generated by Dr. Antoinette Yoxall (a research student under my supervision). 
The introduction of mutant bases was validated by Sanger sequencing (Figure 4. 1). 
Furthermore, the ORF and regulatory regions including the CMV enhancer and 
promoter and the polyA tail were analysed by Sanger sequencing and confirmed to 
harbour no additional mutations from the mutagenesis reactions. All constructs were 
routinely analysed on 0.8% agarose gels to confirm that they had not degraded (data 
not shown). The constructs were used to overexpress wild-type and mutant PLCγ1 in 






Figure 4. 1. Chromatograms confirming introduction of mutant alleles in PLCγ1 
constructs by site-directed mutagenesis. Sequences from the wild-type constructs are 
shown in the top panels and mutant alleles in the bottom panels. The p.R1158H and 




4.3 The p.VYEEDM1161V indel alters total and phosphorylated PLCγ1 expression 
Transfection of HEK293 cells with PLCγ1 constructs was optimised and the ideal 
antibody dilutions to be used for western blotting were determined as described in 
section 2.2.32. The optimised conditions were used to investigate the effect of nine 
PLCγ1 mutations of interest on protein expression and phosphorylation of the p.Y783 
residue, which is known to activate wild-type PLCγ1. The p.Y783 residue has a more 
prominent role in protein activation compared to the other four tyrosine residues that 
are phosphorylated in PLCγ1 as described on page 67.  
HEK293 cells were transfected with wild-type or mutant PLCγ1 vectors alongside a 
vehicle control and untreated cells. Cells were treated with pervanadate for 1 hour 
prior to harvesting and whole-cell lysates were probed with the following primary 
antibodies: anti-PLCγ1 (1:20,000), anti-p-PLCγ1 (1:50,000) and anti-β-actin 
(1:10,000). Eight mutant proteins that harboured a missense mutation demonstrated 
comparable total protein expression to wild-type PLCγ1 (Figure 4. 2). In contrast, the 
in-frame p.VYEEDM1161V indel mutant protein had markedly reduced total PLCγ1 
expression (Figure 4. 2). PLCγ1 phosphorylation levels were similar in mutant and 
wild-type proteins, however the p.VYEEDM1161V protein had increased 
phosphorylation relative to total PLCγ1 expression (Figure 4. 2). This expression 
pattern was also observed in an independent repeat experiment showing that the data 




Figure 4. 2. The p.VYEEDM1161V indel reduces total PLCγ1 expression, but has 
relatively increased protein phosphorylation. Total (150 kDa) and phosphorylated 
PLCγ1 (p-PLCγ1; 155 kDa) expression was analysed in whole-cell lysates of 
transfected HEK293 cells, using β-actin expression (45 kDa) as a loading control. The 
blots shown are representative of two independent transfections and western blot 




Cells transfected with six mutant constructs (p.R48W, p.S312L, p.D342N, p.S345F, 
p.S520F and p.E1163K) but not treated with pervanadate also show comparable 
mutant and wild-type PLCγ1 expression. This demonstrates that pervanadate 






Figure 4. 3. Transfected cells not treated with pervanadate show comparable wild-type 
and mutant PLCγ1 expression. HEK293 cells were transfected with PLCγ1 constructs 
and total PLCγ1 expression (150 kDa) was analysed relative to β-actin expression (45 
kDa) used as a loading control. The blots shown are representative of two independent 
transfections and western blot analyses. 
 
4.4 Five PLCγ1 mutations potently activate downstream signalling 
Activated PLCγ1 produces the secondary messengers IP3 and DAG, which induce 
extensive signalling cascades to activate the NFAT, NFκB and AP-1 transcription 
factor families (Figure 1. 18). To investigate the effect of PLCγ1 mutations on 
downstream signalling, HEK293 cells were co-transfected with PLCγ1 plasmids and 
NFκB- or NFAT-luciferase constructs and transcriptional activity was measured using 
luciferase reporter assays. NFAT activity was analysed to interrogate the IP3-
calcineurin-NFAT pathway. Of the two DAG signalling cascades that activate NFκB 
and AP-1, the NFκB transcription factor was selected for analysis as it has a substantial 
role in the pathogenesis of CTCL. 
4.4.1 Co-transfection optimisation for luciferase reporter assays 
Prior to being used in experiments, the reporter constructs were confirmed by Sanger 
sequencing to encode the appropriate transcription factor binding elements as listed in 
Table 2. 31. To determine the optimal concentration of PLCγ1 plasmid DNA for 
transfections, cells were co-transfected with 0 μg, 0.05 μg, 0.3 μg and 1 μg of the wild-




reporter plasmids. Four hours after transfection, cells were serum-starved overnight to 
remove growth factors within the serum-containing media that can activate PLCγ1 
signalling. Transcriptional reporter activity was normalised to that of vehicle 
transfected cells. The p.R1158H and in-frame indel p.VYEEDM1161V constructs 
were generated at a later time in the project by Dr. Antoinette Yoxall, therefore the 
optimal concentrations were determined in separate experiments. Cells transfected 
with 1 µg of wild-type or mutant PLCγ1 constructs induced the highest levels of NFκB 
activity (Figure 4. 4) and also NFAT and AP-1 activity (data not shown). Therefore, 1 
µg of PLCγ1 plasmid DNA was determined to be optimal for co-transfection of 






Figure 4. 4. Optimisation of HEK293 cell co-transfection with PLCγ1 constructs for 
NFκB-luciferase reporter assays. Cells were co-transfected with the NFκB reporter 
construct, vehicle control (0 µg) and increasing concentrations of wild-type or mutant 
PLCγ1 plasmids. Activity levels were normalised to cells transfected with a vehicle 





4.4.2 Five PLCγ1 mutations significantly elevate NFκB and NFAT activity in basal 
conditions  
The experiments were repeated using the optimal co-transfection conditions to 
confirm the effect of the mutant proteins on NFκB and NFAT activity. The p.S345F, 
p.S520F, p.E1163K, p.D1165H and p.VYEEDM1161V mutant proteins significantly 
elevated NFκB activation 3.3 – 6.1 fold (p≤0.03) compared to wild-type PLCγ1 
(Figure 4. 5. A). The same mutant proteins also significantly increased NFAT 
transcriptional activity between 3.3 – 10 fold (p<0.0001) relative to wild-type PLCγ1 
(Figure 4. 5. B). These data show that the p.S345F, p.S520F, p.E1163K, p.D1165H 
and p.VYEEDM1161V mutant proteins have potent gain-of-function properties in 





Figure 4. 5. Five mutant PLCγ1 proteins significantly increase NFκB and NFAT 
transcriptional activity in basal conditions. Activation fold changes were normalised 
to cells overexpressing wild-type PLCγ1. Data is represented as mean ± SEM. NFκB; 





4.4.3 Optimisation of EGF stimulation for HEK293 cells  
The p.R48W, p.S312L, p.D342N and p.R1158H mutant proteins did not significantly 
increase transcriptional activity in basal conditions. To investigate if these proteins 
alter NFκB activity in stimulated conditions, EGF stimulation of HEK293 cells was 
optimised. HEK293 cells express low levels of the EGF receptor (268), therefore the 
receptor was overexpressed by transfection of the pBABE-EGFR plasmid. Cells were 
co-transfected with increasing concentrations (100 ng, 250 ng, 500 ng, 750 ng and 1 
μg) of the pBABE-EGFR vector, wild-type PLCγ1 plasmid and the NFκB-luciferase 
construct. After serum-starving overnight, the cells were stimulated with 100 ng/mL 
EGF for 8 hours. The dose and duration of EGF stimulation was optimised using 
conditions from the literature as a guide (data not shown). Over-expressing the EGF 
receptor increased NFκB activity in response to EGF stimulation (Figure 4. 6). 
Specifically, co-transfecting cells with 750 ng of the pBABE-EGFR vector induced a 
3.11 fold increase in NFκB activity compared to unstimulated cells that did not 
overexpress the receptor (Figure 4. 6). Thus, 750 ng of the pBABE-EGFR plasmid 
was determined to be optimal for transfections in all subsequent experiments that 











Figure 4. 6. Overexpressing the EGF receptor increases NFκB activity in response to 
EGF stimulation. HEK293 cells were co-transfected with increasing concentrations of 
the pBABE-EGFR plasmid, wild-type PLCγ1 vector and NFκB reporter construct. 
Following serum starvation, cells were stimulated with 100 ng/mL EGF for 8 hours. 
Activity levels were normalised to unstimulated cells overexpressing wild-type 




As mentioned in section 1.12, PLCγ1 can be activated by engagement of the EGFR 
after which the enzyme mediates signalling to the NFκB, NFAT and AP-1 
transcription factors (Figure 1. 15). To confirm that PLCγ1 mediates EGF signalling 
the following experiment was performed. HEK293 cells were co-transfected with 
either wild-type PLCγ1 plasmid or a vehicle control, the pBABE-EGFR vector and 
the NFκB reporter construct. Cells were serum-starved overnight and then stimulated 
with 100 ng/mL EGF for 8 hours. Both vehicle-transfected and PLCγ1-transfected 
cells demonstrated higher NFκB activity after stimulation (Figure 4. 7). Importantly, 
cells overexpressing wild-type PLCγ1 had 2.9 fold greater NFκB activity compared to 
vehicle-transfected cells in stimulated conditions, confirming that PLCγ1 mediates 










Figure 4. 7. PLCγ1 mediates EGF signalling to induce NFκB activation in HEK293 
cells. Cells were co-transfected with the wild-type PLCγ1 vector or vehicle control, 
pBABE-EGFR plasmid and NFκB reporter construct. Following serum starvation, 
cells were stimulated with 100 ng/mL EGF for 8 hours. Activation levels were 
normalised to unstimulated vehicle-transfected cells. Data is represented as mean ± 





4.4.4 The hotspot p.R48W mutation significantly increases NFκB activity in 
stimulated conditions  
As the p.R48W, p.S312L, p.D342N and p.R1158H proteins did not significantly 
increase NFκB activity in basal conditions, these mutant proteins were analysed in 
stimulated cells using the optimised conditions. The p.R48W, p.D342N and p.R1158H 
mutant proteins increased NFκB activity 0.3 – 0.5 fold compared to wild-type PLCγ1 
in stimulated cells, but the p.S312L protein showed reduced protein activity (Figure 
4. 8). 
Figure 4. 8. The p.R48W, p.D342N and p.R1158H mutant proteins increase NFκB 
activation in stimulated cells. HEK293 cells were co-transfected with PLCγ1 vectors, 
the pBABE-EGFR construct and the NFκB reporter plasmid. After serum starvation 
overnight, cells were stimulated with 100 ng/mL EGF for 8 hours. Activation fold 
changes were normalised to stimulated cells overexpressing wild-type PLCγ1. Data is 






The p.R48W mutation was selected for further analysis as this is a hotspot mutation 
that has been reported in SS, AITL and frequently in ATLL (67, 69, 70, 147, 218, 
221). Co-transfection of HEK293 cells with wild-type and the p.R48W mutant 
construct was repeated thrice and the mutant protein was shown to significantly 
increase NFκB activity 1.3 fold compared to wild-type PLCγ1 in stimulated cells 











Figure 4. 9. The p.R48W mutant protein significantly increases NFκB activity in 
stimulated cells. HEK293 cells were co-transfected with PLCγ1 vectors, the NFκB 
reporter construct and the pBABE-EGFR plasmid. Following serum starvation, cells 
were stimulated with 100 ng/mL EGF for 8 hours. Activation fold changes were 
normalised to unstimulated cells overexpressing wild-type PLCγ1. Data is represented 







4.5 Five PLCγ1 mutations directly increase IP production and proximal signalling  
PLCγ1 hydrolyses PIP2 to produce the secondary messengers IP3 and DAG (Figure 1. 
18 and Figure 1. 20). To determine the direct influence of mutations on PLCγ1 activity 
and proximal signalling, COS-7 cells were transfected with PLCγ1 vectors and total 
IP production was quantified by liquid scintillation. The IP quantification experiments 
presented here were performed by our collaborator, Dr. Marta Martins (Instituto de 
Medicina Molecular, Portugal).  
Of the nine PLCγ1 mutations of interest, the p.S312L and p.R1158H mutations were 
excluded from the analyses as these mutant proteins did not demonstrate gain-of-
function effects on downstream signalling (section 4.4.2). All IP data shown are 
representative of two independent experiments. The inter-assay data has not been 
averaged as the raw values from individual experiments vary largely, however, the 
same data trend was observed between experiments. This is in line with the 
presentation of IP data by Poulin et al. (2005) and Bunney et al. (2012) (177, 194). 
The p.S345F, p.S520F, p.E1163K, p.D1165H and p.VYEEDM1161V mutant proteins 
elevated IP production 3.4 – 6.6 fold compared to wild-type PLCγ1 in basal conditions 
(Figure 4. 10). In contrast, the p.R48W and p.D342N mutants had low impact on basal 
PLCγ1 activity by increasing IP production 1.4 and 1.6 fold, respectively compared to 
wild-type. These findings support the data from section 4.4.2 and demonstrate that the 
p.S345F, p.S520F, p.E1163K, p.D1165H and p.VYEEDM1161V proteins are potent 











Figure 4. 10. Five mutant PLCγ1 proteins elevate IP production in basal conditions. 
IP production was measured by liquid scintillation of COS-7 cells transfected with 
PLCγ1 constructs. Data is presented as mean ± SD of internal duplicates. 
Representative data of two independent experiments performed by Dr. Marta Martins 






The p.D342N protein has previously been shown to elevate IP production in 
stimulated COS-7 cells (269). To confirm these findings, COS-7 cells transfected with 
the PLCγ1 p.D342N vector were stimulated 100 ng/mL EGF for 1 hour and IP was 
quantified. Notably, COS-7 cells were not co-transfected with the pBABE-EGFR 
vector as these cells express higher levels (5 fold) of the EGF receptor than HEK293 
cells (268). The p.D342N mutant protein increased IP production 4.8 fold compared 






Figure 4. 11.  The p.D342N mutant protein generates more IP than wild-type PLCγ1 
in stimulated cells. Transfected COS-7 cells were stimulated with 100 ng/mL EGF for 
1 hour and IP production was measured by liquid scintillation. Data is presented as 
mean ± SD of internal duplicates. Representative data of two independent experiments 






4.6 Activating PLCγ1 proteins do not require p.Y783 phosphorylation to increase 
downstream signalling    
The PLCγ1 p.Y783 residue is critical for proximal TCR signalling in vitro. Abrogating 
the p.Y783 residue by mutating the tyrosine residue to phenylalanine (p.Y783F) has 
been shown to drastically reduce but not obliterate IP production in stimulated COS-
7 and TV-1 cells (177, 194). The aim of this section was to determine whether the 
PLCγ1 mutations shown to have gain-of-function activity in sections 4.4.2 and 4.5 
require phosphorylation of the p.Y783 residue to increase downstream signalling by 
assaying NFAT, NFκB and AP-1 transcriptional activity. 
4.6.1 The rationale for selecting mutations for analysis  
The PLCγ1 mutations analysed in this study were grouped based on their location in 
functional protein domains and a representative activating mutation from each group 
was selected for further analysis (Figure 4. 12). The gain-of-function p.S345F 
mutation was chosen from the catalytic X domain, the p.S520F mutation from the γ1-
specific array and the p.E1163K mutation from the C2 domain. 
Figure 4. 12. Mutant proteins selected to investigate if p.Y783 phosphorylation is 
required for protein activity. PLCγ1 mutations were mapped to the functional protein 
domains and one activating mutation (indicated in bold) was selected per functional 




4.6.2 Generation of double mutant constructs 
The PLCγ1-p.Y783F construct, which encodes the mutated p.Y783F residue was a 
kind gift from Professor Matilda Katan (UCL). This construct was used as a template 
for site-directed mutagenesis to incorporate the activating p.S345F, p.S520F and 
p.E1163K mutations. Introduction of the gain-of-function mutations into the PLCγ1-
p.Y783F vector was confirmed by Sanger sequencing (Figure 4. 13). These plasmids 
will henceforth be referred to as “double mutants”. The double mutant vectors were 
further sequenced and confirmed to harbour the p.Y783F residue and no additional 
mutations in the PLCG1 ORF, CMV promoter and enhancer and the polyA tail. 
 
Figure 4. 13. Chromatograms confirming introduction of mutant alleles in the PLCγ1-
p.Y783 construct by site-directed mutagenesis. Sequences from the wild-type 
constructs are shown in the top panels and mutant alleles in the bottom panels. Each 
mutant plasmid harboured two PLCG1 mutations: one identified in SS tumours and 




4.6.3 The PLCγ1 p.Y783F mutation abolishes phosphorylation of PLCγ1 
Expression of the double mutant proteins was analysed to confirm that the mutant 
p.Y783F residue was not phosphorylated in basal conditions. HEK293 cells were 
transfected with vectors encoding wild-type PLCγ1, the p.Y783F mutation, gain-of-
function mutations and double mutants. After 23 hours, the cells were treated with 
pervanadate for 1 hour to stabilise phosphorylation signals and then harvested. 
Western blotting of whole-cell lysates demonstrated total PLCγ1 expression in all cells 
transfected with PLCγ1 plasmids (Figure 4. 14). p-PLCγ1 expression was detected 
only in cells transfected with constructs encoding the tyrosine residue at position p.783 
(Figure 4. 14). This data confirms that the anti-p-PLCγ1 antibody used in this assay 
was specific for the p.Y783 residue and also demonstrates that the phosphorylation 
residue had been effectively abrogated in the double mutant proteins. This expression 
pattern was also observed in an independent repeat experiment and also in EGF-






Figure 4. 14. Abrogation of the p.Y783 residue results in loss of PLCγ1 
phosphorylation. Western blotting confirmed PLCγ1 (150 kDa) expression in 
transfected HEK293 cells and demonstrated absence of phosphorylation (p-PLCγ1; 
155 kDa) in cells transfected with constructs encoding the mutated p.Y783F 






4.6.4 Gain-of-function PLCγ1 proteins do not require phosphorylation to elevate 
transcriptional activity in basal conditions    
The effect of abrogating the p.Y783 phosphorylation residue in the gain-of-function 
mutant proteins was analysed by assaying downstream NFAT, NFκB and AP-1 
transcriptional activity in HEK293 cells. Cells were co-transfected with the wild-type, 
p.Y783F mutant, gain-of-function or double mutant PLCγ1 constructs and either of 
the three transcription reporter plasmids. The NFAT, NFκB and AP-1 transcriptional 
activity induced by the p.S345F, p.S520F, p.E1163K proteins was comparable to that 
of the p.S345F-Y783F, p.S520F-Y783F, p.E1163K-Y783F double mutant proteins 
and no statistically significant difference was determined (Figure 4. 15). These data 
therefore demonstrate that the gain-of-function mutant proteins do not require 

















Figure 4. 15. Activating PLCγ1 proteins induce NFAT, NFκB and AP-1 activity 
without p.Y783 phosphorylation in basal conditions. HEK293 cells were co-
transfected with wild-type, p.Y783F mutant, gain-of-function mutant or double mutant 
PLCγ1 vectors and luciferase reporter constructs. Activity levels were normalised to 
cells overexpressing wild-type PLCγ1. Data is represented as mean ± SEM, n=3 for 




4.6.5 Activating PLCγ1 mutant proteins induce transcriptional activity without 
p.Y783 phosphorylation in stimulated conditions  
Notably, the p.Y783F mutant protein induced transcriptional activity at comparable 
levels to wild-type PLCγ1 (Figure 4. 15). These findings differ from those of Poulin 
et al. (2005) and Bunney et al. (2012) who demonstrated that mutating the 
phosphorylation residue to p.Y783F diminished IP production compared to wild-type 
PLCγ1 (177, 194). Importantly, previous studies analysed the influence of the 
p.Y783F mutant protein in stimulated cells whereas the experiments performed herein 
were in basal conditions.  
Therefore, to determine if the levels of transcriptional activity induced by p.Y783F 
differ from wild-type PLCγ1 in stimulated cells, the experiments were repeated but 
cells were additionally co-transfected with the pBABE-EGFR vector and stimulated 
with 100 ng/mL EGF for 8 hours. This experimental set-up was used in parallel to 
determine if the gain-of-function mutant proteins and corresponding double mutant 
proteins differ in their ability to induce NFκB activity in stimulated conditions.  
In both unstimulated and stimulated cells, the p.Y783F mutant protein induced NFκB 
activity but importantly to a lesser extent than wild-type PLCγ1 (Figure 4. 16). These 
findings are consistent with previous reports, which show that mutating the p.Y783 
phosphorylation residue reduces IP production and phospholipase activity in 
stimulated conditions (172, 177, 194).  
No significant difference was observed in the elevated NFκB activity induced by the 
gain-of-function proteins and corresponding double mutant proteins in stimulated cells 
in six biological repeat experiments (Figure 4. 16). Three of the six experiments were 
performed by Dr. Farrah Bakr, a fellow PhD student. Collectively, data in this section 
show that the gain-of-function PLCγ1 proteins do not require phosphorylation of the 
p.Y783 residue, which is critical for activating wild-type PLCγ1 and suggest that these 














Figure 4. 16. Activating PLCγ1 proteins induce NFκB activity without p.Y783 
phosphorylation in stimulated conditions. HEK293 cells were co-transfected with 
PLCγ1 vectors, the pBABE-EGFR construct and the NFκB reporter plasmid. After 
serum starvation overnight, cells were stimulated with 100 ng/mL EGF for 8 hours. 
Activity levels were normalised to unstimulated cells overexpressing wild-type 
PLCγ1. Data is represented as mean ± SEM; n=6. Student’s t-test, ns=not significant. 
Three experimental repeats were performed by Dr. Farrah Bakr. 
 
4.6.6 The p.R48W and p.D342N mutant proteins may require p.Y783 
phosphorylation to increase downstream signalling 
In stimulated conditions, the hotspot p.R48W mutant protein elevates NFκB activity 
(Figure 4. 9) and the p.D342N protein was confirmed to increase IP production (Figure 
4. 11). Therefore, these mutant proteins were selected to investigate whether they 
require p.Y783 phosphorylation to elicit their gain-of-function effects on NFκB 
signalling in stimulated cells. The increased signalling induced by p.R48W and 
p.D342N in stimulated conditions suggests that these proteins require p.Y783 




As previously described in this section, the PLCγ1-p.Y783F construct was used as a 
template for site-directed mutagenesis to generate the p.R48W-Y783F and p.D342N-
Y783F constructs. Sanger sequencing confirmed the introduction of these mutations 
into the vectors and also validated the presence of the p.Y783F mutation (Figure 4. 
17). The PLCG1 ORF, CMV promoter and enhancer and the polyA tails of the 
plasmids were sequenced and confirmed not to harbour any additional mutations. 
Figure 4. 17. Chromatograms confirming introduction of the p.R48W and p.D342N 
mutations in the PLCγ1-p.Y783F vector. Site-directed mutagenesis was used to 
introduce the c.C142T (p.R48W) and p.G1024A (p.D342N) mutations into the vectors 






HEK293 cells were co-transfected and stimulated with EGF as described in section 
4.6.5. The p.E1163K and p.E1163K-p.Y783F mutant proteins were used as positive 
control samples. Cells expressing p.R48W-Y783F and p.D342N-Y783F demonstrate 
a reduction in NFκB activity compared to cells expressing p.R48W and p.D342N, 
respectively (Figure 4. 18). These are early findings as the experiment was performed 
once due to time constraints. Therefore, further biological repeat experiments are 
required to determine if there is a statistically significant difference in the NFκB 
activity induced by the p.R48W and p.D342N proteins with an intact phosphorylation 
residue compared to mutant proteins expressing the abrogated p.Y783F residue. 
Figure 4. 18. The p.R48W and p.D342N proteins may require p.Y783 phosphorylation 
to induce NFκB activity in stimulated cells. HEK293 cells were co-transfected with 
PLCγ1 vectors, the pBABE-EGFR construct and the NFκB reporter plasmid. 
Following serum starvation, cells were stimulated with 100 ng/mL EGF for 8 hours. 
Activity levels were normalised to unstimulated cells overexpressing wild-type 






4.7 TPCA-1 does not inhibit PLCγ1-induced NFκB activity 
As shown in sections 4.4.2 and 4.5, five PLCγ1 mutations have potent gain-of-function 
properties. To determine if the elevated NFκB activity induced by activating mutations 
can be reduced, TPCA-1, an inhibitor of the IKKβ subunit of the IKK complex (Figure 
1. 18) was selected for analysis. The IKK complex phosphorylates IκBα, which is 
degraded and unveils the NLS of the NFκB (p50/p65) heterodimer, allowing it to 
translocate to the nucleus and initiate transcription. As TPCA-1 inhibits the IKK 
complex it would be expected to inhibit activation of NFκB. 
To identify the optimal concentration of TPCA-1, HEK293 cells were co-transfected 
with the wild-type PLCγ1 vector, pBABE-EGF construct and NFκB reporter plasmid 
and then serum starved overnight. Cells were pre-treated with 10 nM, 1 μM, 2.5 μM, 
5 μM or 10 μM of TPCA-1 for 30 minutes and then stimulated with 100 ng/mL EGF 
for 8 hours to activate the signalling pathway. In this section, NFκB reporter activity 
is expressed as a percentage relative to stimulated or unstimulated cells that were not 
treated with inhibitor as having 100% transcriptional activity. This means of 
representation was chosen to effectively demonstrate reductions in transcriptional 
activity due to inhibitor treatment, which would otherwise be more complicated to 
interpret if expressed as relative fold changes in activity. Cells treated with increasing 
concentrations of TPCA-1 did not show a dose-dependent decrease in NFκB activation 
(Figure 4. 19). Particularly, cells treated with 10 nM, 5 μM and 10 μM demonstrated 
increased NFκB activity. In contrast, the intermediate TPCA-1 concentrations of 1 μM 






Figure 4. 19. TPCA-1 does not reduce wild-type PLCγ1-induced NFκB activity in a 
dose-dependent manner. Activation levels were normalised to EGF-stimulated 
HEK293 cells overexpressing wild-type PLCγ1 but not treated with TPCA-1. Data is 
represented as mean ± SD, n=1 assay performed in triplicate. 
 
To determine if TPCA-1 inhibits the NFκB activity induced by gain-of-function 
mutations, the experiment was repeated by co-transfecting cells with the PLCγ1 
p.E1163K construct. Cells were not transfected with the pBABE-EGFR construct nor 
stimulated as the mutant protein elevates transcriptional activity in basal conditions 
(Figure 4. 5). Treating cells with increasing doses of TPCA-1 did not result in a dose-
dependent decrease in p.E1163K-induced NFκB activity (Figure 4. 20). Cells treated 
with 10 nM, 1 μM and 2.5 μM TPCA-1 had reduced NFκB activity compared to 
untreated cells expressing the p.E1163K protein. Treatment with higher 
concentrations, specifically 5 μM and 10 μM, increased NFκB activity. Therefore, as 
observed in cells overexpressing wild-type PLCγ1, TPCA-1 does not inhibit 






Figure 4. 20. TPCA-1 does not reduce p.E1163K-induced NFκB activity in a dose-
dependent manner. Activation levels were normalised to untreated HEK293 cells 
expressing the p.E1163K protein. Data is represented as mean ± SD, n=1 assay 
performed in triplicate. 
 
To determine if TPCA-1 treatment of cells for 8.5 hours was sub-optimal and 
responsible for inducing NFκB activity at particular doses, time course experiments 
were performed. Cells were transfected with the wild-type or p.E1163K PLCγ1 
vectors and following serum starvation overnight the cells were treated with 1 μM of 
TPCA-1 for 4.5, 6.5 and 8.5 hours. The concentration of 1 μM was chosen as this dose 
effectively reduced NFκB activity in stimulated cells overexpressing wild-type PLCγ1 
(Figure 4. 19) and cells expressing the p.E1163K protein (Figure 4. 20). TPCA-1 did 
not reduce wild-type PLCγ1-induced NFκB activity in stimulated cells at any time-
point (Figure 4. 21. A) and conflict the data shown in Figure 4. 19. Treating p.E1163K-
expressing cells with TPCA-1 for 6.5 and 8.5 hours reduced NFκB activity 30% and 





















Figure 4. 21. TPCA-1 treatment time course in HEK293 cells. (A) Cells expressing 
wild-type PLCγ1 (and transfected with the pBABE-EGFR vector) were pre-treated 
with 1 μM TPCA-1 for 30 minutes and then stimulated with 100 ng/mL EGF for three 
time points. (B) Cells expressing the mutant p.E1163K protein were treated with 1 μM 
TPCA-1 for three time points. Activation levels were normalised to cells not treated 
with inhibitor in each experiment. Data is represented as mean ± SD, n=1 assay 
performed in triplicate. 
 
To obtain a third biological repeat, cells expressing wild-type and p.E1163K protein 
were treated with 1 μM TPCA-1 for 8.5 hours. This dose was selected as it reduced 
NFκB activity in cells expressing wild-type and mutant PLCγ1 (Figure 4. 19 and 
Figure 4. 20). In the repeat experiments, stimulated cells expressing wild-type PLCγ1 
and cells expressing the p.E1163K protein both demonstrated increased NFκB activity 
when treated with TPCA-1 (data not shown). These results clearly demonstrate that 
TPCA-1 does not consistently and effectively inhibit PLCγ1-induced NFκB activity 




To investigate if the inhibitor had become ineffective, a positive control experiment 
was performed as per Lu et al. (2014) (270), using TNFα instead of EGF to activate 
NFκB in HEK293 cells. Cells were transfected with the NFκB reporter plasmid and 
the pRL-TK renilla luciferase vector. After 24 hours, cells were pre-treated with 0 μM, 
1 μM, 2.5 μM, 5 μM and 10 μM of TPCA-1 for 30 minutes and then stimulated with 
10 ng/mL TNFα for 5 hours. As per the findings of Lu et al. (2014) (270), a dose-
dependent decrease in TNFα-induced NFκB activity was observed in cells treated with 
0 μM – 5 μM of TPCA-1 (Figure 4. 22). Cells treated with 10 μM TPCA-1 had 
marginally more NFκB activity than cells treated with 5 μM, however such variation 
in the same experimental system has previously been reported (275). This data 
confirms that TPCA-1 inhibits TNFα-induced NFκB activity. 
Figure 4. 22. TPCA-1 inhibits TNFα-induced NFκB activity in HEK293 cells. Cells 
were co-transfected with the NFκB reporter and pRL-TK transfection control plasmid. 
After 24 hours cells were pre-treated with TPCA-1 for 30 minutes and then stimulated 
with 10 ng/mL TNFα for 5 hours. Activity levels were normalised to stimulated cells 
not treated with inhibitor. Data is represented as mean ± SD, n=1 assay performed in 
triplicate. 
 
Overall, the data presented in this section show that TPCA-1 effectively inhibits 
TNFα-induced but not PLCγ1-induced NFκB activity and cannot be used to reverse 
the gain-of-function effects of PLCγ1 mutations. It may be possible that TPCA-1 is a 
specific inhibitor for the TNFα but not TCR signalling pathway, which both activate 




activity was induced by engaging the EGFR in an analogous set-up based on the fact 
that multiple cell surface receptors can activate PLCγ1 (Figure 1. 15). 
 
4.8 Summary 
To investigate the effect of nine PLCγ1 mutations (p.R48W, p.S312L, p.D342N, 
p.S345F, p.S520F, p.R1158H, p.E1163K, p.D1165H and p.VYEEDM1161V) on 
protein expression and activity, mutant constructs were generated.  
The transfection of HEK293 cells was optimised for western blot analyses and 
luciferase reporter assays. Protein expression analysis revealed that eight mutant 
proteins had comparable PLCγ1 expression to wild-type protein, but the in-frame indel 
p.VYEEDM1161V protein showed a marked reduction in total PLCγ1 expression and 
a relative increase in PLCγ1 phosphorylation. The p.S345F, p.S520F, p.E1163K, 
p.D1165H and p.VYEEDM1161V proteins significantly elevated downstream 
signalling by increasing NFκB and NFAT activity in basal conditions, making them 
potent gain-of-function mutant proteins. Furthermore, the hotspot p.R48W mutation 
significantly increased NFκB activity in stimulated conditions. The p.S345F, p.S520F, 
p.E1163K, p.D1165H and p.VYEEDM1161V proteins in addition to increasing 
downstream signalling, also enhanced IP production and directly increased proximal 
signalling in basal conditions.  
Phosphorylation of the p.Y783 residue has been shown to be critical for PLCγ1 
activation, IP production and proximal signalling (172, 177, 194). The data presented 
in this chapter demonstrates that three gain-of-function PLCγ1 proteins do not require 
p.Y783 phosphorylation to elevate downstream signalling by showing increased 
NFκB, NFAT and AP-1 transcriptional activity in basal conditions. The activating 
mutations also did not show a dependency on p.Y783 phosphorylation to induce NFκB 
activity in stimulated cells. Pilot data showed that the p.R48W and p.D342N mutant 
proteins may be partially dependent on p.Y783 phosphorylation to increase NFκB 
activity in stimulated cells, however this warrants further investigation.  
To investigate if the elevated NFκB activity induced by gain-of-function PLCγ1 
mutations can be reversed, cells were treated with the IKKβ inhibitor, TPCA-1. This 
inhibitor effectively reduced TNFα-induced NFκB activity in a control experiment but 




Chapter 5 Establishing a system to visualise the cellular 
localisation of mutant PLCγ1 
 
5.1 Introduction 
The PLCγ1 p.D342N, p.S345F and p.E1163K mutations have previously been mapped 
onto the structure of the PLCβ3 and/ or PLCβ2 isoforms (67, 160). The mutations were 
proposed to affect residues on the protein surface that is predicted to interact with the 
plasma membrane, where the PLC substrate PIP2 is located.  
In this chapter, the position of nine PLCγ1 mutations (including the aforementioned 
three) will be determined by mapping onto a composite structure of PLCγ2, an isoform 
that is more closely related to PLCγ1 than PLCβ3 or PLCβ2. An in vitro imaging 
system will then be set up using immunofluorescence analysis and confocal 
microscopy to visualise the location of the mutant proteins within cells.  
 
5.2 Activating PLCγ1 mutations map to the protein surface that likely interacts 
with the plasma membrane 
To gain insight into mechanisms of mutant protein activity, PLCγ1 mutations were 
mapped onto a composite structure of PLCγ2 using the DeepView-Swiss-PdbViewer 
and Pymol molecular visualisation software. PLCγ2 has high sequence homology with 
PLCγ1 in key functional domains (Figure 1. 14) (175). The mutations were mapped 
onto the PLCγ2 isoform because only the structure of the PLCγ1 SH2 and SH3 
domains has been resolved. The mutation mapping was performed by Dr. Katy Everett 
(University of Cambridge). 
The PLCγ2 model demonstrates that the p.R48W, p.D342N, p.S345F, p.E1163K, 
p.D1165H and p.VYEEDM1161V mutations map to the protein surface that is 
predicted to interact with the plasma membrane, where the PIP2 substrate of PLC is 
located (Figure 5. 1). The p.S312L and p.S520F mutations orient to the opposite face 
of the protein and the p.R1158H locates towards the centre of PLCγ2. The ability of 
the p.R48W hotspot mutation and p.D342N mutant to increase PLCγ1 signalling in 
stimulated conditions supports their location at the surface of PLCγ2, in close 















Figure 5. 1. PLCγ1 mutations mapped to the PLCγ2 crystal structure. The activating 
PLCγ1 mutations p.S345F, p.E1163K, p.D1165H and p.VYEEDM1161V (indel) 
locate to the PLCγ2 surface that is predicted to interact with the plasma membrane, 
where PIP2 resides. Mutation mapping was performed by Dr. Katy Everett. 
 
5.3 Generation of GFP-tagged mutant constructs  
As the mutations that increase basal PLCγ1 activity (p.S345F, p.E1163K, p.D1165H 
and p.VYEEDM1161V) and the mutations that elevate signalling after stimulation 
(p.R48W and p.D342N) map to the PLCγ2 protein surface that likely interacts with 
the plasma membrane, it is postulated that these mutant proteins may elevate PIP2 
hydrolysis via increased membrane interactions, leading to amplified downstream 
signalling. To investigate whether the p.S345F, p.E1163K, p.D1165H and 
p.VYEEDM1161V proteins interact more with the plasma membrane compared to 
wild-type PLCγ1, immunofluorescence and confocal microscopy analyses were 
optimised. The p.D342N mutant was also selected for analysis as it locates in close 
proximity to the activating p.S345F mutation. The p.S520F mutation was included for 
analysis to visualise the cellular localisation of this activating protein, which does not 




The eGFP-PLCγ1 vector that encodes an eGFP tag upstream the wild-type PLCG1 
ORF was kindly provided by Professor Matilda Katan (UCL). The vector was used as 
a template to generate six GFP-tagged mutant PLCγ1 constructs. The introduction of 
mutant alleles was confirmed by Sanger sequencing (Figure 5. 2). The PLCG1 ORF, 
CMV promoter and enhancer, eGFP tag, and polyA tail sequences of the plasmids 
were confirmed not to harbour any additional mutations. 
Figure 5. 2. Chromatograms confirming introduction of mutant alleles in the eGFP-
PLCγ1 constructs by site-directed mutagenesis. Sequences from the wild-type 




5.4 The GFP tag does not hinder mutant PLCγ1 activity 
HeLa cells were chosen for immunofluorescence analyses as these cells have a large 
cytoplasm, enabling better visualisation of protein localisation. To determine whether 
the GFP tag interferes with the elevated transcriptional activity induced by the PLCγ1 
mutations in the folded protein conformation, HeLa cells were co-transfected with 
wild-type or mutant GFP-tagged or untagged vectors and the NFAT-luciferase 
reporter plasmid. The NFAT activity induced by the GFP-tagged mutant PLCγ1 
proteins was comparable to or greater than that induced by the untagged proteins 
(Figure 5. 3), showing that the N-terminus GFP tag does not interfere with the gain-
of-function properties of mutant PLCγ1 proteins. 
Figure 5. 3. The GFP tag in the eGFP-PLCγ1 constructs does not hinder PLCγ1 
activity. GFP-tagged proteins induce comparable levels of NFAT transcriptional 
activity to untagged (pTriEx-4) PLCγ1 proteins in transfected HeLa cells. Activation 
levels induced by tagged and untagged mutant proteins were normalised to those of 
the corresponding wild-type proteins. Data is represented as mean ± SD; n=1 assay 

































5.5 Optimisation of HeLa cell transfection, staining and confocal microscopy 
settings  
To determine whether the mutant PLCγ1 proteins localise to the plasma membrane, a 
model system was set up in which HeLa cells were transfected with eGFP-PLCγ1 
plasmids and stained with Phalloidin and DAPI to visualise F-actin and the nucleus, 
respectively. Co-localisation of PLCγ1 proteins with the plasma membrane would 
result in yellow-orange pixels from overlapping green (PLCγ1) and red (F-actin) 
fluorescence. The cSH2 domain of PLCγ1 has been shown to interact with the actin-
cytoskeleton, which enables the enzyme to translocate to the plasma membrane where 
it is activated by phosphorylation from RTKs (276). Therefore, the visualisation 
system would also enable investigations to determine whether mutant proteins alter 
the cellular structure. 
The experiments will initially optimise visualisation in basal conditions as the 
activating mutations do not require stimulation to elicit gain-of-function. As wild-type 
PLCγ1 requires stimulation to induce signalling, EGF-stimulation of HeLa cells can 
be optimised and the cells visualised by real-time fluorescence imaging in future 
investigations as per Matsuda et al. (2012) and Wang and Wang (2003) (178, 277). 
The first experiment aimed to ensure that the DAPI and Phalloidin dyes stained their 
specified targets within cells and to confirm that the stained features can be 
successfully visualised by confocal microscopy. HeLa cells (8 x 104) were transfected 
with 500 ng of either wild-type or mutant eGFP-PLCγ1 plasmids and stained with 1 
unit of Phalloidin and 300 nM of DAPI. Cells were visualised using immersion oil and 
a 60X objective on a Nikon A1 inverted microscope and analysed using the NIS 
elements analysis software (Version 4.51) at the Nikon Imaging Centre (KCL). PLCγ1 
expression was confirmed in all transfected cells (Figure 5. 4). Intra- and inter-sample 
variation in GFP expression was observed as some cells demonstrated more intense 
GFP expression. Cells were successfully stained with DAPI and Phalloidin, enabling 
visualisation of the nucleus and cell structure (Figure 5. 4). Imaging of the nucleus, 
however required higher laser power as the staining was weak. Therefore, in 
subsequent experiments cells were stained with a higher concentration of DAPI to 
avoid using high laser power that can photo-bleach the fluorophores. In the merged 




localisation of PLCγ1 with the plasma membrane can be visualised by the orange 
pixels at the cell boundary, however this was not observed in cells expressing wild-
type PLCγ1 (Figure 5. 4). It could not be determined if the p.D1165H mutant protein 
co-localises to the plasma membrane from the merged image as the F-actin staining 
was weak compared to GFP expression (Figure 5. 4). However, in the GFP-only 
channel, an increase in protein expression was observed at the periphery of a 
p.D1165H-transfected cell (Figure 5. 4). Elevated protein expression was also 
observed in the GFP-only channel in cells expressing the p.VYEEDM1161V indel 





Figure 5. 4. Mutant PLCγ1 may have increased co-localisation to the plasma 
membrane in vitro. HeLa cells were transfected with eGFP-tagged PLCγ1 constructs 
and stained to visualise the nucleus and F-actin. Orange pixels at the cell boundary in 
merged images may represent increased co-localisation of PLCγ1 at the plasma 
membrane. Arrows indicate a potential increase in PLCγ1 localisation to the 




The high intensity GFP expression over-powered the F-actin staining, making it 
difficult to visualise co-localisation at the plasma membrane. Therefore, HeLa cells 
were transfected with decreasing concentrations of the wild-type or p.E1163K 
plasmids. p.E1163K was selected for analysis because cells expressing this mutant 
protein produced the most intense GFP signals (Figure 5. 4). HeLa cells (7 x 104) were 
transfected with 350 ng, 200 ng or 100 ng of the eGFP-PLCγ1 plasmids, stained with 
1 unit of Phalloidin and 600 nM of DAPI and analysed using immersion oil with a 
100X objective. The intensity of GFP expression was comparable within and between 
samples, with the exception of two cells expressing p.E1163K (Figure 5. 5). Cells 
transfected with 350 ng of eGFP plasmids enabled optimal visualisation of co-
localisation at the plasma membrane compared to cells transfected with 200 ng or 100 
ng plasmid DNA, therefore this concentration was used for subsequent 
immunofluorescence analyses (Figure 5. 5). 
Figure 5. 5. Optimisation of HeLa cell transfection with GFP-tagged PLCγ1 
constructs. Cells transfected with decreasing concentrations of wild-type and 
p.E1163K PLCγ1 plasmids showed comparable GFP expression. Panels show merged 
immunofluorescence images of two fields of view per sample. Asterisks denote cells 
with more intense GFP expression than other cells and arrows indicate cells that 




Despite increasing the objective from 60X to 100X and reducing the number of seeded 
cells from 8 x 104 to 7 x 104, it was difficult to visualise single cells due to high 
confluency. Therefore, 1 x 104 HeLa cells were transfected with 350 ng of wild-type 
or p.D1165H plasmid DNA. F-actin and DAPI staining was weak in previous 
experiments and required high laser power for detection. Therefore, cells were stained 
with higher concentrations of Phalloidin (4 units) and DAPI (1 μM) to prevent photo-
bleaching and analysed using a 100X objective and oil immersion. Cells expressing 
GFP-tagged wild-type PLCγ1 varied greatly in shape (Figure 5. 6). Increased 
localisation of PLCγ1 to the cell periphery was observed in the GFP-only channel in 
cell 1 and 2 but not in cell 3 (Figure 5. 6). However, the increased GFP localisation in 
the first cell appears to be an artefact as the pattern of localisation was not observed in 
the other two cells in this experiment and also previous experiments. Co-localisation 
of PLCγ1 to the cell membrane was observed in the second cell (Figure 5. 6). 
Figure 5. 6. HeLa cells expressing GFP-tagged wild-type PLCγ1 vary in cell shape. 
Cells were transfected and stained to enable visualisation of the nucleus and F-actin. 






Cells transfected with the PLCγ1 p.D1165H mutant also demonstrate variable 
morphology. The p.D1165H-transfected cell (expressing GFP) showed less defined F-
actin organisation compared to the adjacent untransfected cell (Figure 5. 7. A). The 
cells shown in Figure 5. 7. B further demonstrate the variability in cell shape and also 
show increased PLCγ1 localisation at the membrane in both the GFP-only channel and 
the merged image. Figure 5. 7. C shows an amplification of the merged image from 
Figure 5. 7.B, which demonstrates co-localisation of the mutant p.D1165H protein 
with the plasma membrane in both cells. 
Figure 5. 7. HeLa cells expressing the GFP-tagged p.D1165H mutant protein have 
variable cellular morphology. Cells were transfected and stained to enable 
visualisation of the nucleus and F-actin. Arrows indicate potential co-localisation of 




Overall, clearly visualising increased co-localisation of mutant PLCγ1 to the plasma 
membrane compared to wild-type protein was difficult as PLCγ1 was expressed 
throughout the cytoplasm. Furthermore, it was challenging to determine whether the 
activating PLCγ1 proteins alter cellular structure because of the large variation in 
morphology observed. To be able to confidently quantify co-localisation and 
determine mutation-induced differences in cellular structure, at least 20 cells 
expressing wild-type and each mutant protein would need to be analysed. This was 
unachievable due to time constraints, however the experimental system to successfully 
transfect and stain HeLa cells has been established for use in future experiments. 
 
5.6 Summary 
The PLCγ1 p.S345F, p.E1163K, p.D1165H and p.VYEEDM1161V gain-of-function 
mutations were shown to map to the PLCγ2 protein surface that likely interacts with 
the plasma membrane. The p.R48W and p.D342N mutant proteins, which elevate 
signalling in stimulated conditions, also map to this surface. Thus, it was hypothesised 
that these mutant proteins may have increased interactions with the plasma membrane 
as a mechanism of elevating substrate hydrolysis and increasing downstream 
signalling. To investigate whether mutant proteins have increased membrane 
interactions, an imaging system was established. Firstly, mutant GFP-tagged PLCγ1 
constructs were generated and the transfection and staining of HeLa cells to visualise 
PLCγ1 localisation was optimised for immunofluorescence analysis. Further 
investigations are required to quantify co-localisation of wild-type and mutant PLCγ1 
with the plasma membrane and to confidently determine any mutation-induced 







Chapter 6 Concluding remarks 
 
6.1 Discussion 
6.1.1. Novel findings presented in this study 
This thesis addresses the hypothesis that PLCγ1 variants are true gain-of-function 
mutations that increase TCR signalling and contribute to the pathogenesis of SS. 
Accordingly, PLCG1 mutations were shown to persist in multiple SS tumour 
compartments over extended periods of time. PLCG1 mutations are reported in several 
types of mature T-cell lymphomas, which occur throughout the gene and in particular 
at five hotspots. This study showed that five PLCγ1 mutations potently activate 
proximal and downstream signalling via the DAG-PKCθ-NFκB, DAG-PKCθ-AP-1 
and IP3-calcineurin-NFAT pathways independently of cellular activation signals. 
Importantly, the gain-of-function mutant proteins increased downstream signalling in 
a p.Y783 phosphorylation-independent manner. The data presented propose a critical 
role of the C2 domain in regulating PLCγ1 activity. Overall, this thesis provides strong 
evidence for the development of novel PLCγ1 mutation-specific inhibitors as a form 
of targeted therapy for mature T-cell lymphoma patients harbouring PLCG1 
mutations. 
6.1.2. PLCG1 mutations occur frequently in mature T-cell lymphomas 
PLCG1 is frequently mutated in numerous mature T-cell lymphomas. To determine 
the overall frequency of PLCG1 mutations in different disease subsets, a 
comprehensive literature analysis of all WES and targeted gene sequencing studies of 
mature T-cell lymphoma samples was performed. This analysis was done with the help 
of Dr. Christine Jones (KCL). PLCG1 was determined to be most frequently mutated 
in ATLL, followed by PTCL-nos, HSTL, AITL, CTCL (MF and SS) and TPLL, but 
not in anaplastic large cell lymphomas, enteropathy-associated T-cell lymphomas and 
natural killer/T-cell lymphomas, the reasons for which remain unclear (Table 6. 1). 
Interestingly, the mutations reported in TPLL and HSTL are disease-specific and may 
contribute to disease pathogenesis in a unique way. Notably, deep sequencing studies 
have only analysed advanced stage MF samples and investigations into early stage 




Table 6. 1. Whole-exome and targeted gene sequencing studies reporting PLCG1 
mutations in mature T-cell lymphomas. ATLL: adult T-cell leukaemia/lymphomas, 
PTCL-nos: peripheral T-cell lymphomas-not otherwise specified, MF: Mycosis 
Fungoides, AITL: angioimmunoblastic T-cell lymphomas, SS: Sézary Syndrome, 
HSTL: hepatosplenic T-cell lymphoma, TPLL: T-cell-prolymphocytic leukaemia, 
ALCL: anaplastic large cell lymphoma, EATL: enteropathy-associated T-
cell lymphoma, NKTCL: natural killer/T-cell lymphoma. 
Malignancy Mutation frequency References 
ATLL 36.2%  (134/370) (221) 
PTCL-nos 18.2%  (4/22) (66, 218, 278) 
MF 15.1%  (8/53) (71, 148, 160) 
HSTL 15.0%  (3/20) (222) 
AITL 12.0%  (11/92) (65, 66, 218, 220, 278) 
SS 11.3%  (44/388) (67-71, 147, 160, 161) 
TPLL 5.6  (2/36) (223) 
ALCL 0%  (0/23) (279) 
EATL 0%  (0/89) (66, 280-282) 
NKTCL 0%  (0/27) (66, 283) 
 
Two further studies performed selective sequencing of exon 11 and/ or 15 to screen 
for the PLCγ1 p.S345F and p.S520F mutations in mature T-cell lymphomas (Table 6. 
2) (216, 217). These variants were screened for as they have been shown to be 
activating mutations in CTCL (160). The two studies used highly sensitive sequencing 
techniques that preferentially amplify low frequency mutant alleles for detection (as 
will be discussed later) (216, 217). Due to the different methodology used, the 
frequencies from the selective sequencing studies were not included in the above-






Table 6. 2. PLCG1 mutation frequencies reported by exon-specific sequencing of 
mature T-cell lymphomas. c-ALCL: cutaneous-anaplastic large cell lymphomas, LyP: 
lymphomatoid papulosis. 
Malignancy Exons sequenced Mutation frequency Reference 
PTCL-nos 11 14.6%  (6/41) 
Manso et al. 2014  
(217) 
AITL 11 11.7%  (7/60) 
SS 11 & 15 5.1%  (2/39) 
Caumont et al. 2015  
(216) 
MF 11 & 15 2.7%  (1/37) 
c-ALCL 11 & 15 0%  (0/14) 
LyP 11 & 15 0%  (0/4) 
 
The analysis reported here shows that 15.1% of MF and 11.3% of SS tumours harbour 
PLCG1 mutations (Table 6. 1), which negates the report by Caumont et al. (2015) that 
PLCG1 mutations are uncommon in CTCL (Table 6. 2) (216). The low mutation 
frequency reported by the latter study is likely due to the sequencing of only two 
exons. Analysis of deep sequencing studies of mature T-cell lymphomas (Figure 1. 
22) and COSMIC data both show that PLCG1 mutations occur throughout the gene 
but more frequently at five hotspots. Notably, the COSMIC database was identified to 
consistently under-report PLCG1 mutations compared to an in-depth analysis of all 
NGS studies on mature T-cell lymphomas, as demonstrated by the hotspot mutation 
frequencies in Table 6. 3. This data supports that comprehensive literature analyses 






Table 6. 3. PLCγ1 hotspot mutation counts in mature T-cell lymphomas. Counts 








p.R48W 53 66 (67, 69, 70, 147, 218, 221) 
p.S345F 63 74 
(65, 67, 68, 70, 71, 147, 148, 
160, 161, 216-218, 220, 221) 
p.S520F 9 11 (68, 70, 147, 160, 218, 221) 
p.E1163K 21 27 (67-70, 147, 218, 221) 
p.D1165H 18 21 (70, 147, 218, 221) 
 
WGS and WES studies on CTCL tumours have demonstrated a highly heterogeneous 
tumour mutation profile affecting genes involved in T-cell activation, JAK/STAT 
signalling, DNA damage response, cell fate, cell survival, chromatin modification and 
many more (67-71, 148, 161). Nevertheless, a meta-analysis of 220 CTCL tumours 
analysed by nine deep sequencing studies highlighted that the cell cycle regulation 
gene TP53 and the TCR signalling gene PLCG1, most frequently harboured point 
mutations in 14% and 9% of cases, respectively (162). These findings were confirmed 
by another meta-analysis of 139 CTCL tumours (from seven NGS studies), which 
showed that TP53 and PLCG1 were the most frequently mutated oncogenes in 19% 
and 10% of cases, respectively (166). The analysis performed here reports a similar 
PLCG1 mutation frequency in 11.8% of CTCL tumours (Table 6. 1). Importantly. 
Chang et al. (2018) identified that mutations in PLCG1, CARD11 and TNFRSF2B, 
which are involved in NFκB signalling occur in mutual exclusivity in SS, suggesting 
that aberration of one gene is sufficient to disrupt this pathway and induce oncogenesis 
(166).  
6.1.3. PLCG1 mutations activate three signalling pathways to induce NFκB, NFAT 
and AP-1 transcriptional activity  
This study shows that mutant PLCγ1 proteins have potent gain-of-function properties 
that activate three signalling cascades to induce NFκB, NFAT and AP-1 activity in 




activation independent of TCR engagement. The data presented herein is the first to 
show direct activation of NFκB activity by PLCγ1 mutations in vitro. Previous studies 
have shown that PLCγ1 mutations identified in PTCL elevate MALT1 activity in 
transfected HEK293T cells (218). Increased MALT1 activity is suggestive of elevated 
NFκB activity, however unlike the data presented in this thesis, Vallois et al. (2016) 
do not directly show the effect on transcriptional activity. The only reported 
interrogations of NFκB in relation to PLCγ1 mutations are immunohistochemical 
analyses of MF samples, which showed no segregation of nuclear p50 and p52 NFκB 
subunit expression in patients with or without PLCγ1 mutations (160). However, a 
significant relationship between expression of the p.S345F mutation and nuclear 
localisation of p50 has been reported in PTCL samples (217). Activation of NFκB by 
mutant PLCγ1 is significant as this transcription factor is characteristically 
constitutively active in CTCL, ATLL and some PTCL subtypes (112, 113, 118, 119). 
Elevated autocrine TNFα production in SS tumours and HUT-78 cells, increased 
nuclear localisation of the p65 NFκB subunit in MF and gene rearrangements in 
NFKB2 in CTCL tumours and cell lines are known mechanisms that raise NFκB 
activity (112, 114, 117). Data presented here strongly supports that bona fide gain-of-
function PLCγ1 mutations are a novel and additional mechanism by which NFκB is 
constitutively active in CTCL and other mature T-cell lymphomas. 
This study is the first to report the gain-of-function effects of PLCγ1 mutations on AP-
1 transcriptional activity. Our group has previously shown that copy number gain of 
JUNB, an AP-1 subunit, increases expression of this subunit in CTCL (121). 
Therefore, activating PLCγ1 mutations are an alternative mechanism by which AP-1 
activity is augmented in CTCL. 
This study is the first to analyse the direct effect of disease-associated PLCγ1 
mutations on proximal signalling by quantifying IP production. The p.D342N mutant 
protein has previously been shown to increase IP production in a study that analysed 
the effect of mutating residues close to the active site of PLCγ1 (269). Assays that 
quantify IP1 have been used to demonstrate the gain-of-function potential of the 
PLCγ1 p.R707Q mutation that frequently occurs in angiosarcomas (213). The assay 
quantifies IP1 as a surrogate for IP3 production as the latter is rapidly metabolised. 




The data presented herein confirms and extends the findings of Vaqué et al. (2014) 
and Vallois et al. (2016) by showing that PLCγ1 mutations significantly enhance 
NFAT activation in vitro (160, 218). Importantly, the in-frame indel potently enhances 
NFAT activation and IP production, showing its gain-of-function effects on distal and 
proximal signalling down the IP3-calcineurin-NFAT signalling pathway. The 
activating effects of mutant PLCγ1 proteins are supported by the significant 
relationship between the p.S345F mutation and nuclear NFAT expression in MF 
tumours (160). A similar pattern of nuclear NFAT expression was also reported in the 
same number of PTCL tumours, however the relationship failed to reach statistical 
significance (217). The p.S345F mutant protein has transforming properties in vitro as 
demonstrated by an increased number of foci formed compared to wild-type PLCγ1 
in transfected NIH3T3 cells that co-expressed the anti-apoptotic protein BCL2, which 
aids foci formation (160). 
The NFκB, NFAT and AP-1 transcription factors have common targets including the 
Th2 cytokines genes IL-4, IL-5, IL-10 and IL-13 and the anti-apoptotic genes BCL-2, 
cIAP1 and cIAP2 (123). The expression of these cytokines is elevated in CTCL and 
provides a Th2-dominant milieu that promotes growth of tumour cells (96-99, 102). 
The anti-apoptotic genes mentioned are also characteristically overexpressed in CTCL 
and lead to apoptosis resistance of tumour cells (123). As PLCγ1 mutations potently 
activate all three transcription factors, it is likely that the mutations also induce 
increased expression of Th2 cytokines and anti-apoptotic genes in CTCL, however 
this remains to be confirmed. Increased expression of anti-apoptotic genes and Th2 
cytokines may also be due to constitutive MYC, STAT3 and STAT5 activity in CTCL 
(124).   
6.1.4. PLCG1 mutations persist over time and in multiple tumour compartments 
The PLCG1 mutations detected in SS tumours by our deep sequencing study were 
validated by Sanger sequencing in all 11 patients, confirming that the mutant alleles 
were not sequencing artefacts. The identification of PLCG1 mutations in diagnostic 
samples strongly suggests that these mutations contribute to oncogenesis. 
Furthermore, the mutations were detected in multiple tumour tissues in 9/11 patients 
and shown to persist over prolonged periods of time in 6/8 patients for whom serial 




obtained over extended periods of time and in multiple tumour compartments strongly 
suggests positive selection of the mutations. Some mutations could not be detected in 
serial tumour tissue samples due to (i) a lack of sample availability, (ii) therapeutic 
interventions that reduced tumour burden or (iii) diffuse tumour infiltrates in the skin 
and a lack of detection sensitivity by Sanger sequencing. More sensitive sequencing 
techniques could be used to identify mutant alleles in lesional CTCL skin. One such 
technique is the locked nucleic acid-clamped real-time PCR methodology that 
selectively amplifies mutant alleles. This method has successfully been used to detect 
the PLCγ1 p.S345F mutation in CTCL and nodal PTCLs (160, 217). An alternative 
high resolution melting technique has been used to detect mutant alleles encoding the 
PLCγ1 p.S345F and p.S520F mutations in CTCL and the BRAF p.V600E mutation in 
melanoma cases (216, 284). Furthermore, Albitar et al. (2017) have developed a 
sequencing assay that is over 100 times more sensitive than Sanger sequencing and 
can detect less than 1 mutant allele in a background of 1000 wild-type alleles for the 
BTK p.C481S and PLCγ2 p.R665W, pS707Y, p.L845F mutations in Ibrutinib-
resistant CLL tumours (285). As mutations occur throughout the PLCG1 gene, 
sequencing 32 exons using these highly sensitive sequencing techniques in a large 
number of diagnostic samples would not be feasible, justifying the more suitable 
approach of using targeted gene sequencing for mutation detection at diagnosis. 
Nevertheless, the high sensitivity techniques would be beneficial when screening 
several samples for specific mutations or for detecting mutant alleles in early stage 
disease or lesional skin in CTCL in which tumour cells may be sparse. 
6.1.5. Activating PLCγ1 mutations may have increased interactions with the plasma 
membrane  
According to a current model PLCγ1 is maintained in an inactive state by an auto-
inhibitory interaction of the X-Y catalytic domains with the cSH2 domain, which 
blocks substrate from accessing the active site (Figure 6. 1. A) (172). When the critical 
p.Y783 residue is phosphorylated by RTKs and nRTKs, it interacts with the cSH2 
domain and changes the protein conformation, which disrupts the auto-inhibitory 
interaction and makes the active site available for substrate hydrolysis (Figure 6. 1. B-
C) (175). The p.S345F and p.S520F mutations are predicted to map to domains that 




in a way that disrupts auto-inhibition and results in constitutively active mutant 
proteins (Figure 6. 1. D-E) (175, 194).  
Figure 6. 1. Gain-of-function PLCγ1 mutations disrupt auto-inhibition, leading to 
constitutively active mutant proteins. (A) PLCγ1 activity is regulated by an auto-
inhibitory interaction between the catalytic X-Y and cSH2 domains. (B, C) When the 
p.Y783 residue is phosphorylated it interacts with the cSH2 domain, disrupts auto-
inhibition and makes the active site available for substrate hydrolysis. (D, E) The 
activating mutations p.S345F and p.S520F are predicted to locate to the XY-cSH2 and 
cSH2-split PH interaction surfaces, respectively and are likely to disrupt auto-
inhibition.  
 
The p.D342N, p.S345F and p.E1163K mutations have previously been mapped to the 
PLCβ3 and/ or PLCβ2 isoforms and predicted to locate to the protein surface that faces 
the plasma membrane (67, 160). In this study, the PLCγ1 mutations were mapped to 
the 3D protein structure of the PLCγ2 isoform, which is more closely related to PLCγ1 
than PLCβ3 and PLCβ2, to gain insight into the potential mechanisms by which the 
mutations alter protein expression and activity. Four of the five activating mutations 
(p.S345F, p.E1163K, p.D1165H and p.VYEEDM1161V) map to the PLCγ2 protein 
surface that is predicted to interact with the plasma membrane where the PLCγ 
substrate PIP2 resides. Therefore, it is hypothesised that these activating mutant 
proteins may have increased interactions with the plasma membrane to enhance PIP2 




The activating p.S345F hotspot mutation is predicted to have increased interactions 
with the plasma membrane and is also likely to disrupt protein auto-inhibition (Figure 
6. 1) and thus may be acting by a dual mechanism. Such a mechanism has also been 
suggested for the PLCγ2 p.D993G mutation, however unlike the PLCγ1 p.S345F 
mutation the former mutant protein requires stimulation to induce IP production (269). 
The immunofluorescence system established in this thesis can be used in future studies 
to determine whether the p.S345F mutant protein has increased interactions with the 
plasma membrane. This system was optimised to address two important questions. 
Firstly, do gain-of-function PLCγ1 mutant proteins have increased interactions with 
the plasma membrane compared to wild-type protein? The imaging system enabled 
successful visualisation of GFP-tagged wild-type and mutant proteins and also 
detected co-localisation of PLCγ1 at cell boundaries, however determining a clear 
increase in localisation to the membrane was difficult as PLCγ1 was expressed 
throughout the cytoplasm. PLCγ1 interacts with the actin cytoskeleton via its cSH2 
domain (276). Therefore, the second question raised was do cells expressing mutant 
proteins have altered cellular morphology? Using the imaging system, differences in 
cell shape were observed in transfected and untransfected cells. Visualisation of more 
cells is required to quantify co-localisation and cellular features including area and 
perimeter to be able to confidently determine any differences in cell shape induce by 
mutant PLCγ1. 
6.1.6. Gain-of-function PLCγ1 mutations increase transcriptional activity in a 
p.Y783 phosphorylation independent manner 
Phosphorylation of the p.Y783 residue is essential to activate wild-type PLCγ1 and 
induce IP production as demonstrated by Poulin et al. (2005), who showed diminished 
IP production in stimulated Null TV-1 cells expressing the mutant p.Y783F protein 
compared to cells expressing wild-type PLCγ1 (177). Subsequently, Gresset et al. 
(2010) showed using purified proteins and in vitro kinase assays that the mutant 
p.Y783F protein had drastically reduced phospholipase activity when incubated with 
the FGFR2K receptor which phosphorylates and activates PLCγ1 (172). Thereafter, 
Bunney et al. (2012) showed a reduction in IP production in stimulated COS-7 cells 
expressing the mutant p.Y783F protein (194). These studies all demonstrate that the 
p.Y783 residue is critical for proximal signalling. Furthermore, Serrano et al. (2005) 




mutant protein reduced NFAT and AP-1 activity in PMA- and Ionomycin-stimulated 
Jγ1 and P10-14 cells (193), confirming that the p.Y783 residue is important for wild-
type PLCγ1 activity. A similar methodology was used in this study and demonstrated 
that the p.Y783F mutant protein reduced NFκB activation in EGF-stimulated HEK293 
cells, but to a lesser extent than the reduction in NFAT and AP-1 activity reported by 
Serrano et al. (2005). This may be due to the use of different cell lines, stimuli and 
reporter constructs by the two studies.  
Mechanistically, this study has shown that three gain-of-function PLCγ1 proteins do 
not require phosphorylation of the critical p.Y783 residue to increase downstream 
signalling in basal and stimulated conditions. As mentioned, it is hypothesised that the 
mutations located at the surface of the protein (p.S345F, p.E1163K, p.D1165H and 
p.VYEEDM1161V) may have increased interactions with the plasma membrane and 
elevate PIP2 hydrolysis to enhance downstream signalling. As the mutant proteins may 
increase substrate hydrolysis from increased membrane interactions, they may not 
need phosphorylation of p.Y783 to activate the protein as is required for wild-type 
PLCγ1. This thesis shows that two of the surface-oriented mutations (p.S345F and 
p.E1163K) enhanced transcriptional activity without p.Y783 phosphorylation. Based 
on the proximity of p.D1165H to p.E1163K and inclusion of both residues within the 
p.VYEEDM1161V indel, it may be possible that p.D1165H and the indel mutant 
proteins also do not require phosphorylation to induce downstream signalling but this 
requires functional investigations. The phosphorylation-independent nature of the 
activating proteins in basal conditions suggests that they do not require extracellular 
stimuli to induce activity and supports the notion that these proteins may constitutively 
activate T-cells without TCR engagement, however this remains to be confirmed. 
NFκB and AP-1 are activated by the secondary messenger lipid DAG, however studies 
have not investigated the effect of abrogating the p.Y783 phosphorylation residue on 
DAG production. This may be due to the traditional techniques used namely thin layer 
chromatography or high performance liquid chromatography being technically 
challenging, inefficient and having long processing times to distinguish DAG (which 
remains in the plasma membrane) from other membrane lipids prior to quantification 
(286). However, more recent methodologies including mass spectrometry have 




mutant PLCγ1 proteins on DAG production and also PIP2 turn over as per Haag et al. 
(2012) (287).  
6.1.7. Possible explanations for four PLCγ1 mutant proteins not having gain-of-
function properties  
The PLCγ1 p.S312L mutant protein, as predicted by pathogenicity prediction 
algorithms did not influence protein expression or activity in basal conditions. This 
mutation maps to the opposite PLCγ2 protein surface compared to the gain-of-function 
proteins and is not hypothesised to facilitate increased interactions with the plasma 
membrane as a means of increasing protein activity. Notably, early findings presented 
here show that in stimulated cells, the p.S312L protein induces lower levels of NFκB 
activity than wild-type PLCγ1, suggesting that this may potentially be a loss-of-
function protein, however this warrants further investigation. A single gene can 
harbour both loss- and gain-of-function mutations as demonstrated for the RHOA gene 
in ATLL tumours (271). 
The p.R1158H mutation affects an evolutionarily conserved residue and was predicted 
to be damaging by all six pathogenicity algorithms. Nevertheless, functional analyses 
showed no effect on protein expression or activity in basal conditions. This mutation 
occurs in the C2 domain, which also harbours the gain-of-function p.E1163K, 
p.D1165H and p.VYEEDM1161V mutations. However, when mapped to the 3D 
PLCγ2 model, the p.R1158H mutation was shown to locate to the centre of the protein 
unlike the activating mutations, which mapped to the protein surface that likely 
interacts with the membrane. The p.R1158H mutant protein may therefore not have 
increased interactions with the plasma membrane in basal conditions. A pilot 
experiment demonstrated that p.R1158H increased NFκB activity in stimulated 
conditions, suggesting that although the mutant protein cannot drive tumourigenesis it 
may contribute to the process when induced by external signals, but this would need 
to be confirmed. 
The p.R48W and p.D342N mutant proteins require stimulation to induce their 
activating effects. The p.R48W hotspot mutation was predicted to be damaging by all 
six algorithms and shown to alter a highly conserved residue in vertebrates. In the 
PLCγ2 model, p.R48W mapped to the protein surface that is predicted to interact with 




activating p.S345F mutation. Data presented here show that p.R48W is not a true gain-
of-function protein as it requires cellular stimulation to increase NFκB activity. The 
dependence on cellular stimuli to induce protein activity suggests that p.R48W 
requires phosphorylation of the p.Y783 residue as implied by early experimental data, 
but this requires validation. p.R48W locates to the PH domain, a domain that does not 
facilitate the initial translocation of PLCγ1 to the plasma membrane but plays an 
important role in stabilising the enzyme to the membrane in stimulated cells as a means 
of sustaining PLCγ1 activity (178). Therefore, the p.R48W mutant protein may 
enhance the function of the PH domain and stabilise mutant PLCγ1 at the plasma 
membrane for longer durations in stimulated cells. p.R48W is the most frequently 
occurring PLCγ1 mutation in ATLL tumours (14.3%; 53/370) (221) and is the second 
most frequent PLCγ1 hotspot mutation in mature T-cell lymphomas (Table 6. 3). 
ATLL is a peripheral T-cell malignancy of CD4+ T-lymphocytes. Infection with the 
HTLV-1 oncoretrovirus is causally associated with ATLL, however accumulation of 
genetic aberrations over time are required for oncogenesis (288). Therefore, it may be 
possible that persistent HTLV-1 infections in ATLL provide the stimulated 
environment required for p.R48W to induce increased signalling. In HTLV-1 infected 
cells, the viral oncoprotein Tax binds to the IKK complex and activates NFκB (289). 
As PLCγ1 regulates IKK activation via the CARMA/BCL10/MALT1 signalosome, 
the p.R48W mutant protein may further amplify Tax-induced NFκB activity in 
infected cells, however this hypothesis remains to be functionally validated. PLCG1 
variations including pathogenic mutations shown to induce gain-of-function were 
frequently detected in ATLL cell lines derived from the aggressive acute disease stage 
compared to cell lines generated from the less aggressive carrier disease stage. This 
suggests that PLCG1 mutations have the ability to transform HTLV-1 infected cells 
into aggressive tumour cells.  
The p.D342N mutant protein has previously been shown to increase IP production in 
stimulated cells in a study that analysed the effect of mutating residues close to the 
active site of PLCγ1 (269). The data in this thesis confirms this finding and also shows 
that the mutation maps to the surface of the PLCγ2 protein that likely interacts with 
the plasma membrane. Early data suggests that p.D342N in addition to p.R48W, may 
be partially dependent on p.Y783 phosphorylation to induce increased signalling in 




The functional interrogations performed demonstrate that the in silico pathogenicity 
prediction algorithms should be used only to gain insight into the effects of mutations 
on protein structure and function to prioritise mutations for functional analysis. Of the 
eight mutations predicted to be damaging by all six algorithms, five (62.5%) were 
identified to increase proximal and downstream signalling. The remaining three 
mutations did not alter protein activity or expression in basal conditions, 
demonstrating that only functional analyses can confirm the effect of mutations on 
protein function.  
6.1.8. The PLCγ1 C2 domain may have a critical role in regulating protein activity 
The indel p.VYEEDM1161V protein showed reduced total PLCγ1 expression 
compared to wild-type protein, suggesting that the indel may affect protein stability, 
subjecting it to degradation at a faster rate than its wild-type counterpart. Nevertheless, 
in its potentially shorter life span, the mutant protein strongly increased IP production 
and NFκB and NFAT transcriptional activity. 
To date, only missense PLCγ1 mutations identified in cancer have been analysed and 
p.VYEEDM1161V is the first disease-associated PLCγ1 indel to be functionally 
interrogated. PLCγ1 deletions have previously been analysed, however these deletions 
were experimentally generated to gain a deeper understanding of protein activity 
regulation. Specifically, Gresset et al. (2010) used deletion mapping to show that 
deletion of the cSH2 domain greatly increased IP production in HEK293 cells, 
demonstrating that this domain is critical for regulating PLCγ1 activity by auto-
inhibition (172). Interestingly, disease-associated deletions have been reported in the 
closely related PLCγ2 isozyme. Linkage analysis of three families affected by PLAID 
identified a deletion of the n-terminus of the cSH2 domain in two families and a 
deletion spanning the cSH2-SH3 domains in the third family (235). Quantification of 
IP production by COS-7 cells transfected with constructs harbouring these deletions, 
demonstrated that the mutant proteins augment PLCγ2 activity by disrupting protein 
auto-inhibition (235). Thus, the cSH2 domains in PLCγ1 and PLCγ2 are well 
established critical regulators of protein auto-inhibition. The data presented in this 
study demonstrates that the C2 domain indel has potent gain-of-function properties 
and proposes a novel regulatory role of the C2 domain as a critical regulator of PLCγ1 




factor and mediate interactions with the plasma membrane (290). Therefore, mutations 
in the C2 domain are likely to influence the interaction of PLCγ1 with PIP2. 
The p.VYEEDM1161V indel defines the critical regulatory p.V1161 – p.M1166 
residues in the C2 domain, which also encompass the p.E1163K and p.D1165H gain-
of-function mutations. The p.R1158 residue is unlikely to be a critical residue as the 
p.R1158H mutation did not influence protein activity and downstream signalling. 
Interestingly, ATLL tumours have been reported to harbour C2 domain deletions with 
deletion of the p.E1163 residue in one tumour and deletions spanning the p.1169 – 
p.1173 residues in 11 tumours (221). This suggests that in addition to the p.1161 – 
p.1166 residues shown by this thesis to be crucial for PLCγ1 regulation, the p.1169 – 
p.1173 residues may also be important in regulating protein activity. Based on the data 
presented, it is postulated that an inhibitory protein may be interacting with PLCγ1 to 
regulate protein activity and the C2 domain indel is likely to abolish the interaction 
interface between PLCγ1 and such regulatory proteins. Further studies are required to 
establish potential protein-protein interactions between the PLCγ1 C2 domain and 
negative regulatory proteins.  
Based on protein sequence homology and functional analogy of PLCγ1 and PLCγ2 in 
TCR and BCR signalling, it is likely that the C2 domain of PLCγ2 also has regulatory 
functions. Frequent somatic mutations including hotspot mutations and small deletions 
in the C2 domains of PLCγ1 and PLCγ2 have been reported in mature T-cell 
lymphomas and Ibrutinib-resistant CLLs, respectively (67-70, 147, 218, 221, 238, 
240, 241). The PLCγ1 C2 domain has the highest number of residues affected by 
mutations compared to the other protein domains (Figure 1. 22). Specifically, 59 of 
the 138 C2 domain residues (p.1114 – p.1173) were calculated to be altered by 
missense mutations, deletions or indels in 6.3% (71/1136) of all mature T-cell 
lymphomas by WGS, WES, TCS and selective sequencing studies. Jones et al. (2017) 
report a region of hotspot mutations affecting the highly conserved p.1140 – p.1144 
residues in the C2 domain of PLCγ2 in Ibrutinib-resistant CLL tumours (240). 
Frequent mutations of the C2 domain residues supports the notion that this domain is 
a critical regulator of PLCγ activity. 
Importantly, the PLCγ2 C2 mutations co-occur with BTK mutations. In contrast, 




involved in NFκB signalling (166). Multiple PLCγ2 mutations have been reported per 
Ibrutinib-resistant CLL tumour (238-241). Similarly, ATLL tumours can harbour 
multiple PLCγ1 mutations (221), an observation not made in other types of mature T-
cell lymphomas. This study showed that cell lines derived from the aggressive acute 
ATLL tumours also harbour more than one PLCG1 mutation. It is likely that multiple 
PLCG1 mutations in ATLL tumours and cell lines may be acting in synergy to further 
enhance PLCγ1 activity compared to tumours with a single PLCG1 mutation. Such 
synergistic effects of multiple PLCγ2 mutations identified to co-occur in a single 
Ibrutinib-resistant CLL case have recently been reported (291). The gain-of-function 
p.R665W, p.L845F and p.S707Y PLCγ2 mutations were shown to further elevate IP 
production in transfected COS-7 cells compared to cells expressing each mutation 
individually (291). Further investigations are required to determine if co-occurring 
PLCγ1 mutations in ATLL also have cumulative effects on protein activity. 
Significantly, the KOB acute ATLL cell line was identified to harbour the PLCγ1 
p.R48W and p.M750V mutations that were reported to co-occur in a single ATLL 
tumour by Kataoka et al. (2015) (221). This cell line may therefore serve as a model 
to interrogate the functional effect of these two PLCγ1 mutations. 
6.1.9. Targeting enhanced PLCγ1 activity with inhibitors  
There are currently no PLCγ1 inhibitors that could attenuate the elevated protein 
activity induced by the gain-of-function mutant proteins. The PLC inhibitor U73122, 
has been frequently used in experiments and has been shown to inhibit PLC in cellular 
systems (175). Vaqué et al. (2014) demonstrated that HEK293T cells overexpressing 
wild-type PLCγ1 or the activating mutant p.S345F and p.S520F proteins had reduced 
NFAT activity when treated with U73122, showing that the inhibitor is effective (160). 
Of note, the U73122 inhibitor is known to have a broad range of cellular targets 
including calcium channels, potassium channels, telomerase and phospholipase D and 
therefore lacks specificity for PLC isozymes (230, 292-295). The influx of calcium 
ions across the plasma membrane through calcium channels is induced by the release 
of calcium from intracellular stores in a process known as capacitative calcium entry 
(296). The reduction in NFAT activity reported by Vaqué et al. (2014), may not be 
directly attributable to inhibition of PLCγ1 as it cannot be distinguished whether 
U73122 inhibits PLCγ1 or capacitative calcium entry, both of which activate the 




stimulated keratinocytes and NFκB translocation in stimulated rat osteoclasts (297, 
298). The CTCL cell lines MyLa and HUT-78 show reduced cell proliferation, 
viability and nuclear NFAT activity in response to U73122 treatment (160). These cell 
lines do not harbour PLCG1 mutations, therefore the effect of U73122 in CTCL cell 
lines or primary tumour cells expressing activating PLCγ1 mutations should be 
investigated. Paradoxically, U73122 has been shown to activate PLCγ1 (>10 fold) and 
also induce PLCβ3 (8 fold) and PLCβ2 (2 fold) activity in a cell-free system (230). 
U73122 was demonstrated to form a covalent interaction with PLCβ3, which induces 
the activity of this PLC isozyme (230). As this interaction was identified in a cell-free 
system it does not give insight into the interaction of U73122 with other cellular 
targets. In light of the ability of U73122 to activate PLCγ1, this inhibitor was not 
selected for use in this thesis. 
As mutant PLCγ1 proteins trigger three signalling cascades two approaches can be 
taken to inhibit the elevated signalling. Firstly, targeting the signalling pathway 
upstream of mutant PLCγ1 to inhibit activation of all three cascades and secondly, 
directing inhibitors to block signalling downstream of PLCγ1 to attenuate each branch 
of signalling independently. Targeting individual pathways downstream of PLCγ1 
have shown mixed results. NFκB is a crucial therapeutic target as this transcription 
factor is constitutively active in CTCL and has elevated activity in ATLL and some 
PTCL subtypes (118, 119). This thesis showed that the IKKβ inhibitor, TPCA-1 
inhibited TNFα-induced but not PLCγ1-induced NFκB activity, making it an 
unsuitable inhibitor to block the elevated signalling induced by mutant PLCγ1. The 
TCR and TNF receptor (TNFR) activate the canonical NFκB pathway but PLCγ1 does 
not mediate signalling from the TNFR (299). A deeper understanding into the 
mechanisms by which TPCA-1 inhibits NFκB activity is therefore required. The 
proteasome inhibitor Bortezomib, which inhibits degradation of the NFκB inhibitor 
IκBα, has been shown to be well tolerated and effective in a phase II trial on relapsed 
or refractory CTCL (300). Bortezomib inhibits NFκB activity in HUT-78 cells by 
inducing translocation and accumulation of IκBα in the nucleus, which sequesters 
p65/p50 heterodimers (123). This inhibitor has also demonstrated anti-tumour activity 
in multiple myeloma (MM) but has been shown to elevate NFκB activity in tumour 




findings presented here demonstrate that inhibitors of the NFκB pathway may further 
enhance or reduce elevated transcriptional activity in particular milieus. 
The calcineurin inhibitor FK-506 (Tacrolimus) effectively reduces NFAT activity 
induced by the p.S345F and p.S520F mutations in transfected HEK293T cells (160). 
Tacrolimus also reduces the proliferation and viability of the MyLa, HUT-78 and HH 
CTCL cell lines and significantly inhibits nuclear NFAT activity in MyLa and HUT-
78 cells, demonstrating that the calcineurin pathway is sensitive to inhibition (160). 
As mentioned, these cell lines endogenously express wild-type PLCγ1, therefore it 
remains to be determined if Tacrolimus would also be effective in CTCL cells that 
express mutant PLCγ1. The topical calcineurin inhibitors Tacrolimus and 
Pimecrolimus are used to treat atopic dermatitis but were marked with a ‘black box 
warning’ by the U.S. FDA due to the potential risk of developing malignancies (302). 
Nevertheless, a case with patch stage MF has been successfully treated with a 0.1% 
tacrolimus ointment (303). These findings would need to be validated in more patients 
to confirm that this topical therapy is effective in early stage MF. A phase two 
multicentre clinical trial of Pimecrolimus appears to be safe and effective for use in 
early stage (Ia – IIa) MF patients and the majority of patients that responded to the 
therapy had elevated calcineurin pathway activation (unpublished data presented by 
Professor Ortiz-Romero, EORTC-CLTF meeting 2018). Notably, Tacrolimus and 
Pimecrolimus would only be sufficient in targeting the elevated NFAT activity 
induced by mutant PLCγ1 and additional inhibitors would be required to inhibit the 
two DAG signalling pathways. 
Targeting signalling upstream of PLCγ1 to inhibit the gain-of-function effects of 
mutant proteins is another strategy that can be investigated. Ibrutinib is an effective 
inhibitor that achieves remission in CLL patients (249). This inhibitor targets BTK, 
which activates PLCγ2 in B-lymphocytes (249). The activating BTK p.C481S and 
PLCγ2 p.R665W, p.L845F and p.S707Y mutations have been uniquely identified in 
relapsed CLL tumours but not in baseline samples suggesting that they confer 
resistance to Ibrutinib (238-240, 242). As PLCγ1 and PLCγ2 have homologous roles 
in TCR and BCR signalling and because Ibrutinib targets BTK and ITK in B- and T-
cells (304), it may be plausible to hypothesise that gain-of-function PLCγ1 mutations 
also confer resistance to Ibrutinib. If this was true then CTCL patients could be 




considered for Ibrutinib treatment. Moreover, ITK expression is upregulated in CTCL 
and has been proposed to be used as a diagnostic marker (305, 306). Upregulated ITK 
expression is also associated with a poor prognosis for CTCL patients (305-307). The 
altered expression further supports inhibition of this kinase as a therapeutic strategy 
for CTCL. Ibrutinib has recently been reported to increase CD4+ and CD8+ activated 
T-cell proliferation in CLL patients (308). This would be a highly undesirable effect 
in CTCL, a malignancy of mature malignant skin-resident CD4+ T-cells (308). 
Furthermore, a pilot clinical trial has shown that Ibrutinib has limited clinical efficacy 
in CTCL (309). Nevertheless, other small molecule ITK inhibitors such as ONO-
7790500, BMS-509744 and PF-06465469 have shown promising results by reducing 
ITK and PLCγ1 phosphorylation, calcium flux and IL-2 and IL-21 production in Jurkat 
cells (310). Furthermore, the ITK inhibitor ONO-7790500 and the chemotherapy drug 
doxorubicin act in synergy to further reduce Jurkat cell survival compared to 
treatment with each agent alone (310). Therefore, the safety and efficacy of 
combinations of ITK inhibitors and chemotherapeutic compounds could be tested in 
pre-clinical and clinical trials for CTCL if deemed safe in the former. 
The data presented in this study highlights that PLCγ1 is a significant therapeutic 
target and demonstrates that the development of novel PLCγ1-specific inhibitors to 
inhibit all three signalling cascades is fundamental. A potential caveat with the 
development of specific inhibitors is that PLCγ1 is ubiquitously expressed and the 
inhibitor would not only target T-cells but other tissues that express the protein at 
comparable levels including but not limited to the brain, ovary, prostate, bladder and 
colon (311). Thus, PLCγ1-specific inhibitors may result in cytotoxicity and adverse 
effects. Furthermore, due to the high protein sequence homology of the PLCγ1 and 
PLCγ2 isoforms, it would be difficult to develop PLCγ1-specific inhibitors that do not 
also inhibit PLCγ2 activity, leading to potential further cytotoxicity and adverse 
reactions. Therefore, novel mutation-specific PLCγ1 inhibitors should be developed 
for mature T-cell lymphomas and angiosarcomas and mutation-specific PLCγ2 
inhibitors for Ibrutinib-resistant CLL, PLAID and APLAID. Generating effective 
mutation-specific inhibitors may be challenging as the crystal structure of PLCγ1 has 
not been resolved, however the PLCδ structure has been used to identify novel PLCγ-
specific inhibitors by virtual high throughput screening (312). Promisingly, this screen 




to PLCγ (312). As CTCL tumours and mature T-cell lymphomas are genetically highly 
heterogeneous, patients may benefit from a personalised cocktail of specific inhibitors 
based on their tumour mutation profiles. This would be a more targeted therapeutic 






1. PLCG1 mutations persist over time and in multiple tumour compartments in the 
majority of SS patients, strongly suggesting positive selection of these mutations 
by tumour cells. 
2. The p.S345F, p.S520F, p.E1163K, p.D1165H and p.VYEEDM1161V gain-of-
function proteins induce constitutive activation of PLCγ1 by directly increasing 
proximal signalling via IP production and significantly increase downstream 
signalling to the NFκB and NFAT transcription factors.  
3. The mutant protein encoded by the hotspot p.R48W requires cellular stimulation 
to significantly induce NFκB activity.  
4. The p.S345F, p.S520F and p.E1163K gain-of-function mutant proteins do not 
require phosphorylation of the p.Y783 residue to increase NFκB, NFAT and AP-
1 transcriptional activity in basal conditions and NFκB activity in stimulated 
conditions. 
5. The p.S345F, p.E1163K, p.D1165H and p.VYEEDM1161V activating mutations 
map to the PLCγ2 protein surface that is predicted to interact with the plasma 
membrane. The p.R48W and p.D342N mutations, which increase protein activity 
in stimulated conditions map in close proximity to the activating mutations. 
6. The C2 domain of PLCγ1 harbours residues that are fundamental for protein 
activity regulation. 
7. The data presented provides compelling evidence for the development of novel 





6.3 Future work 
The questions raised from this thesis are presented below and possible approaches to 
interrogate them are proposed. Experiments to (i) gain a deeper mechanistic 
understanding of mutant protein activity, (ii) investigate the ability of mutations to 
contribute to tumourigenesis and (iii) analyse the efficacy of novel inhibitors, have 
been categorised accordingly. 
Mechanistic interrogations 
1. Do the gain-of-function p.S345F, p.E1163K, p.D1165H and p.VYEEDM1161V 
proteins have increased interactions with the cell membrane compared to wild-
type PLCγ1? 
o The immunofluorescence system optimised in this study can be used to 
obtain further cellular images and co-localisation of PLCγ1 with the 
plasma membrane can be quantified using the ImageJ image processing 
software. 
2. Do the p.R48W and p.D342N mutant proteins require phosphorylation of the 
p.Y783F residue to induce NFκB reporter activity in stimulated cells? 
o Early experimental results indicate that these mutant proteins may be 
partially dependent on phosphorylation, however biological repeats are 
required to confirm this. 
3. Do the p.R48W and p.D342N mutant proteins localise more to the plasma 
membrane than wild-type PLCγ1 in stimulated cells? 
o If the mutant proteins are shown to be stimulation-dependent, HeLa cells 
transfected with GFP-tagged PLCγ1 constructs can be analysed by real-
time fluorescence imaging as per Matsuda et al. (2012) and Wang and 
Wang (2003) (178, 277), to determine if EGF stimulation induces 
increased or prolonged interaction of mutant proteins with the membrane. 
4. Can the PLCγ1 p.Y783F phosphorylation mutant localise to the plasma membrane 
in basal or stimulated conditions? 
o The p.Y783 residue is phosphorylated by RTKs and non-RTKs after 




protein has abnormal cellular localisation, HeLa cells expressing the 
mutant protein can be visualised using the established system for basal 
conditions and by real-time fluorescence imaging for EGF-stimulated 
cells.  
5. Do gain-of-function PLCγ1 mutations affect the cell structure? 
o Differences in cellular morphology were observed in this study. To further 
investigate changes in cellular shape, the established imaging system can 
be used to visualise further cells and features including cell area, perimeter 
and circularity can be quantified using ImageJ. 
6. Does abrogation of the p.Y783 phosphorylation residue in gain-of-function PLCγ1 
proteins affect IP production? 
o COS-7 cells can be transfected with gain-of-function and double mutant 
constructs and IP production can be quantified by liquid scintillation to 
determine if the mutant proteins require protein phosphorylation to elevate 
proximal signalling. 
7. Do negative regulatory proteins bind to the C2 domain of PLCγ1 to regulate 
protein activity? 
o Wild-type and the p.VYEEDM1161V mutant protein can be expressed in 
Jurkat cells to determine interactions between PLCγ1 and other proteins by 
co-immunoprecipitation and mass spectrometry. Differences in binding 
proteins would likely be due to abrogated interactions as a result of the 
indel in the C2 domain. 
Tumourigenesis investigations 
To investigate whether gain-of-function PLCγ1 mutations contribute to 
lymphomagenesis, wild-type and mutant PLCG1 cDNA would need to be cloned into 
lentiviral vectors. The vectors can be used to transduce primary human CD4+ T cells 
(i.e. serve as knock-in cells) to enable investigations into how mutant PLCγ1 proteins 
transform primary cells by analysing key cellular parameters including: 
1. Cell viability using the CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega), which uses ATP quantification to determine if cells expressing mutant 




2. Cell proliferation using the CyQUANT Cell Proliferation Assay Kit (Thermo 
Fisher) to determine cell numbers based on DNA content. This assay would 
establish whether PLCγ1 mutants alter the rate of cell proliferation. 
3. Apoptosis using the annexin V-PE apoptosis detection kit (BD Pharmigen). 
Annexin V-PE is conjugated to the PE fluorochrome which binds to 
phosphatidylserine (PS) in apoptotic cells. PS is normally located on the inner 
leaflet of the plasma membrane but is exposed to the outer leaflet in cells 
undergoing early apoptosis. Annexin V-PE labelled can be quantified by flow 
cytometry. This assay would require effective and mutation-specific inhibitors to 
induce apoptosis, which would inform on whether cells expressing mutant PLCγ1 
are more or less resistant to cell death compared to those expressing wild-type 
protein. 
Inhibitor analyses 
1. Can mutation-specific PLCγ1 inhibitors attenuate the elevated transcriptional 
activity induced by PLCγ1 mutations in vitro? 
o When novel inhibitors are developed, the mutant proteins can be expressed 
in HEK293 cells and treated with inhibitors to determine the effect on 
NFκB, NFAT and AP-1 reporter activity. 
2. Can mutation-specific PLCγ1 inhibitors reduce the increased IP production 
induced by PLCγ1 mutations in vitro? 
o COS-7 cells can be transfected with PLCγ1 constructs, treated with novel 
inhibitors and IP production quantified by liquid scintillation.  
3. Can mutation-specific PLCγ1 inhibitors reduce cell viability, proliferation and 
apoptosis in lymphoma cell lines and primary human CD4+ T-cells transduced 
with PLCγ1 mutants?  
o The KKI cell line, identified in this study to harbour the activating p.S345F 
mutation can be used to determine the effect of inhibitor treatment on cell 
viability, proliferation and apoptosis.  
o Primary cells transduced with wild-type and mutant PLCγ1 constructs can 
be treated with specific inhibitors and key parameters that contribute to 




4. Can mutation-specific PLCγ1 inhibitors reduce cell viability, proliferation and 
apoptosis in primary SS tumour cells?  
o Our research group has frozen enriched CD4+ T-cells from patients 
harbouring the gain-of-function p.S345F and p.E1163K mutations. The 
effect of novel mutation-specific PLCγ1 inhibitors on tumour cells can be 
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Appendix Table 1. Next-generation sequencing studies performed on advanced stage 
MF and SS tumours. WGS: whole-genome sequencing, WES: whole-exome 
sequencing, TCS: targeted capture sequencing, CNV: copy number variation analysis, 
RNA: whole-transcriptome analysis.
Malignancy Reference WGS WES TCS CNV RNA 
MF 
Vaqué et al. 2014  
(160) 
     
MF 
McGirt et al. 2015  
(148) 
     
MF 
Ungewickell et al. 2015  
(71) 
     
MF 
da Silva Almeida et al. 2015  
(69) 
     
SS 
Vaqué et al. 2014  
(160) 
     
SS 
Choi et al. 2015  
(67) 
     
SS 
Kiel et al. 2015  
(68) 
     
SS 
Wang et al. 2015  
(70) 
     
SS 
da Silva Almeida et al. 2015  
(69) 
     
SS 
Prasad et al. 2016  
(161) 
     
SS 
Woollard et al. 2016  
(147) 




Appendix Table 2. NFAT target genes and functions. 
Gene Target gene function References 
BDNF Stimulates neuronal growth and differentiation (313) 
CD40LG Co-stimulatory T-cell ligand  (196, 314, 315) 
CD5 Regulates anti-tumour immune responses of T-cells (196, 316) 
c-myc Proto-oncogene, stimulates proliferation (317) 
CSF2 Stimulates proliferation (196) 
EGR-1 Transcriptional regulator (313) 
FASLG Stimulates apoptosis (196, 314) 
IFNG Cytokine produced by Th1 cells (196, 314) 
IGF1 Stimulates proliferation (313) 
IL10 Cytokine produced by Th2 cells (313) 
IL12 Th1-inducing cytokine (313) 
IL13 Cytokine produced by Th2 cells (196, 313) 
IL1b Pro-inflammatory cytokine (318) 
IL2 Cytokine secreted by T-cells (196, 313, 314) 
IL2RA 
CD25; IL-2 receptor α-chain; mediates IL-2 
signalling in T-cells 
(196) 
IL4 Th2-inducing cytokine (314, 317) 
IL5 Cytokine produced by Th2 cells (196, 318) 
IL6 Th17-inducing cytokine (313) 
IP3R1 IP3 receptor (313) 
NFKB1 DNA binding subunit of the NFκB (318) 
RCAN1-4 Negative regulators of calcineurin (313) 
REL 




Regulates growth, proliferation, differentiation and 
apoptosis 
(313) 






Appendix Table 3. AP-1 target genes and functions. 
Gene Target gene function References 
BCL2 Inhibits apoptosis  (319) 
BCL2L1 Inhibits apoptosis (319) 
BCL2L11 Stimulates apoptosis (319) 
BCL3 Inhibits apoptosis (319) 
CCND1 Cyclin D1; cell cycle progression regulator (319) 
CDKN1A Inhibits proliferation (319) 
CDKN2A 
Tumour suppressor, inhibits proliferation, stimulates 
apoptosis 
(319) 
CSF2 Stimulates proliferation (319) 
DNMT1 Epigenetic regulator (319) 
EGFR Stimulates proliferation (319) 
FAS Cell surface death receptor (319) 
FASLG Stimulates apoptosis (320) 
FGF7 Stimulates proliferation (319) 
HBEGF Stimulates proliferation (319) 
IFNG Cytokine produced by Th1 cells (321) 
IL13 Cytokine produced by Th2 cells (196) 
IL2RA 
CD25; IL-2 receptor α-chain; mediates IL-2 
signalling in T-cells 
(196) 
IL4 Th2-inducing cytokine (196) 
IL5 Cytokine produced by Th2 cells (196) 
TP53 Inhibits proliferation, stimulates apoptosis (319) 






Appendix Table 4. NFκB target genes and functions. 
Genes Target gene function References 
Bax  Stimulates apoptosis  (322) 
BCL-2 Inhibits apoptosis  (323) 
BCL-3 Inhibits apoptosis (324) 
BRCA2 Tumour suppressor (325) 
BTK Stimulates proliferation (326) 
CASP4 Apoptosis regulator  (327) 
c-myb Proto-oncogene (328) 
c-myc Proto-oncogene (329) 
c-rel Proto-oncogene (330) 
CCND1 Cyclin D1; cell cycle progression regulator (331, 332) 
CCND2 Cyclin D2; cell cycle progression regulator (333) 
EGFR Stimulates proliferation (334, 335) 
FAS Cell surface death receptor (336, 337) 
FASLG Stimulates apoptosis (337, 338) 
GATA3 T-cell differentiation  (339) 
IFNG Cytokine produced by Th1 cells (340, 341) 
IL2 Cytokine produced by Th1 cells (342) 
IL10 Cytokine produced by Th2 cells (343, 344) 
IL13 Cytokine produced by Th2 cells (345) 
JUNB Proto-oncogene (346) 
NFKB1 NFkB p105 subunit precursor (347) 
NFKB2 NFkB p100 subunit precursor (348) 
NFKBIA  IkB-α; NFkB inhibitor (349, 350) 
NFKBIE IkB-ε: NFkB inhibitor (351) 
STAT5A Stimulates proliferation (345) 
TNF Regulates proliferation and apoptosis (352) 
TP53 









Appendix Figure 1. The PLCG1 c.C142T; p.R48W mutation in patient 2. 
 
Appendix Figure 2. The PLCG1 c.C935T; p.S312L mutation in patient 3. 
 
Appendix Figure 3. The PLCG1 c.G1024A; p.D342N mutation in patient 4. 




Appendix Figure 4. The PLCG1 c.G1024A; p.D342N mutation in patient 5. 
Sequencing and analysis were performed by Dr. Begum.  
 
Appendix Figure 5. The PLCG1 c.C1034T; p.S345F mutation in patient 6. Sequencing 
and analysis were performed by Dr. Begum. 
 
Appendix Figure 6. The PLCG1 c.C1034T; p.S345F mutation in patient 7. Sequencing 




Appendix Figure 7. The PLCG1 c.C1559T; p.S520F mutation in patient 8. 
 
Appendix Figure 8. The PLCG1 c.G3487A; p.E1163K mutation in patient 9. 
 
 




Appendix Figure 10. The PLCG1 c.G3493C; p.D1165H mutation in patient 11.  
 
Appendix Figure 11. The PLCG1 c.C142T; p.R48W mutation persists in multiple 
tumour compartments for 1 year in patient 2. DNA from a healthy control individual 





Appendix Figure 12. The PLCG1 c.G1024A; p.D342N mutation in a diagnostic blood 
sample from patient 4. The mutation was absent thereafter as the patient developed 
lymphopenia from multiple therapies including chemotherapy, biologics and retinoids 
and Campath monoclonal antibody therapy. DNA from a healthy control individual 






Appendix Figure 13. The PLCG1 c.C1559T; p.S520F mutation persists for 15 years 
in patient 8. Fluctuations in the tumour burden may account for the variable intensity 
of the mutant allele detected. DNA from a healthy control individual was sequenced 










Appendix Figure 14. The PLCG1 c.G3487A; p.E1163K mutation in multiple tumour 
compartments in patient 10. DNA from a healthy control individual was sequenced to 
show the wild-type allele in the top panel. 
 
 
Appendix Figure 15. The PLCG1 c.G3493C; p.D1165H mutation persists in patient 
11. DNA from a healthy control individual was sequenced to show the wild-type allele 








Appendix Figure 16. The heterozygous PLCG1 c.G1948T; p.E650STOP variant in the 
CY-6 cell line. 
 




























Frequent and Persistent PLCG1 Mutations in
Sézary Cells Directly Enhance PLCg1 Activity
and Stimulate NFkB, AP-1, and NFAT Signaling
Varsha M. Patel1,4, Charlotte E. Flanagan1,4, Marta Martins2, Christine L. Jones1, Rosie M. Butler1,
Wesley J. Woollard1, Farrah S. Bakr1, Antoinette Yoxall1, Nelema Begum1, Matilda Katan3,
Sean J. Whittaker1 and Tracey J. Mitchell1
Phospholipase C Gamma 1 (PLCG1) is frequently mutated in primary cutaneous T-cell lymphoma (CTCL). This
study functionally interrogated nine PLCG1 mutations (p.R48W, p.S312L, p.D342N, p.S345F, p.S520F, p.R1158H,
p.E1163K, p.D1165H, and the in-frame indel p.VYEEDM1161V) identified in Sézary Syndrome, the leukemic
variant of CTCL. The mutations were demonstrated in diagnostic samples and persisted in multiple tumor
compartments over time, except in patients who achieved a complete clinical remission. In basal conditions,
the majority of the mutations confer PLCg1 gain-of-function activity through increased inositol phosphate
production and the downstream activation of NFkB, AP-1, and NFAT transcriptional activity. Phosphorylation of
the p.Y783 residue is essential for the proximal activity of wild-type PLCg1, but we provide evidence that
activating mutations do not require p.Y783 phosphorylation to stimulate downstream NFkB, NFAT, and AP-1
transcriptional activity. Finally, the gain-of-function effects associated with the p.VYEEDM1161V indel suggest
that the C2 domain may have a role in regulating PLCg1 activity. These data provide compelling evidence to
support the development of therapeutic strategies targeting mutant PLCg1.
Journal of Investigative Dermatology (2019) -, -e-; doi:10.1016/j.jid.2019.07.693
INTRODUCTION
Cutaneous T-cell lymphoma (CTCL) is an extra-nodal mature
T-cell lymphoma derived from skin-homing memory CD4þ
T-cells (Kim et al., 2005). Sézary Syndrome (SS) is a rare
leukemic subtype of CTCL, closely related to Mycosis Fun-
goides (MF), and is associated with a dismal prognosis and an
urgent need for effective therapies (Swerdlow, 2017).
Recent next generation sequencing (NGS) studies, including
our own work, have identified the dysregulation of T-cell
signaling and differentiation pathways as a defining feature of
mature T-cell lymphomas, including CTCL (Choi et al., 2015; da
Silva Almeida et al., 2015; Kataoka et al., 2015; Kiel et al., 2015;
Kiel et al., 2014; McGirt et al., 2015; McKinney et al., 2017;
Palomero et al., 2014; Prasad et al., 2016; Sakata-Yanagimoto
et al., 2014; Simpson et al., 2015; Ungewickell et al., 2015;
Vallois et al., 2016; Vaqué et al., 2014;Wang et al., 2015;Wang
et al., 2017;Woollard et al., 2016; Yoo et al., 2014). After TP53,
the PLCg1 gene PLCG1, has been identified as the second most
commonly mutated gene in SS (Chang et al., 2018; Park et al.,
2017) and is also frequently mutated in advanced stage MF
(McGirt et al., 2015; Ungewickell et al., 2015; Vaqué et al.,
2014), and adult T-cell leukemia/lymphoma (Kataoka et al.,
2015). PLCg1 plays a pivotal role in T-cell receptor (TCR)
signaling and is activated by receptor and non-receptor tyrosine
kinases, which trigger signaling cascades to activate the tran-
scription factors NFkB, NFAT, and AP-1 (Smith-Garvin et al.,
2009). These transcription factors regulate the expression of
genes involved in cell proliferation, survival, differentiation, and
death (Smith-Garvin et al., 2009). Nuclear accumulation and
constitutive activation of NFkB signaling has been consistently
reported in Sézary cells and CTCL cell lines, but the underlying
mechanism remains unexplained (Giri and Aggarwal, 1998;
O’Connell et al., 1995; Sors et al., 2006). Increased NFkB ac-
tivity is also a key feature of other mature T-cell lymphomas,
including adult T-cell leukemia/lymphoma and sub-types of
peripheral T-cell lymphomas (Martı́nez-Delgado et al., 2005;
Yamagishi and Watanabe, 2012). Elevated NFkB activation in-
duces the expression of anti-apoptotic genes, including BCL-2,
leading to apoptosis resistance, another hallmark of CTCL
(Juvekar et al., 2011).
This study investigates the functional effects of nine PLCG1
mutations reported in SS patients on PLCg1 activity. We show
that 5 of 9 variants confer the constitutive activation of PLCg1
as demonstrated by the significant induction of downstream
NFkB, NFAT, and AP-1 transcriptional activity and increased
proximal activity in basal conditions, as well as confirming
previous findings showing the induction of NFAT transcrip-
tional activity. Furthermore, we provide evidence that these
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gain-of-function mutations increase downstream signaling
without phosphorylation of the PLCg1 p.Y783 residue. We
also propose a role for C2 domain residues in the regulation
of PLCg1 activity, and our findings suggest that mutant PLCg1
proteins represent potential therapeutic targets in CTCL.
RESULTS
Persistence of PLCG1 mutations in multiple SS tumor
compartments
Our recent NGS study identified seven coding PLCG1 mu-
tations in tumor cells from 11 SS patients, including four
recurrent aberrations (p.R48W, p.D342N, p.S345F, and
p.E1163K) (Woollard et al., 2016). In this study, Sanger
sequencing confirmed all 11 mutations in DNA from diag-
nostic blood samples and demonstrated persistence in
different tumor compartments, including serial blood sam-
ples, lesional skin, involved lymph nodes, and RNA extracted
from tumor-enriched peripheral blood CD4þ T-cells. Using
four representative cases, we demonstrate that PLCG1 mu-
tations persist several years after diagnosis in multiple tumor
compartments, strongly implicating their role as driver mu-
tations (Figure 1). In Sézary cells from patient 1, the p.E1163K
mutation was detected in all four tumor compartments at
diagnosis. In patient 2, the p.S345F mutation persisted in the
blood for 17 months after diagnosis but was not detected after
triple therapy (interferon-a, photopheresis, and bexarotene)
led to resolution of the leukemic disease. Subsequently, the
mutation was detected in an involved lymph node when the
patient developed nodal progression at 72 months. In patient
3, the p.S345F mutation was detected in the blood and
Sézary cell-derived RNA up to 51 months after diagnosis but
was absent in the blood 78 months post diagnosis at the time
of a complete clinical remission following chemotherapy.
Finally, in patient 4, the p.R48W mutation was detected in
the blood and at the transcriptional level at diagnosis but not
in lesional skin, which is likely attributed to a lack of
detection sensitivity associated with a sparse cutaneous tu-
mor cell infiltrate. The mutant allele and clonal TCR rear-
rangement were absent in the blood after the patient
achieved complete remission following allogeneic hemato-
poietic stem cell transplantation.
PLCG1 mutations are frequent in CTCL and other mature
T-cell lymphomas
To identify the most frequent PLCG1 mutations and those to
prioritize for functional studies, we performed a compre-
hensive analysis of previously published NGS studies (whole-
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Figure 1. Persistence of mutant PLCG1 alleles in multiple tumor compartments in SS patients. Sanger sequencing of the DNA extracted from PBMCs, lesional
skin biopsies and involved lymph nodes. RNA was isolated from enriched CD4þ tumor cells and reverse transcribed into cDNA. The chromatograms were
analyzed using the FinchTV software. CD3þ/CD4þ counts/ml are shown as a proxy for tumor burden. N/A, but no diagnostic TCR clonal gene rearrangement
was detected in the post-transplant sample. N/A, CD3þ/CD4þ unavailable; PBMC, peripheral blood mononuclear cells; TCR, T-cell receptors.
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mature T-cell lymphomas (Supplementary Table S1). PLCG1
mutations were found in 36.2% of adult T-cell leukemia/
lymphomas, 18.2% of peripheral T-cell lymphomas-not
otherwise specified, 15% of hepatosplenic T-cell lymphomas,
12% of angioimmunoblastic T-cell lymphomas, 11.8% of
CTCLs (MF and SS), and 5.6% of T-cell-prolymphocytic leu-
kemias but not identified in anaplastic large cell lymphomas,
enteropathy-associated T-cell lymphomas, and natural killer/
T-cell lymphomas. Collating all the mutations reported by































































































































































































































































































































































































NSVWNSQLDAV TYLTGDQFSSESSL SKIYYSEETSS EFAFLRFVVYEEDMFSDQN
VYEEDM1161V
NLAFLRFVVYEEDMFSDPNAKLSFSDDIEQTYLTGDQLRSESSPNSIWDEKYDAVKSTPERRTVQVPLCγ2
Figure 2. PLCG1 is frequently mutated in mature T-cell lymphomas. (a) PLCg1 mutations identified by next generation sequencing of different mature T-cell
lymphomas were plotted to determine the incidence of each mutation per disease type. (b) Schematic representation of the eight missense mutations and one in-
frame indel (p.VYEEDM1161V) examined in this study mapped to the PLCg1 functional protein domains. (c) PLCg1 and PLCg2 residues were aligned using the
Clustal Omega software. PLCg1 mutations analyzed in this study and the corresponding PLCg2 mutations reported in B-cell ibrutinib-resistant chronic
lymphocytic leukemia are shown. AITL, angioimmunoblastic T-cell lymphomas; ATLL, adult T-cell leukemia/lymphoma; HSTL, hepatosplenic T-cell lymphoma;
MF, Mycosis Fungoides; SS, Sézary Syndrome; PTCL-nos, peripheral T-cell lymphomas-not otherwise specified; TFH-derived PTCL, follicular helper T-cell-
derived lymphomas; TPLL, T-cell-prolymphocytic leukemia.
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mutations (p.R48W, p.S345F, p.S520F, p.E1163K, and
p.D1165H) (Figure 2a) with p.S345F being the most
frequently reported in 74 individual tumors. All five muta-
tions were detected in the SS tumors in our NGS study
(Woollard et al., 2016). The seven PLCG1 mutations
(p.R48W, p.S345F, p.S520F, p.E1163K, p.D1165H, p.S312L,
and p.D342N) confirmed by Sanger sequencing and two
additional variants reported in SS (p.R1158H and the
p.VYEEDM1161V indel) (Kiel et al., 2015) were selected for
further analyses (Figure 2b). Pathogenicity predictions sug-
gested that all but one of these mutations (p.S312L) are pre-
dicted to be damaging by a consensus drawn from 5 of 6
algorithms for missense mutations and 3 of 4 algorithms for
the indel (see Supplementary Table S2). PLCg2 is an isozyme
of PLCg1, and both have high protein sequence identity in all
critical functional domains (Koss et al., 2014). PLCg2 has an
analogous role to PLCg1 and is a critical mediator of B-cell
receptor signaling (Koss et al., 2014). Aligning the isozyme
sequences revealed that the PLCg1 p.D342N, p.D1165H,
and p.M1166 (deleted in p.VYEEDM1161V) mutant residues
correspond to the PLCg2 p.D334H, p.D1140E/G/N/Y, and
p.M1141K/R mutations somatically acquired in B-cell
ibrutinib-resistant chronic lymphocytic leukemia (Figure 2c)
(Burger et al., 2016; Jones et al., 2017; Maddocks et al.,
2015).
Gain-of-function PLCg1 mutations drive NFkB
transcriptional activation
We generated mutant constructs for the nine PLCg1 muta-
tions and compared activity and expression with the wild-
type PLCg1 using an NFkB luciferase reporter assay and































































































































Figure 3. PLCg1 mutations increase NFkB transcriptional activity. (a) Schematic representation of PLCg1 mediating TCR signaling via IP3 and DAG to the
NFkB, AP-1, and NFAT transcription factors. (b) HEK293 cells were co-transfected with PLCg1-pTriEx-4, pRL-TK Renilla-luciferase, and NFkB-firefly-luciferase
plasmids. Cells were starved overnight, and their transcriptional activity was analyzed. Activation fold changes were normalized to cells overexpressing
wild-type PLCg1. Data is represented as the mean  the standard error of the mean; n ¼ 4. Student’s t-test, *P < 0.05, **P < 0.01, ***P < 0.001. (c, d) HEK293
cells were transfected with PLCg1-pTriEx-4 vectors and treated with 100 mM pervanadate before they were harvested. Lysates were probed with (c) an
anti-PLCg1 antibody and (d) an anti-p-PLCg1 antibody to analyze the total and phosphorylated protein expression, respectively, relative to b-actin expression as
a loading control. DAG, diacylglycerol; IP3, inositol trisphosphate; TCR, T-cell receptors; WT, wild-type.
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mutant PLCg1 proteins (p.S345F, p.S520F, p.E1163K,
p.D1165H, and p.VYEEDM1161V) significantly increased
NFkB transcriptional activity 3.3 e 6.1-fold relative to the
wild-type protein (P  0.03), suggesting that they represent
gain-of-function mutations (Figure 3b).
Next, we sought to confirm previous reports showing that
PLCg1 mutations can activate NFAT transcriptional activity in
basal conditions. Our data is entirely consistent with pub-
lished findings (Vallois et al., 2016; Vaqué et al., 2014) and
confirm that the p.S345F, p.S520F, p.E1163K, and p.D1165H
mutations significantly elevate NFAT transcriptional activity
3.3 e 4.8-fold relative to the wild-type (P  0.0013;
Supplementary Figure S1). However, in addition, we found
that the p.VYEEDM1161V indel was the most potent activator
(10-fold; P < 0.0001) of the NFAT transcriptional activity
compared to the other mutant proteins. Interestingly and
consistent with a published report (Vallois et al., 2016), in
HEK293T cells, p.R48W had no significant effect on NFAT
transcriptional activity compared to the wild-type protein.
Western blotting detected a reduction in the total mutant
PLCg1 expression associated with the p.VYEEDM1161V
indel, while all other mutant proteins had expression com-
parable to that of the wild-type protein (Figure 3c). However,
a PLCg1 p.Y783 phosphorylation-specific (p-PLCg1) anti-
body revealed that the p.VYEEDM1161V indel is associated
with increased protein phosphorylation relative to total
PLCg1 expression, while the other mutations showed levels
of phosphorylation similar to that of the wild-type protein
(Figure 3d).
PLCg1 mutations activate proximal signaling in basal
conditions through a direct increase in inositol phosphate
production
To confirm the observed gain-of-function in transcriptional
activity associated with the five PLCg1 mutations in basal
conditions, proximal PLCg1 signaling was investigated.
PLCg1 hydrolyzes phosphatidylinositol 4,5-bisphosphate to
produce IP3 and diacylglycerol. IP3 releases intracellular
calcium to activate calmodulin/calcineurin signaling and
drive NFAT activation (Hogan et al., 2003). We used our
previously published method (Everett et al., 2009) to assay
inositol phosphate (IP) production in COS-7 cells transfected
with PLCg1 gain-of-function mutants (p.S345F, p.S520F,
p.E1163K, p.D1165H, and p.VYEEDM1161V) and wild-type
constructs. Consistent with the transcriptional activation
data, all five mutations were associated with a 3.4 e 6.6-fold
increase in IP production than that of the wild-type PLCg1 in
basal conditions (Figure 4).
PLCg1 p.R48W is activating in a T-cell line
Given the high incidence rate of p.R48W in SS (Figure 2a), it
was surprising that this variant lacked gain-of-function
properties. Therefore, to exclude the possibility that our
findings were cell line-specific, we tested the two most
common variants reported in CTCL (p.R48W and p.S345F) in
T-cell lines. Overexpression of PLCg1 in the SS-derived cell
line SeAx and Jurkat cell lines was associated with high
cytotoxicity (data not shown), which has also been reported
in other lymphoid cell lines (Vaqué et al., 2014). Therefore,
we used the J.gamma1 T-cell lymphoma line (Irvin et al.,
2000), which is a PLCG1 null line derived from Jurkat cells.
The absence of PLCg1 expression in the J.gamma1 cells
compared with the parent Jurkat cell line was confirmed by
western blotting (Figure 5a). In basal conditions, p.R48W
significantly increased NFAT and AP-1 transcriptional activity
2.47- and 2.35-fold, respectively, relative to the wild-type (P
 0.001; Figure 5b and c). NFkB activity was also increased
(Figure 5d). However, this finding was not statistically sig-
nificant, which may be attributed to the high levels of
endogenous NFkB activity in this cell line (data not shown).
In addition, p.S345F significantly activated NFkB, AP-1 (both
P  0.05), and NFAT (P  0.001), consistent with the data in
the HEK293 cells.
Phosphorylation of p.Y783 is not essential for transcriptional
activation by gain-of-function PLCg1 mutations
In normal physiological conditions, activation of the wild-
type PLCg enzymes is associated with the phosphorylation
of specific tyrosine residues in the highly conserved PLCg-
specific array domains by receptor and non-receptor tyrosine
kinases (Koss et al., 2014). Moreover, studies have shown that
mutating the PLCg1 p.Y783 residue (to p.Y783F) drastically
reduces but does not obliterate IP production in vitro (Bunney
et al., 2012; Poulin et al., 2005). To determine whether the
activating mutations require p.Y783 phosphorylation to in-
crease downstream transcriptional activity, the phosphoryla-
tion residue was mutated to p.Y783F in plasmids harboring
the p.S345F, p.S520F, and p.E1163K mutations. These mu-
tations were chosen to represent bona fide gain-of-function
mutations in specific PLCg1 domains, namely the catalytic
X-box domain (p.S345F), the PLCg-specific array (p.S520F),
and the C2 domain (p.E1163K). The absence of p-PLCg1 was
shown in cells transfected with vectors harboring the mutated
p.Y783F residue (Figure 6a). In cells transfected with either
the p.S345F, p.S520F, and p.E1163K plasmids, or the
p.S345F-Y783F, p.S520F-Y783F, and p.E1163K-Y783F vec-
tors, there was no significant difference between the single
and double mutants in NFAT, NFkB, and AP-1 transcriptional
activity (Figure 6bed). To exclude the possibility that these
observations were cell type-specific, we also tested p.S345F












































Figure 4. PLCg1 mutations elevate proximal signaling. COS-7 cells were
transfected with PLCg1-pTriEx-4 vectors, and IP production was quantified by
liquid scintillation counting. The IP production was normalized to cells
overexpressing wild-type PLCg1. The data are represented as the mean 
standard deviation and are representative of two independent experiments. IP,
inositol phosphate; WT, wild-type.
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T-cell lymphoma line. These data confirm the findings in
HEK293 cells and suggest that phosphorylation of the PLCg1
p.Y783 residue is not essential for the PLCg1 activity asso-
ciated with gain-of-function mutations (Figure 6eeg).
DISCUSSION
This study has demonstrated that the majority of PLCg1 var-
iants identified in SS act as gain-of-function mutations by
significant induction of both NFkB and AP-1 transcriptional
activity and increased proximal activity in basal conditions.
In addition, we have confirmed previous studies showing that
PLCg1 mutations activate NFAT transcriptional activity.
Importantly, our results indicate that these gain-of-function
mutations can increase downstream signaling without phos-
phorylation of the PLCg1 p.Y783 residue.
We have also shown that identical PLCG1 mutations are
present in multiple tumor compartments and persist several
years after diagnosis, suggesting that these are probably
driver gene mutations, which are positively selected. Our
review of the published literature also confirms a high prev-
alence of PLCG1 mutations in CTCL (MF 15% and SS 11%)
and other mature T-cell malignancies, notably adult T-cell
leukemia/lymphoma.
In CTCL, several genes involved in TCR signaling harbor
mutations, including CARD11, CD28, and TNFRSF1B, as
well as PLCG1 (Chang et al., 2018; Choi et al., 2015; da Silva
Almeida et al., 2015; Park et al., 2017; Ungewickell et al.,
2015; Vaqué et al., 2014; Wang et al., 2015; Woollard
et al., 2016). Although one study reported that PLCG1 mu-
tations were uncommon in CTCL, occurring in only 3-5% of
cases (Caumont et al., 2015), our data and other reports
suggest that PLCG1 mutations are among the most common
mutations in CTCL, occurring in approximately 10% of tu-
mors (Chang et al., 2018; Park et al., 2017; Woollard et al.,
2016). This apparent inconsistency is likely attributable to
the selective sequencing of only two PLCG1 exons harboring
hotspot mutations by Caumont et al. (2015), whereas PLCG1
mutations occur throughout the gene. Importantly, a recent
study analyzing integrated NGS datasets from 139 CTCL (MF
and SS) cases identified PLCG1 as the most frequently
mutated gene involved in the NFkB pathway (Chang et al.,
2018). Furthermore, analysis of the mutations within the
NFkB pathway revealed that mutations in PLCG1, CARD11,
and TNFRSF1B were mutually exclusive in SS. Our study
demonstrates that gain-of-function PLCg1 mutations in SS
can activate both proximal IP and distal NFkB pathway
signaling in the absence of p.Y783 phosphorylation and
stimulation, which to our knowledge is previously unre-
ported. This is a potentially crucial mechanism driving the
hyperactivation of TCR signaling. Interestingly, in B-cell
malignancies, approved therapies, such as ibrutinib, target
B-cell receptor activation, but resistance can emerge owing
to the acquisition of downstream activating PLCG2mutations
(Liu et al., 2015).
Our data also extends to previous reports showing that
recurrent PLCg1 mutations in CTCL and angioimmunoblastic
T-cell lymphoma increase NFAT activation (Vallois et al.,
2016; Vaqué et al., 2014). These studies used the canonical
human embryonic kidney cell line HEK293T, and consistent
with our findings, show that p.R48W is not activating in basal
conditions. However, given the high frequency of p.R48W in
SS, suggesting that this mutation is positively selected, it
seemed unlikely that it would not be associated with PLCg1
gain-of-function. Reassuringly, our data demonstrates that in
a T-cell line, p.R48W is associated with increased NFAT and
AP-1 transcriptional activity, and it could be argued that this










































































Figure 5. PLCg1 p.R48W is activating
in a T-cell lymphoma cell line. (a)
Whole cell lysates from J.gamma1 and
Jurkat cells were probed with an anti-
PLCg1 antibody to analyze the total
protein expression using GAPDH
expression as a loading control. (b-d)
J.gamma1 cells were co-transfected




were starved overnight and then lysed;
n ¼ 3 for each assay. Activation fold
changes were normalized to cells
overexpressing wild-type PLCg1. Data
are represented as the mean 
standard error of the mean; n ¼ 3.
Student’s t-test, *P < 0.05, **P < 0.01,
***P < 0.001. GAPDH,
glyceraldehyde-3-phosphate
dehydrogenase; WT, wild-type.
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Interestingly, functional studies of CARD11 mutations
reported in CTCL have also demonstrated the activation
of NFkB signaling (da Silva Almeida et al., 2015).
Enhanced NFkB, NFAT, and AP-1 activity may contribute
to increased T helper type 2 cytokine expression in
CTCL, inhibiting the anti-tumor effects of the T helper
type 1 cytokines IL-2 and IFNg, thereby providing
an advantageous microenvironment for tumor cells
(Miyagaki and Sugaya, 2014). Further study is required to
determine the effect of specific PLCG1 mutations on key





































































































































































































































Figure 6. Mutant proteins mediate gain-of-function effects without PLCg1 phosphorylation. (a) HEK293 cells transfected with PLCg1-pTriEx-4 vectors were
treated with 100 mM pervanadate before they were harvested. The lysates were probed with anti-PLCg1 and anti-p-PLCg1 antibodies to analyze the total
and phosphorylated protein expression using b-actin expression as a loading control. (b-d) HEK293 and (e-g) J.gamma1 cells were co-transfected with PLCg1-
pTriEx-4, pRL-TK Renilla-luciferase and pGL3-NFAT-firefly-luciferase, NFkB-firefly-luciferase, or pGL3-AP-1-luciferase vectors. Cells were starved overnight and
then lysed; n¼ 3 for each assay. Activation fold changes were normalized to cells overexpressing wild-type PLCg1. Data are represented as the mean  standard
error of the mean. Student’s t-test. ns, not significant; WT, wild-type.
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PLCg1 is maintained in an inactive state by an auto-
inhibitory interaction between the catalytic X-Y domains
and the cSH2 domain (Supplementary Figure S2) (Gresset
et al., 2010; Koss et al., 2014). The phosphorylated
p.Y783 residue interacts with the cSH2 domain to disrupt
the auto-inhibitory interface and renders the active site
available for substrate hydrolysis (Poulin et al., 2005) and
subsequent activation of the wild-type PLCg1 to produce
IP (Bunney et al., 2012; Poulin et al., 2005). Germline
deletions of the PLCg2 cSH2 and cSH2-SH3 domains
disrupt auto-inhibition and elevate protein activity in rare
inherited conditions, such as phospholipaseCg2eAssociated
Antibody Deficiency and Immune Dysregulation
(Ombrello et al., 2012). The p.S345F and p.S520F muta-
tions have also been proposed to act via the disruption of
auto-inhibition (Koss et al., 2014). The p.S345F and
p.E1163K mutations are predicted to be located at the
protein surface that faces the plasma membrane, based on
a 3-dimensional PLCb2/3 model (Choi et al., 2015; Vaqué
et al., 2014). Similarly, using our PLCg2 model, we sug-
gest that p.R48W, p.S345F, p.E1163K, p.D1165H, and
p.VYEEDM1161V mutations are also likely to interact with
the plasma membrane where the PLCg substrate, phos-
phatidylinositol 4,5-bisphosphate, resides (Supplementary
Figure S3). We hypothesize that these mutant proteins
may have increased affinity for the plasma membrane and
therefore could enhance phosphatidylinositol 4,5-
bisphosphate hydrolysis, leading to amplified down-
stream signaling. Furthermore, this may also explain why
these gain-of-function mutations appear to act indepen-
dently of p.Y783 phosphorylation. However, the hotspot
p.S345F mutation is also predicted to disrupt auto-
inhibition (Koss et al., 2014) and may therefore act by a
dual mechanism, as suggested for the PLCg2 Ali5
(p.D993G) mutation (Everett et al., 2009).
Importantly, we have shown that the p.VYEEDM1161V
indel in the PLCg1 C2 domain is also a potent mediator of
gain-of-function and therefore conclude that, in addition to
the cSH2 domain, the C2 domain is fundamental for
regulating PLCg1 activity. The C2 domains in PLCg1 and
PLCg2 harbor somatic hotspot mutations in mature T-cell
lymphomas and ibrutinib-resistant chronic lymphocytic
leukemia, respectively, (Choi et al., 2015; da Silva Almeida
et al., 2015; Jones et al., 2017; Kataoka et al., 2015; Kiel
et al., 2015; Vallois et al., 2016; Wang et al., 2015;
Woollard et al., 2016) and based on protein sequence
homology and functional analogy of PLCg1 and PLCg2, it
is likely that the PLCg2 C2 domain also has regulatory
functions. Notably, the p.VYEEDM1161V indel reduced the
total PLCg1 protein expression, suggesting that it affects
protein stability and may be subjected to degradation faster
than the wild-type PLCg1. Further functional work is
now required to determine if the p.VYEEDM1161V indel
harbors key regulatory residues that control PLCg1 activity.
U73122, is an inhibitor of phospholipase C, which has
been shown to reduce elevated NFAT activity in HEK293T
cells transfected with wild-type and mutant PLCg1 (Vaqué
et al., 2014), but U73122 paradoxically activates the
PLCb3 isozyme, highlighting the lack of specific PLCg1
inhibitors (Klein et al., 2011).
In summary, this comprehensive study has shown that the
PLCg1 mutations reported in CTCL represent bona fide gain-
of-function mutations that drive constitutive activation of
proximal and distal PLCg1 signaling cascades. These data




All patients fulfilled the WHO-EORTC diagnostic criteria for SS and
were classified as blood stage B2 (Swerdlow, 2017). An identical
clonal TCR rearrangement was demonstrated in peripheral blood
and lesional skin. Tumor samples were obtained with written
informed consent from a nationally approved research tissue bank
(IRAS Project ID: 238203).
Polymerase chain reaction and Sanger sequencing
PCR, reverse transcriptaseePCR, and Sanger sequencing (Biosci-
ence, Cambridge, United Kingdom) were used to validate the mu-
tations in tumor-derived DNA and RNA and to confirm the
introduction of mutant bases into the PLCg1-pTriEx-4 vectors.
Sequencing chromatograms were analyzed using FinchTV (Geo-
spiza Incorporation, Seattle, WA).
Mutation mapping to protein domains
PLCg1 mutations were mapped to the functional protein domains
based on the amino acid numbering and protein domain schematic
presented by Bunney et al. (2012).
Protein sequence alignment
Human PLCg1 and PLCg2 protein sequences were obtained from
the Genome browser Ensembl (Zerbino et al., 2018) and aligned
using the multiple sequence alignment software Clustal Omega
(Sievers et al., 2011).
Site-directed mutagenesis
The PLCg1-pTriEx-4 vector was used to generate mutant constructs
with the QuikChange Lightning Site-Directed Mutagenesis Kit (Agi-
lent Technologies, Santa Clara, CA).
Cell lines
HEK293 and COS-7 cells were obtained from the ECACC (Salisbury,
United Kingdom). Jurkat cells were obtained from Public Health
England (Salisbury, United Kingdom). J.gamma1 cells were obtained
from the ATCC (Manassas, VA) and SeAx cells were a gift from
Professor M. Vermeer (Leiden University Medical Centre, Leiden,
Netherlands). Adherent cells were cultured in DMEM, and non-
adherent cells were maintained in RPMI 1640 Medium (both Life
Technologies, Carlsbad, CA). Cultures were supplemented with 10%
(v/v) Fetal bovine serum (Biosera, Nuaille, France), 100 units/ml
penicillin and 100 mg/ml streptomycin (Life Technologies). SeAx
cells were supplemented with 3 ng/ml rhIL-2 (R&D systems, Min-
neapolis, MN). Cultures were routinely tested for Mycoplasma
contamination using PCR (van Kuppeveld et al., 1994).
Dual-luciferase reporter assays
HEK293 cells were co-transfected with 1 mg PLCg1-pTriEx-4 vectors,
0.05 mg pRL-TK Renilla-luciferase construct, and 0.1 mg of NFkB-
firefly-luciferase, pGL3-NFAT-firefly-luciferase, or pGL3-AP-1-
luciferase reporter plasmids as described by Vaqué et al. (2014).
J.gamma1 cells were co-transfected with 0.5-5 mg PLCg1-pTriEx-4
vectors, 0.5-1 mg pRL-TK Renilla-luciferase construct, and 1 mg of
NFkB-firefly-luciferase, or 5 mg pGL3-NFAT-firefly luciferase/pGL3-
AP-1-luciferase reporter plasmids. Transfections were performed by
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electroporation as per the manufacturer’s instructions (Lonza, Basel,
Switzerland). Lysates were analyzed using the dual-luciferase re-
porter assay system (Promega, Madison, WI). The assays were
repeated at least three times.
Western blotting
HEK293 cells were transfected with 2 mg PLCg1-pTriEx-4 plasmids
and 6 ml FuGene HD Transfection Reagent (Promega). After 23
hours, the cells were treated with 100 mM pervanadate (protein-
tyrosine phosphatase inhibitor) for 1 hour to stabilize the PLCg1
phosphorylation (Kunze et al., 2014) and then harvested. HEK293,
Jurkat, and J.gamma1 whole cell lysates were probed with anti-
bodies listed in Supplementary Table S3. The experiments were
repeated twice.
Inositol phosphate quantification assay
IP production was quantified in counts per minute in COS-7 cells
transfected with 2.5 mg PLCg1-pTriEx-4 vectors (Everett et al., 2009).
The assays were repeated at least twice. IP levels were normalized to
the wild-type PLCg1 activity.
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SUPPLEMENTARY METHODS AND MATERIALS
Comprehensive literature analysis
The PubMed database was used to identify publications
incorporating the World Health Organization classification of
T-cell lymphomas (T-cell prolymphocytic leukemia, T-cell
large granular lymphocyte leukemia, adult T-cell leukemia/
lymphoma, extra-nodal natural killer/T-cell lymphoma (nasal
type), enteropathy-associated T-cell lymphoma, hep-
atosplenic T-cell lymphoma, Mycosis Fungoides / Sézary
Syndrome, primary cutaneous CD30-positive T cell lym-
phoproliferative disorders, primary cutaneous anaplastic
large cell lymphoma, lymphomatoid papulosis, peripheral T-
cell lymphoma-not otherwise specified, angioimmunoblastic
T-cell lymphoma, and anaplastic large cell lymphoma) in
combination with either the term “whole-exome sequencing”
or “next-generation sequencing”. The resulting publications
and the corresponding supplementary data were interrogated
for PLCG1 mutations. Mutations identified by subsequent
targeted gene sequencing were also included to obtain the
overall frequency of PLCG1 mutations per disease subtype.
Pathogenicity prediction
SIFT, Provean, PolyPhen2, Mutation Taster2, MutPred2 and
CADD were used to predict the potential effect of the PLCG1
variants on the protein level (Adzhubei et al., 2013; Choi and
Chan, 2015; Kircher et al., 2014; Kumar et al., 2009; Li et al.,
2009; Schwarz et al., 2014). A consensus prediction was
determined using the criteria of 5 of 6 algorithms having the
same result for missense mutations. The PolyPhen2 and
MutPred2 algorithms only predict the effect of point muta-
tions, therefore the criteria of 3 of 4 algorithms having the
same result was used to predict the effect of the indel.
3-dimensional protein modeling
The 3-dimensional model of the full length PLCg protein was
generated by using the structure of PLCg2 to represent the
PLCg core. PLCg2 structures from the Protein Data Bank
were used for modeling; spPH (PDB: 2K2J), nSH2 (PDB:
2DX0), cSH2 (PDB: 2EOB), and SH3 (PDB: 2EQI). First, the
structure of the tandem SH2 domains from PLCg1 (PDB:
3GQI) was used to arrange these domains relative to each
other. Docking of the domains to the triosephosphate isom-
erase barrel was carried out using the ClusPro web-server
(Comeau et al., 2004a, 2004b). The two SH2 domains were
docked with the catalytic domain, and the spPH domain was
docked to this complex, followed by the SH3 domain. At
each stage, the most likely conformation was chosen based
on biochemical data. The models were analyzed using
DeepView-Swiss-PDBViewer (Guex and Peitsch, 1997) and
Pymol version 1.8 (Schrodinger LLC, New York, NY). PLCG1
mutations were subsequently mapped to this model.
SUPPLEMENTARY REFERENCES
Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human
missense mutations using PolyPhen-2. Curr Protoc Hum Genet 2013;76:
7e20.
Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect
of amino acid substitutions and indels. Bioinformatics 2015;31:2745e7.
Comeau SR, Gatchell DW, Vajda S, Camacho CJ. ClusPro: a fully automated
algorithm for protein-protein docking. Nucleic Acids Res 2004a;32(Web
Server Issue):W96e9.
Comeau SR, Gatchell DW, Vajda S, Camacho CJ. ClusPro: an automated
docking and discrimination method for the prediction of protein com-
plexes. Bioinformatics 2004b;20:45e50.
Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environ-
ment for comparative protein modeling. Electrophoresis 1997;18:
2714e23.
Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general
framework for estimating the relative pathogenicity of human genetic var-
iants. Nat Genet 2014;46:310e5.
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous
variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:
1073e81.
Li B, Krishnan VG, Mort ME, Xin F, Kamati KK, Cooper DN, et al. Automated
inference of molecular mechanisms of disease from amino acid sub-
stitutions. Bioinformatics 2009;25:2744e50.
Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation
prediction for the deep-sequencing age. Nat Methods 2014;11:361e2.
VM Patel et al.
Gain-of-function PLCG1 mutations in Sézary Syndrome
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Supplementary Figure S2. Gain-of-function PLCg1 mutations disrupt auto-inhibition, leading to constitutively active mutant proteins. (a) PLCg1 is
maintained in an inactive state by an auto-inhibitory interaction between the X-Y catalytic domains and the cSH2 domain, which blocks the substrate from
accessing the active site. (b, c) Receptor and non-receptor tyrosine kinases phosphorylate the p.Y783 residue, which interacts with the cSH2 domain and
disrupts the auto-inhibitory interface, making the active site available for substrate hydrolysis. (d, e) The activating mutations p.S345F and p.S520F are predicted



























































Supplementary Figure S1. PLCg1 mutations significantly increase NFAT
transcriptional activity. Five mutations significantly enhance NFAT activity in
basal conditions in HEK293 cells. Transcriptional activity was analyzed
using dual-luciferase reporter assays. Data is represented as the mean 
standard error of the mean; n ¼ 3 Student’s t-test, *P < 0.05, **P < 0.01, ***P
< 0.001. WT, wild-type.
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Journal of Investigative Dermatology (2019), Volume -10.e2
Supplementary Figure S3. Bona fide activating PLCg1 mutations p.R48W, p.S345F, p.E1163K, p.D1165H, and the indel p.VYEEDM1161V map to the surface
of the protein that is predicted to interact with the plasma membrane. (a) Side and (b) top view of the PLCg1 mutations mapped to the PLCg2 protein structure.
Supplementary Table S1. Whole-exome and targeted gene sequencing studies reporting PLCG1 mutations in
mature T-cell lymphomas
Malignancy Mutation frequency References
ATLL 36.2% (134/370) (Kataoka et al., 2015)
PTCL-nos 18.2% (4/22) (Palomero et al., 2014; Sakata-Yanagimoto et al., 2014; Vallois et al., 2016)
MF 15.1% (8/53) (McGirt et al., 2015; Ungewickell et al., 2015; Vaqué et al., 2014)
HSTL 15.0% (3/20) (McKinney et al., 2017)
AITL 12.0% (11/92) (Palomero et al., 2014; Sakata-Yanagimoto et al., 2014; Vallois et al., 2016; Wang et al., 2017;
Yoo et al., 2014)
SS 11.3% (44/388) (Choi and Goh, 2015; da Silva Almeida et al., 2015; Kiel et al., 2015; Prasad et al., 2016;
Ungewickell et al., 2015; Vaqué et al., 2014; Wang et al., 2015; Woollard et al., 2016)
TPLL 5.6 (2/36) (Kiel et al., 2014)
ALCL 0% (0/23) (Crescenzo et al., 2015)
EATL 0% (0/89) (Moffitt and Ondrejka, 2017; Nairismagi et al., 2016; Palomero et al., 2014; Roberti et al., 2016)
NKTCL 0% (0/27) (Jiang et al., 2015; Palomero et al., 2014)
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ATLL, adult T-cell leukemia/lymphoma; EATL,
enteropathy-associated T-cell lymphoma; HSTL, hepatosplenic T-cell lymphoma; MF, Mycosis Fungoides; NKTCL, natural killer/T-cell lymphoma; PTCL-
nos, peripheral T-cell lymphoma-not otherwise specified; SS,: Sézary Syndrome; TPLL, T-cell-prolymphocytic leukemia. Refer to the main manuscript for
references.
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Supplementary Table S3. Antibodies used for western blotting
Antibody Product code Dilution
Rabbit monoclonal anti-PLCg1 5690 1:20,000
Rabbit polyclonal anti-p-PLCg1 2821 1:50,000
Rabbit polyclonal anti-b-Actin 4967 1:10,000
Rabbit monoclonal anti-GAPDH 2118 1:2,000
All antibodies listed were manufactured by Cell Signaling Technology (Danver, MA).
Supplementary Table S2. Pathogenicity predictions performed using multiple algorithms for nine SS-associated





change SIFT Provean PolyPhen2 MutationTaster MutPred2 CADD Consensus
c.C142T p.R48W Damaging Deleterious Probably damaging Disease causing Damaging Deleterious Damaging
c.C935T p.S312L Tolerated Deleterious Benign Disease causing Neutral Deleterious Inconclusive
c.G1024A p.D342N Tolerated Deleterious Probably damaging Disease causing Damaging Deleterious Damaging
c.C1034T p.S345F Damaging Deleterious Probably damaging Disease causing Damaging Deleterious Damaging
c.C1559T p.S520F Damaging Deleterious Probably damaging Disease causing Damaging Deleterious Damaging
c.G3473A p.R1158H Damaging Deleterious Probably damaging Disease causing Damaging Deleterious Damaging
c.G3487A p.E1163K Damaging Deleterious Probably damaging Disease causing Damaging Deleterious Damaging
c.G3493C p.D1165H Damaging Deleterious Probably damaging Disease causing Damaging Deleterious Damaging
c.GTGTATGAG
GAAGACAdelG
p.VYEEDM1161V Damaging Deleterious N/A Disease causing N/A Deleterious Damaging
Abbreviation: N/A, Not applicable.
VM Patel et al.
Gain-of-function PLCG1 mutations in Sézary Syndrome
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